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Summary		
	The	therapy	of	most	cancers	has	greatly	benefited	from	the	use	of	 targeted	drugs.	However,	 their	effects	are	often	short-lived	since	many	tumors	develop	resistance	against	 these	 drugs.	 Resistance	 of	 tumor	 cells	 against	 drugs	 can	 be	 adaptive	 or	acquired	 and	 is	 often	 caused	 by	 genetic	 or	 non-genetic	 heterogeneity	 between	tumor	 cells.	 A	 potential	 solution	 to	 overcome	 drug	 resistance	 is	 the	 use	 of	 drug	combinations	addressing	multiple	targets	at	once.		Finding	 potent	 drug	 combinations	 against	 heterogeneous	 tumors	 is	 challenging.	One	 reason	 is	 the	 high	 number	 of	 possible	 combinations.	 Another	 reason	 is	 the	possibility	of	inter-patient	heterogeneity	in	drug	responses,	making	patient	tailored	treatments	 necessary.	 These	 require	 screens	 on	 patient	 material,	 which	 would	drastically	 benefit	 from	 miniaturization,	 as	 it	 is	 the	 case	 in	 droplet-based	microfluidics.	However,	drug	screens	in	droplets	against	primary	tumor	cells	have	so	 far	 only	 been	 performed	 at	 a	 modest	 chemical	 complexity	 (55	 treatment	conditions)	and	with	low	content	readouts.			In	 this	 thesis	we	 aimed	 at	 developing	 a	 droplet-based	microfluidic	workflow	 that	allows	 the	 generation	 of	 high	 numbers	 of	 drug	 combinations	 in	 picolitre-sized	droplets	and	their	multiplexed	analysis.	To	this	end,	we	have	established	a	pipeline	to	produce	up	to	420	drug	combinations	in	droplets.	We	were	able	to	significantly	increase	the	number	of	possible	combinations	by	building	a	microfluidic	setup	that	comprises	 valve	 and	 micro-titer	 plate	 based	 injection	 of	 drugs	 into	 microfluidic	devices	for	droplet	generation		Furthermore,	 we	 integrated	 a	 DNA-based	 barcoding	 approach	 to	 encode	 each	treatment	 condition,	 enabling	 their	multiplexed	analyses	 since	all	droplets	 can	be	stored	 and	 processed	 together,	 which	 highly	 increases	 the	 throughput.	 With	 the	established	 approach	 we	 can	 perform	 barcoding	 of	 each	 cells’	 transcriptome	according	to	the	drugs	it	was	exposed	to	in	the	droplet.	Thereby,	the	effects	of	drug	combinations	on	gene	expression	can	be	studied	in	a	highly	multiplexed	way	using	RNA-Sequencing.		We	applied	the	developed	approach	to	run	combinatorial	drug	screens	in	droplets	and	 analysed	 the	 effects	 of	 in	 total	 630	drug	 combinations	on	 gene	 expression	 in	
K562	cells.	The	low	number	of	cells	needed	(max.	2	million	cells)	for	such	screens,	could	enable	their	application	directly	on	tumor	biopsies,	 thus	paving	the	way	for	personalized	 therapy	 approaches.	 Since	 the	 established	 workflow	 is	 compatible	with	 single	 cell	 readouts,	 we	 also	 envision	 its	 application	 to	 analyse	 drug	resistances	in	heterogeneous	tumor	samples	on	the	single	cell	level.			 	
	 	 	
Zusammenfassung		
	Die	 meisten	 Krebsarten	 haben	 stark	 von	 der	 Entwicklung	 zielgerichteter	Medikamente	zur	Behandlung	von	Krebs	profitiert.	Jedoch	sind	diese	oft	kurzlebig	da	 viele	 Tumoren	 Resistenzen	 gegen	 die	 eingesetzten	 Medikamente	 entwickeln.	Tumorzellen	 können	 adaptive	 oder	 erworbene	 Resistenzen	 aufweisen,	 welche	häufig	durch	genetische	oder	nicht-genetische	Heterogenität	verursacht	wird.	Eine	mögliche	Lösung	ist	die	Behandlung	von	Krebs	mit	Medikamentenkombination	da	mit	diesen	mehrere	Ziele	in	Tumorzellen	gleichzeitig	angegriffen	werden.		Das	 Finden	 potenter	 Medikamentenkombinationen	 ist	 jedoch	 eine	 große	Herausforderung,	 da	 die	 Anzahl	möglicher	 Kombination	 immens	 ist.	 Zudem	 kann	die	 Heterogenität	 zwischen	 Patienten	 eine	 Behandlung	 zugeschnitten	 auf	individuelle	 Patienten	 notwendig	 machen	 und	 somit	 müssten	 Medikamente	 auf	Tumorzellen	 des	 entsprechenden	 Patienten	 getestet	 werden.	 Dies	 kann	 durch	miniaturisierte	 Medikamentenscreens	 unter	 der	 Verwendung	 von	 Tröpfchen-basierter	Mikrofluidik	 ermöglicht	werden.	Bisher	 gelang	 es	 jedoch	nur	den	Effekt	einer	 geringen	 Anzahl	 verschiedener	 Medikamentenkombinationen	 (55)	 in	größeren	Tropfen	(mehrere	Nanoliter)	auf	primäre	Tumorzellen	zu	testen.		Das	 Ziel	 dieser	 Dissertation	 war	 es	 einen	 Methode	 der	 Tröpfchen	 basierten	Mikrofluidik	 zu	 entwickeln,	 welche	 es	 ermöglicht	 eine	 hohe	 Anzahl	 an	Kombinationen	 in	 Picoliter	 großen	 Tröpfchen	 zu	 erzeugen.	 Zu	 diesem	 Zwecke,	haben	 wir	 eine	 Methode	 entwickelt,	 die	 es	 ermöglicht	 420	 Kombinationen	 von	Medikamenten	 in	 Tröpfchen	 zu	 generieren.	 Wir	 konnten	 eine	 signifikante	Erhöhung	möglicher	Kombination	erzielen,	 indem	wir	 eine	Ventil	 und	Mikrotiter-Platten	basierte	Injektion	von	Medikamenten	zur	Tröpfchen-Erzeugung	entwickelt	haben.		Zudem	 wurde	 eine	 DNA-basiertes	 Barcodeverfahren	 entwickelt,	 welches	 es	ermöglicht	alle	Kombination	gemeinsam	zu	prozessieren	und	analysieren	wodurch	der	Durchsatz	von	Screens	erheblich	gesteigert	werden	kann.	Des	weiteren	wurde	das	Barcodeverfahren	dazu	verwendet	das	Transkriptome	der	Zellen	entsprechend	der	 Medikamentenkombinationen	 zu	 kennzeichnen.	 Hierdurch	 kann	 der	 Effekt	welche	Medikamente	auf	die	Expression	von	Genen	in	Tumorzellen	haben,	anhand	von	RNA	Sequenzierung	untersucht	werden.	Wir	haben	das	entwickelte	Verfahren	
angewendet,	 um	die	Effekte	 von	 insgesamt	630	Medikamentenkombinationen	auf	die	Gene-Expression	 in	K562	Zellen	zu	untersuchen.	Die	geringe	Anzahl	an	Zellen	(max.	 2	Millionen),	 die	 für	 solche	Experimente	nötig	 sind,	 können	dazu	beitragen	dass	 diese	 zukünftig	 direkt	 mit	 Tumor-Biopsien	 durchgeführt	 werden.	 Da	 das	Verfahren	 es	 zudem	 ermöglicht	 einzelne	 Zellen	 zu	 untersuchen,	 könnte	 dieses	zukünftig	 dazu	 verwendet	werden	 die	 Effekte	 von	Medikamenten	 auf	 heterogene	Tumorproben	auf	der	Ebene	von	einzelnen	Zellen	zu	analysieren.				 	
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1. Introduction				
1.1. Microfluidics		The	term	microfluidics	refers	 to	approaches,	 in	which	small	amounts	of	 fluids	are	handled	 and	 analysed	 in	 structures	with	defined	 geometries	 (i.e.	 channels)	 at	 the	scale	 of	 micrometres.	 The	 fluid	 volumes	 handled	 in	 microfluidic	 devices	 range	between	10-6	and	10-18	litres	depending	on	the	dimensions	of	used	channels,	which	range	 between	 ten	 and	 several	 hundreds	 of	 micrometres	 (Whitesides,	 2006).	Microfluidic	 principles	 have	 been	 applied	 to	 systems	 used	 in	 biology	 long	 before	microfluidics	as	a	defined	technology	was	widely	used	in	the	field	of	life	sciences.	In	fluorescence	assisted	cell	sorting	(FACS)	a	sheath	fluid	is	used	to	focus	a	stream	of	cells	 into	a	 laser	beam,	enabling	high-throughput	analysis	of	single	cells	(Hulett	et	al.,	1969).	Another	example	is	the	use	of	capillary-array	electrophoresis	for	Sanger	sequencing,	 where	 the	 use	 of	 capillaries	 with	 an	 inner	 diameter	 of	 50	 µm	dramatically	 increased	 the	 sequencing	 throughput	 during	 the	 Human	 Genome	Project	(Dovichi	and	Zhang,	2000).	Here	a	reduction	 in	the	 fluid	volumes	used	for	the	analysis	of	samples	caused	an	increase	in	throughput.	The	use	of	sub-microliter	volumes	has	the	advantages	of	reduced	sample	consumption,	increased	sensitivity	due	 to	 lower	 diluting	 volumes	 and	 increased	 throughput.	 The	 transition	 of	microfluidics	from	capillary-based	systems	towards	more	sophisticated	devices	has	strongly	benefited	from	manufacturing	approaches	developed	in	the	field	of	semi-conductors:	 The	 establishment	 of	 lithographic	 methods	 allowed	 to	 produce	miniaturized	printed	circuit	boards	transporting	electrons,	and	these	methods	were	later	 on	 adapted	 to	 also	 enable	 the	 manufacturing	 of	 microfluidic	 channels	transporting	molecules	and	cells	on	silicon-based	microchips.	Fabrications	of	nano-	and	microstructures	for	micro-electronics	based	on	silicon	using	photolithography	was	 adapted	 by	 microfluidics	 to	 produce	 chips	 in	 which	 liquids	 are	 directed	
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through	 defined	 geometries	 (Whitesides,	 2006).	 Although	 in	 some	 early	 cases	microfluidic	was	done	in	silicon	channels,	the	development	of	soft	photolithography	made	microfluidics	 accessible	 for	 a	 larger	 research	 community	 and	 provided	 the	basis	 for	 its	 applicability	 in	 biology.	 Here,	 photolithography	 is	 used	 to	 produce	master	moulds	with	a	positive	relief	of	the	channel	structures.	Replicas	from	master	moulds	 are	 fabricated	 by	 pouring	 Poly-Di-Methyl-Siloxane	 (PDMS)	 over	 the	structures	and	 the	 cured	PDMS	casts	 are	 removed	 from	 the	moulds	and	 channels	are	sealed	by	covalently	bonding	it	to	glass	or	PDMS	(Duffy	et	al.,	1998).	This	allows	rapid	and	cheap	 fabrication	of	microfluidic	devices,	 in	which	 fluid	 flow	 is	 in	most	cases	 controlled	using	external	pumps	connected	with	devices	over	 inlets	 (Eicher	and	 Merten,	 2011).	 A	 detailed	 description	 of	 microfluidic	 device	 fabrication	techniques	and	operations	can	be	found	in	the	Material	and	Methods	section	of	this	thesis.	Besides	the	fabrication,	PDMS	has	the	advantage	of	being	biocompatible	due	to	 its	high	gas-permeability	and	 thus	allowing	 long	 term	culturing	and	 imaging	of	cells	(Huberts	et	al.,	2013;	Luni	et	al.,	2016),	tissues	and	organisms	(Choudhury	et	al.,	 2012;	 Sivagnanam	 and	 Gijs,	 2013)	 in	 microstructures	 using	 standard	 light	microscopy.				The	injection	of	fluids	into	channels	of	a	microfluidic	device	allows	precise	control	of	 transported	 reagents	or	 cells,	 since	 flow	velocities	 can	be	adapted	by	 changing	the	 injected	 volume	over	 time	 and,	 due	 to	 the	 low	 channel	 dimensions,	 turbulent	flow	is	avoided.	Instead	flow	in	a	microfluidic	channel	follows	laminar	flow	regimes,	since	 at	 the	 generally	 used	 scales	 viscous	 forces	 become	 dominant.	 This	phenomenon	can	be	explained	using	the	Reynolds	number	(Re),	which	gives	ratio	between	inertial	and	viscous	forces		
𝑅𝑒 =  𝜌𝜐𝐷!µ 	where	𝜌	is	the	fluid	density,	𝜐	velocity	of	the	fluid	and	µ	the	fluid	viscosity.	Since	𝐷!	is	defined	as	the	length	scale	of	the	system,	which	in	case	of	microfluidic	devices	is	in	 the	 range	 of	 micrometres,	 Reynolds	 numbers	 for	 such	 devices	 are	 generally	smaller	 than	 5	 (Vyawahare	 et	 al.,	 2010).	 Therefore,	 injected	 water-based	 fluids	behave	 like	 viscous	 fluids	 and	 form	 stable	 laminar	 flow	 regimes	 in	 a	microfluidic	channel.	Two	or	more	miscible	 fluids	 flowing	 in	parallel	 through	a	channel	do	not	mix	 with	 each	 other	 apart	 from	 diffusion,	 which	 depends	 on	 the	 Péclet	 number	
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(Pe).	Pe	is	given	by	the	channel	length	l,	the	fluid	velocity	v	and	diffusion	coefficient	D.		
𝑃𝑒 = 𝑙𝑣𝐷 	By	adapting	channel	dimensions	and	flow	rates	used	for	injection,	this	relationship	can	be	 exploited	 to	 generate	 complex	 concentration	gradients	within	microfluidic	channels.	How	the	described	and	further	principles	of	microfluidics	are	applied	 in	various	systems	will	be	illustrated	in	the	following	chapters.	
1.2. Single-phase	microfluidics		In	its	simplest	form	a	single-phase	microfluidic	system	can	be	a	chamber	providing	a	 micro-scale	 environment,	 with	 precise	 temporal	 control	 of	 its	 composition	 by	adaptations	 of	 the	 injected	 reagents.	 Yet	 these	 setups	 provide	 a	 powerful	 tool	 to	analyse	 and	perturb	 complex	 biological	 system	as	 recently	 described	by	 studying	signal	 dynamics	 during	 mouse	 embryonic	 development	 (Sonnen	 et	 al.,	 2018).	Embryonic	 tail	 buds	were	 placed	 in	 a	microfluidic	 chamber,	 where	 the	 effects	 of	temporally	 controlled	 drug	 pulses	 were	 studied	 using	 long-term	 imaging	 to	decipher	 the	 relationship	 between	 Wnt	 and	 Notch	 signalling	 during	 segment	formation.	Due	to	low	dimensions,	such	a	chamber	can	be	easily	modified	to	obtain	laminar	flow	of	two	or	more	reagents	by	their	continuous	injections.	This	allows	the	generation	of	different	environments	in	a	single	chamber	and	thereby	to	study	their	spatial	 and	 temporal	 effects	 on	 the	 development	 of	 organisms	 (Lucchetta	 et	 al.,	2005).			Furthermore,	 laminar	 flow	 in	 micro-channels	 can	 be	 used	 to	 generate	concentration	 gradients	 by	 adapting	 the	 channel	 length	 and	 flow	 rates	 to	 obtain	sufficient	 mixing	 by	 diffusion	 (Péclet	 Number	 <	 1)	 as	 fluids	 flow	 through	 the	channel	 (Kim	 et	 al.,	 2010).	 Gradients	 of	 chemokines	 find	 wide	 applications	 in	microfluidics	 to	 analyse	 their	 effects	 on	 cell	 migration.	 Rapid	 established	chemokine	 gradients	 (2	min)	were	 used	 to	 study	 effects	 of	 CCL21	 and	 CCL19	 on	dendritic	 cell	 migration	 and	 found	 different	 responses	 based	 gradient	concentrations	(Haessler	et	al.,	2011).	This	study	illustrates	how	fluid	dynamics	in	micro-channels	can	be	applied	to	complex	biological	systems	and	provides	the	basis	for	a	more	systematic	and	quantitative	analysis.		
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While	 the	 number	 of	 distinct	 environments	 generated	 by	 laminar	 flow	 is	 limited,	compartmentalization	 of	 microfluidic	 devices	 by	 valves	 are	 used	 to	 increase	 the	diversity	of	conditions	and	reactions	on	a	single	device.	Most	widely	used	are	Quake	valves,	which	make	use	of	the	elastic	nature	of	PDMS	to	open	and	close	channels	by	pneumatic	 pressure	 (Unger	 et	 al.,	 2000).	 In	 these	 more	 sophisticated	 designs,	channels	can	be	closed	to	facilitate	compartments	disconnected	from	other	regions	of	 the	 chip.	Most	 prominently,	 these	 valves	 are	 used	 for	 single	 cell	 sequencing	 of	genomes	(Fan	et	al.,	2011;	Wang	et	al.,	2012)	and	transcriptomes	in	the	Fluidigm	C1	system	 by	 trapping	 and	 barcoding	 of	 single	 cells	 in	 chambers.	 However,	 valve-based	compartmentalization	has	also	proven	its	power	for	other	systems	genomic	approaches	such	as	 identification	of	binding	motifs	 for	a	 large	set	of	 transcription	factors	(Isakova	et	al.,	2017).	Furthermore,	confining	single	cells	in	chambers	using	valves	increases	the	sensitivity	for	various	proteomic	approaches	since	the	dilution	factor	of	proteins	released	from	a	cell	can	be	reduced	dramatically.	This	enabled	the	simultaneous	 detection	 of	 secreted	 proteins	 from	 thousands	 of	 single	 T-cells	 by	antibodies	 and	 could	 identify	 functional	 heterogeneity	 between	 cytotoxic	 T-cells	isolated	from	cancer	patients	(Ma	et	al.,	2011).	Since	convectional	secretion	assays	(e.g.	ELISA)	 cannot	detect	 several	 secreted	proteins	at	once	and	 furthermore	 lack	the	 sensitivity	 to	 distinguish	 between	 the	 numbers	 of	 secreted	 proteins	 down	 to	several	 hundreds,	 these	 findings	 would	 have	 been	 impossible	 to	 achieve	 in	conventional	tissue	culture	formats	such	as	micro-titre	plates.	
1.3. Two-phase	droplet-based	microfluidics	Valve-based	compartmentalization	in	a	one-phase	system	is	still	 limited	to	several	thousand	 chambers	 per	 device.	 Using	 two-phase	 systems,	 this	 limitation	 can	 be	overcome	 by	 several	 orders	 of	 magnitude.	 Two	 immiscible	 reagents	 are	 used	 to	generate	 discrete	 units	 from	 one	 reagent	 by	 a	 continuous	 phase	 of	 the	 other	reagent.	For	this	work,	the	two	phases	refer	to	a	continuous	oil	phase,	which	is	used	to	form	droplets	 from	an	aqueous	phase.	Channel	geometries	are	used	to	produce	droplets	 from	an	aqueous	phase	with	defined	size	and	content.	Depending	on	 the	geometries	 of	 the	 channels	 and	 the	 flow	 rates,	 the	 volumes	 of	 produced	 droplets	are	 between	 50	 fl	 and	 1	 nl.	 Since	 each	 of	 these	 droplets	 form	 a	 confined	compartment,	 each	 droplet	 is	 considered	 as	 a	 reaction	 vessel,	 which	 can	 be	produced	in	a	passive	process	at	kilohertz	frequencies	(kHz).	The	basic	concept	of	
	 	 I	N	T	R	O	D	U	C	T	I	O	N	
	 	 23	
droplet	production	is	to	form	an	interface	between	two	immiscible	fluids	(e.g.	water	and	 oil),	 followed	 by	 the	 passive	 segregation	 of	 one	 phase	 (water)	 into	 the	continuous	 phase	 (oil).	 Early	 reports	 used	 a	 co-flow	 system	 in	which	 the	 tip	 of	 a	capillary	 is	 used	 to	 inject	 one	 phase	 into	 a	 stream	 of	 an	 immiscible	 phase.	 The	stream	 of	 the	 continuous	 phase	 breaks	 the	 aqueous	 phase	 into	 droplets	(Umbanhowar	et	al.,	2000).	Then	Quake	and	colleagues	introduced	the	concept	of	a	T-junctions	for	droplet	production.	Here,	droplets	were	formed	by	two	immiscible	phases	 being	 injected	 orthogonal	 to	 each	 other.	 The	 continuous	 phase	 shears	 off	droplets	at	 the	T-junction,	whose	size	can	be	adapted	by	changing	the	ratio	of	 the	flow	velocities	(Thorsen	et	al.,	2001).	A	third	approach	for	droplet	production	was	introduced,	 which	 makes	 use	 of	 a	 flow-focussing	 junction.	 The	 formation	 of	droplets	at	a	 flow-focussing	 junction	 is	achieved	by	 the	concentric	acceleration	of	the	dispersed	phase	by	the	continuous	phase	followed	by	a	constriction	that	opens	into	 a	 wider	 channel.	 The	 acceleration	 of	 an	 aqueous	 phase	 by	 a	 continuous	 oil	phase,	 results	 in	 a	 narrow	 aqueous	 stream	 that	 breaks	 into	 droplets	 due	 to	 the	constriction	 (Anna	 et	 al.,	 2003).	 In	 order	 to	 form	a	 stable	 emulsion	 for	 long-term	storage,	 the	 surface	 tension	 between	 the	 immiscible	 phases	 needs	 to	 be	 reduced,	which	 is	achieved	by	adding	surfactant	 to	 the	continuous	phase.	Since	 fluorinated	oils	are	widely	used	as	a	continuous	phase	for	droplet	production,	surfactants	made	of	perfluorinated	poly-ethers	linked	to	polyethylene-glycol	were	developed	(Holtze	et	al.,	2008).	The	popularity	of	fluorocarbon	oils	and	surfactants	arises	from	its	high	biocompatibility	 (Giaever	 and	 Keese,	 1983),	 its	 high	 oxygen	 and	 carbon	 dioxide	solubility	 (Lowe	 et	 al.,	 1998)	 and	 its	 low	 solubility	 of	 hydrocarbons	 (Lonostro,	1995).	 These	 properties	 allow	 the	 encapsulation	 of	 cells	 into	 droplets	 and	 their	incubation	in	droplets	over	several	days	(Clausell-Tormos	et	al.,	2008).		
1.3.1. Droplet	manipulations	The	small	volume	but	high	numbers	of	samples	used	in	droplet-based	experiments,	made	it	necessary	to	develop	specialized	tools	to	perform	automated	manipulations	of	droplets	after	they	have	been	generated.	After	off-chip	incubations,	droplets	can	be	reinjected	into	microfluidic	devices	for	their	analysis	and	manipulations.	Droplet	analysis	often	 includes	 fluorescence-based	measurements	 for	the	quantification	of	biochemical	 assays	 after	 an	 incubation	 time.	 For	 this	 purpose	 a	 laser	 beam	 is	focussed	 onto	 the	 channel	 network	 and	 emitted	 light	 is	 quantified	 by	
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photomultiplier	 tubes	 (PMTs).	Due	 to	 the	 low	 timescale	of	 fluorescence	detection	(sub-milliseconds),	it	is	well	suited	for	high-throughput	droplet-based	microfluidics	(Solvas	 et	 al.,	 2011).	 Droplet	 manipulation	 steps	 include	 processes	 that	 aim	 at	mimicking	liquid	handling	steps	performed	at	macro-scale.		
Droplet	fusion		Merging	 of	 droplets	 is	 used	 to	 add	 reagents	 to	 start	 or	 stop	 reactions	 within	 a	droplet	 or	 for	 dilution	 of	 droplet	 content.	 This	 operation	 is	 comparable	 to	 a	pipetting	 step	 used	 for	marco-scale	 liquid	 handling.	Merging	 two	droplets	 can	 be	achieved	in	a	passive	process	in	which	two	droplets	are	brought	into	contact	while	their	interfaces	are	destabilized	by	an	expansion	of	the	channel	width	(Bremond	et	al.,	 2008).	 Pairing	 and	 fusing	 two	 droplets	 was	 also	 demonstrated	 at	 kHz	frequencies	 by	 injecting	 surfactant	 stabilized	 droplets	 into	 a	 channel	 and	 pairing	each	 of	 them	 with	 a	 non	 surfactant-stabilized	 droplet	 (Mazutis	 et	 al.,	 2009).	 An	active	way	of	merging	two	droplets	is	their	contact-based	fusion	under	an	electrical	field	generated	by	electrodes	along	the	channel	(Priest	et	al.,	2006).	These	methods	are	 powerful	 for	 running	 sequential	 and	 complex	 reactions	 within	 the	 same	droplets	 like	 the	 fragmentation	 of	 DNA	 followed	 by	 its	 amplification	 (Lan	 et	 al.,	2016).		Similar	 to	 droplet	 fusion,	 reagents	 can	 be	 added	 to	 pre-existing	 droplets	 in	 a	process	 called	 pico-injection.	 Surfactant	 stabilized	 droplets	 are	 injected	 into	 a	microfluidic	 device	 and	 spaced	 out	 using	 oil.	 Droplets	 pass	 through	 a	 narrow	channel	 and	 pass	 by	 a	 pico-injector	 nozzle,	 which	 is	 used	 to	 inject	 reagents.	 An	electric	 field	 generated	 by	 an	 electrode	 opposite	 of	 the	 nozzle	 destabilizes	 the	surfactant	 film	 surrounding	 droplets	 and	 allows	 reagents	 from	 the	 nozzle	 to	 be	injected	into	each	droplet	passing	by	(Abate	et	al.,	2010).	More	details	can	be	found	in	the	material	and	methods	chapter	of	this	thesis.		
Droplet	Sorting		Sorting	 of	 droplets	 is	 performed	 to	 enrich	 specific	 droplets	 based	 on	 their	properties.	Fluorescence	activated	droplet	sorting	(FADS)	is	considered	the	droplet	based	 counterpart	 to	 FACS	 and	 does	 include	 the	 detection	 of	 a	 fluorescence	reporter	followed	by	a	sorting	decision	that	results	in	the	collection	or	disposal	of	a	droplet.	 The	 main	 advantage	 compared	 to	 FACS	 based	 sorting	 is	 that	 instead	 of	
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sorting	cells,	entire	assays	(including	soluble	reagents)	are	sorted	and	thereby	rare	screening	results	can	be	enriched	from	a	large	population	(Baret	et	al.,	2009).	The	basic	 concept	 of	 sorting	 droplets	 is	 their	 detection	 upstream	 of	 a	 channel	bifurcation	and	based	on	the	measured	signal,	the	trajectory	of	the	droplet	is	either	changed	 to	direct	droplets	 into	 the	 collection	 channel	 or	droplets	 are	 send	 to	 the	waste	by	not	 interfering	with	 the	streamline.	By	applying	an	electric	 field	when	a	droplet	 of	 interest	 passed	 the	 detection	 point,	 the	 droplet	 is	 deflected	 into	 the	collection	 channel	 (Baret	 et	 al.,	 2009).	 Such	 methods	 were	 used	 for	 directed	evolution	 of	 enzymes	 encapsulated	 along	 with	 fluorescence	 reporter	 substrates.	Iterative	 selections	 of	 horseradish	 peroxidase	 by	 FADS	were	 performed	 to	 select	enzymes	with	increased	catalytic	activity	from	a	library	with	108	mutants	in	about	10	hours	which	is	a	thousand	fold	increase	in	speed	compared	to	conventional	plate	based	screens	(Agresti	et	al.,	2010).	
1.3.2. Cells	in	droplets	As	already	discussed	before,	 the	compartmentalization	of	cells	 into	small	volumes	is	advantageous	for	many	assays	since	the	analytic	performance	can	be	enhanced.	Encapsulating	cells	into	droplets	is	therefore	of	great	interest	since	it	allows	rapid	production	of	cell	containing	compartments.	By	injection	of	a	cell	suspension	into	a	device	 for	 droplet-generation,	 the	 segregation	 of	 the	 suspension	 into	 droplets	results	 in	 the	distribution	of	 cells	 into	discrete	units.	The	number	of	 cells	 in	 each	droplet	is	dependent	on	the	cell	concentration	and	the	size	of	the	droplet.	Since	the	droplet	size	is	constant	at	a	given	flow	rate,	the	number	of	cells	per	droplet	can	be	controlled	 by	 adjusting	 the	 density	 of	 cells,	 resulting	 in	 a	 Poisson	 distribution	 of	probabilities	 for	 the	 number	 of	 cells	 per	 droplet.	 For	 cell	 concentrations	 smaller	than	106	cells/ml	and	660	pl	sized	droplets,	the	probability	of	empty	droplets	is	the	highest	 (~0.6),	 followed	 by	 a	 probability	 of	~0.3	 for	 having	 one	 cell	 in	 a	 droplet	(Clausell-Tormos	et	al.,	2008).	Due	to	the	low	probability	of	obtaining	droplets	with	more	than	one	cell	(p<0.07)	and	the	high	frequency	of	droplet	production,	droplet	based	 microfluidics	 has	 become	 a	 popular	 tool	 to	 study	 single	 cells.	 By	encapsulating	 heterogeneous	 cell	 populations	 into	 droplets,	 each	 droplet	containing	 a	 single	 cell	 represents	 a	 genetic	 or	 phenotypic	 unique	 unit	with	 high	local	 concentrations	 of	 metabolites.	 This	 advantage	 was	 used	 in	 a	 functional	antibody	screen	using	hybridoma	cells	 (El	Debs	et	al.,	2012).	This	 is	a	well-suited	
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example	 to	 illustrate	 the	 power	 of	 droplet-based	 microfluidics:	 A	 by	 definition	heterogeneous	cell	population	was	encapsulated	at	 the	single	cell	 level	 to	analyse	the	 function	 of	 proteins	 secreted	by	 the	 cells	 and	 select	 for	 droplets	 containing	 a	cell	 of	 interest.	 Translating	 hybridoma	 cell	 based	 antibody	 screens	 into	 droplet-based	 microfluidic	 can	 accelerate	 the	 discovery	 of	 new	 potent	 monoclonal	antibodies.	Due	to	the	low	dilution	of	antibodies	in	picolitre	volumes,	it	is	feasible	to	study	 antibodies	 secreted	 from	 primary	 B-cells	 since	 femto-gram	 concentrations	are	detectable	(Eyer	et	al.,	2017;	Shembekar	et	al.,	2018).	A	limitation	for	screening	cells	 in	 droplets	 is	 long-term	 cultivation	 due	 to	 depletion	 of	 media	 and	 the	accumulation	 of	 toxic	 metabolites.	 The	 cell	 viability	 of	 cells	 in	 picolitre-sized	droplets	generally	drops	after	two	or	three	days	(Clausell-Tormos	et	al.,	2008).	This	problem	 can	 be	 partially	 compensated	 by	 increasing	 the	 droplet	 size.	 Another	possibility	is	the	co-encapsulation	of	cells	with	agarose,	which	polymerizes	to	form	solid	spheres.	This	allows	removal	of	the	oil	phase	and	long-term	cultivation	of	cells	surrounded	by	media	to	form	spatially	defined	spheroids	(Sart	et	al.,	2017).		
1.4. Drug	combinations	The	 development	 of	 new	 drugs	 can	 be	 very	 expensive,	 time	 consuming	 and	approval	 of	 new	 compounds	 is	 difficult.	 The	 two	 major	 reasons	 for	 drugs	 not	getting	an	approval	 for	the	market	are	 low	efficacies	and	or	safety	concerns	(Kola	and	 Landis,	 2004).	 Low	 efficacies	 can	 be	 caused	 by	 redundancies	 in	 signalling	networks,	 resulting	 in	 the	 activation	 of	 alternative	 routes	 to	 compensate	 for	 the	inhibition	of	one	protein	(Jia	et	al.,	2009).	Additionally,	preclinical	studies	on	animal	models	 often	 lack	 clinical	 transferability	 and	 therefore	 efficacies	 for	 drug	candidates	 can	 vary	 between	 preclinical	 and	 clinical	 phases	 (Hackam	 and	Redelmeier,	 2006).	 Toxicity	 of	 drugs	 can	 arise	 from	 drug	 pleiotropy	 due	 to	 non-selective	 interactions	 with	 off-targets	 (Klaeger	 et	 al.,	 2017)	 and	 from	 diverse	functions	of	drug	targets.	Drug	combinations	have	the	potential	 to	overcome	both	problems,	 by	 increasing	 efficacies	 of	 drug	 treatments	 and	 thereby	 reducing	 the	toxicity	 since	 lower	 concentrations	 can	 be	 used.	 Furthermore,	 drug	 combinations	from	 pre-existing	 and	 approved	 drugs	 offer	 a	 cheap	 and	 fast	 way	 to	 overcome	resistances	 and	 to	 define	 new	 treatments	with	 enhanced	 efficacies	 and	 therefore	play	an	important	role	in	the	development	of	new	treatment	strategies.	
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A	drug	combination	can	be	defined	as	good,	when	the	effect	of	 the	combination	is	stronger	 than	 the	 summed	 effect	 of	 the	 individual	 drugs,	 an	 effect	 called	 drug	synergy.	 Synergistic	 effects	 are	 caused	 by	 three	main	 actions:	 Anti-counteractive	actions,	complementary	actions	and	 facilitating	actions	 (Sun	et	al.,	2013).	An	anti-counteractive	actions	result	from	inhibiting	the	response	caused	by	one	drug	with	a	second	 drug.	 The	 disruption	 of	 the	 peptidoglycan	 cell	 wall	 by	 one	 drug	 would	eventually	activate	 the	cell	wall	repair	machinery.	The	additional	 inhibition	of	 the	cell	wall	repair	system	with	a	second	drug	can	have	a	synergistic	effect,	since	it	can	accelerate	 bacterial	 cell	 death.	 Drug	 synergy	 from	 complementary	 actions	 is	induced	by	drugs	that	target	proteins	of	the	same	or	different	pathways,	which	are	important	 for	 the	 regulation	 of	 the	 same	 biological	 functions.	 Thereby	 bypass	reactions	 by	 activation	 of	 alternative	 signalling	 routes	 can	 be	 prevented.	 This	approach	 is	 common	 for	 therapies	used	 in	cancer	where	several	drugs	aim	at	 the	induction	of	apoptosis.	In	synergy	due	to	facilitating	actions	one	drugs	improves	the	efficacy	 of	 another	 drug.	 Such	 synergy	 was	 observed	 for	 the	 inhibition	 of	endogenous	ligands	by	one	drug	resulting	in	an	enhanced	binding	of	a	second	since	the	competition	for	binding	the	target	was	reduced	(Jia	et	al.,	2009).	The	increase	in	drug	 efficacies	 often	 allows	 treatments	 at	 lower	 concentrations	 and	 thereby	 a	reduction	 in	 toxicity	 is	 achieved.	 Besides	 synergism,	 drug	 combinations	 show	antagonistic	effects	caused	by	interfering	or	counteractive	actions.	Treatment	with	a	drug	that	incorporates	into	the	DNA	in	combination	with	a	drug	that	induces	cell	cycle	arrest	could	have	a	counteractive	effect.		Finding	good	drug	 combinations	 is	 challenging	 since	 the	number	of	 combinations	increases	exponentially	with	every	new	drug	and	thus	often	exceeds	feasibility.	All	pairwise	combination	of	FDA-approved	drugs	(~1500)	results	 in	over	one	million	combinations.	In	order	to	accelerate	the	process	of	finding	new	combinations,	high-throughput	 drug	 screening	 approaches	 and	 computational	 methods	 have	 been	developed.	Multiplexed	drug	screenings,	in	which	compounds	are	pooled	and	then	screened	 for	 synergy,	 decreases	 the	 number	 of	 combinations	 in	 a	 first	 screening	round.	Pools	of	drugs	with	enhanced	efficacies	were	 tested	 in	 a	 second	 screening	round	to	identify	active	combinations	(Borisy	et	al.,	2003;	Tan	et	al.,	2012).	Tan	et	al.	used	this	approach	to	screened	5x105	drug	combinations	with	synergistic	effects	against	 HIV	 replication	 and	 used	 less	 than	 3%	 of	 the	 wells	 compared	 to	conventional	pairwise	drug	screens.	Drug	combinations	harbour	great	potential	for	
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cancer	 treatment	 as	 demonstrated	 by	 a	 recent	 study	 that	 predicted	 and	 tested	combinations	 from	 218	 compounds	 to	 find	 synergistic	 drug	 pairs	 on	 cells	 from	leukaemia	 patients	 (He	 et	 al.,	 2018).	 The	 use	 of	 robotics	 for	 large-scale	 liquid	handling	on	one	hand	enables	to	screen	high	numbers	of	drug	combinations	but	on	the	 other	 hand	 these	 screens	 are	 expensive	 and	 often	 not	 feasible	 for	 biological	samples	 with	 small	 cell	 numbers	 like	 tumor	 biopsies.	 Computational	 approaches	aim	at	overcoming	 these	 limitations	by	using	 training	data	 to	predict	 sensitivities	towards	 drugs.	 Pharmacogenomics	 integrates	 high	 dimensional	 datasets	 from	multiple	 sources	 (genomics,	 transcriptomics,	proteomics	etc.)	and	drug	responses	to	build	models,	which	associate	genotypes	and	phenotypes	with	drug	sensitivities.	These	models	provide	predictions	on	how	a	drug	response	is	affected	by	genotypes	or	phenotypes	and	thereby	knowledge	on	multiomics	data	from	patients	or	disease	models	can	be	used	to	tailor	treatments	(Bansal	et	al.,	2014;	Menden	et	al.,	2018).	Crucial	 for	 good	 predictions	 of	 drug	 combinations	 is	 the	 availability	 of	 large	training	datasets	and	public	available	resources	like	databases	for	pathway	activity	and	 drug	 properties.	 The	 lack	 of	 medical	 relevant	 training	 datasets	 (e.g.	 drug	screenings	 on	 tumor	 biopsies)	 often	 results	 in	 a	 reduced	 translatability	 of	computational	models.	Additionally,	 the	 readouts	of	 conventional	drug	screenings	are	 relative	 simple	 (e.g.	 growth	 reduction)	 and	 do	 not	 necessarily	 account	 for	dynamic	 responses	 of	 drug	 treatments.	 Therefore,	 the	 development	 of	 new	strategies	 for	 combinatorial	 drug	 screenings	 with	 deep	 characterizations	 of	 drug	response	could	provide	a	powerful	solution	for	defining	new	treatments	based	on	drug	combinations.		
1.4.1. Drug	screening	and	microfluidics:	A	perfect	match?	In	 large-scale	 screens	 using	 robotics,	 a	 reduction	 in	 reagents	 and	 material	 is	achieved	 by	 increasing	 the	 number	 of	wells	 per	micro-titre	 plates.	 Droplet-based	microfluidics	 offers	 a	 dramatic	 increase	 in	 the	 number	 of	 compartments	 since	volumes	 drop	 to	 picolitre	 scale,	 resulting	 in	 a	 massive	 reduction	 in	 sample	consumption.	 Performing	 drug	 screens	 in	 droplets	 seems	 like	 a	 great	 solution,	especially	for	drug	combinations.	Despite	its	great	potential	to	enable	cheaper	and	faster	screens	of	drug	combinations,	microfluidics	was	and	still	is	lacking	behind	its	promise.	 This	 discrepancy	 is	 due	 several	 limitations	 that	 arise	 when	 translating	drug	screens	into	droplet-based	microfluidics.	A	bottleneck	for	generating	chemical	
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diverse	droplets	is	that	the	composition	of	the	aqueous	phase	injected	into	a	drop-maker	needs	to	be	diverse	as	well.	For	emulsions	with	chemically	diverse	droplets,	different	compounds	must	be	loaded	onto	a	microfluidic	device,	which	is	very	slow	(minutes)	compared	to	droplet	production	(up	to	several	kHz)	and	thus	limits	the	throughput.	Stabilizing	droplets	with	surfactant	generally	occurs	above	the	critical	micelle	 concentration	 and	 consequently	 micelle	 formation	 is	 a	 common	phenomenon	in	emulsions.	Since	micellar	structures	can	transport	small	molecules	between	droplets,	retention	of	a	compound	within	droplets	depends	on	its	chemical	properties	 (Gruner	 et	 al.,	 2016).	 Efficacies	 of	 drug	 combinations	 are	 generally	assessed	 by	 determining	 a	 reduction	 in	 growth,	 which	 depends	 on	 long-term	incubations	(e.g.	72h).	However,	at	these	timescales	depletion	of	growth	media	can	become	 problematic	 when	 using	 subnanolitre	 volumes.	 Additionally,	 the	 rate	 in	which	 cells	 proliferate	 in	 droplets	 is	 slower	 as	 compared	 to	 plate-based	 systems	and	 limited	 to	 suspension	 cells	 (Clausell-Tormos	 et	 al.,	 2008).	 Furthermore,	 in	plate-based	drug	screens	each	drug	is	assigned	to	a	specific	well	on	a	plate,	allowing	its	 identification	 and	 pairing	 of	 treatment	 conditions	 with	 assay	 readouts.	 Free-floating	 droplets	 of	 an	 emulsion	 stored	 together	 in	 a	 tube	 have	 no	 spatial	 order.	However,	 information	 on	 droplet	 contents	 is	 crucial	 for	 the	 identification	 of	 hits.	Several	 studies	 have	 demonstrated	 how	 these	 limitations	 can	 be	 overcome	 or	avoided.		A	 first	 proof-of-concept	 study	 performed	 drug	 screens	 in	 droplets	 used	 a	 drug	library	 containing	 Mitomycin	 C	 at	 8	 different	 concentrations,	 which	 was	encapsulated	 into	 droplets.	 Each	 concentration	 was	 encoded	 by	 a	 unique	concentration	of	 a	 fluorescence	dye	enabling	 their	detection.	Droplets	were	 fused	with	droplets	containing	cells	and	after	an	 incubation	of	24h	cell	viability	and	cell	death	 was	 measured	 (Brouzes	 et	 al.,	 2009).	 The	 power	 of	 droplet-based	microfluidics	for	screening	compound	libraries	was	shown	by	Miller	and	colleagues	who	made	use	of	dispersion	to	dilute	samples	in	a	tubing.	Thereby	high-resolution	dose-response	relationships	(10,000	concentrations)	between	an	enzyme	and	more	than	700	compounds	were	analysed	(Miller	et	al.,	2012).	Here	concentrations	were	also	encoded	by	the	dilution	of	a	fluorescence	dye	and	substrate	conversion	by	the	enzyme	was	measured	 only	 a	 few	minutes	 after	 the	 encapsulation	 and	 thus	 drug	exchange	 was	 negligible.	 While	 these	 two	 approaches	 only	 screened	 single	compounds,	 the	 encapsulation	 of	 pairwise	 combinations	 required	 more	 complex	
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strategies.	 Generation	 of	 drug	 combinations	 in	 droplets	 was	 achieved	 by	 droplet	fusion	 of	 two	 droplets	 containing	 a	 single	 compound	 or	 valve-based	 approaches	where	compounds	from	several	inlets	were	encapsulated	into	droplets.		To	exemplify	valve-based	approaches,	a	recently	published	workflow	developed	in	our	 laboratory	will	be	described.	Valves	were	applied	 to	produce	combinations	of	drugs	 in	 large	droplets	called	plugs	(~500	nL)	stored	sequentially	 in	 tubings.	The	valve	system	was	set	up	by	using	the	pins	of	braille	display,	normally	used	for	blind	people	to	read,	to	close	and	open	channels.	A	microfluidic	chip	bound	to	an	elastic	membrane	 is	aligned	with	 its	 channels	on	 top	of	 the	pins	and	 their	actuation	was	used	 to	either	direct	 injected	drugs	 for	plug	production	or	 the	waste	outlet.	Since	the	 produced	 plugs	were	 stored	 in	 a	 sequential	 order	 using	microfluidic	 tubings,	the	 information	 on	 plug	 composition	 was	 maintained.	 Additionally,	 plugs	 were	spaced	 out	 by	 mineral	 oil	 preventing	 their	 coalescence	 so	 that	 no	 surfactant	 for	their	stabilization	was	necessary	preventing	surfactant-based	drug	exchange.	In	the	presented	 study	 this	 system	was	 used	 to	 screen	 tumor	 biopsies	 against	 45	 drug	combinations	 (Eduati	 et	 al.,	 2018).	The	 low	cell	number	necessary	 in	each	 screen	allowed	 testing	 drug	 combinations	 directly	 on	 tumor	 biopsies.	 The	 valve-based	approach	presented	by	Eduati	et	al.	was	used	and	developed	into	the	workflow	for	screening	drug	combinations	in	picolitre-sized	droplets	presented	in	this	thesis.		
1.5. Next-generations	sequencing	and	microfluidics	The	 development	 of	 todays	 widely	 used	 sequencing	 platforms	 was	 largely	dependent	 on	 microfluidics.	 Emulsion	 PCR	 based	 Roche	 454	 sequencing	 or	 flow	chambers	 for	 solid-phase	 based	 sequencing	 used	 by	 Illumina	 systems	 apply	microfluidic	 principles	 such	 as	 reduction	 in	 sample	 volumes	 to	 perform	 high-throughput	sequencing	(Metzker,	2010).	Whereas	standard	protocols	for	preparing	sequencing	 libraries	 does	 not	 include	 microfluidic	 workflows,	 the	 advantages	 of	compartmentalizing	 reactions	 during	 these	 steps	 is	 becoming	 more	 popular,	especially	 for	 single	 cell	 sequencing	 assays.	 High-throughput	 sequencing	 or	 next-generation	 sequencing	 (NGS)	 of	 genomes	 relies	 on	 the	 fragmentation	 of	 input	material	(i.e.	Genomes).	Millions	of	DNA-fragments	are	sequenced	and	the	obtained	reads	are	subsequently	aligned	to	a	reference	genome.	Due	to	amplification	errors	between	 different	 fragments	 during	 library	 preparation,	 the	 coverage	 over	 a	
	 	 I	N	T	R	O	D	U	C	T	I	O	N	
	 	 31	
genome	 (number	 of	 reads	 at	 a	 certain	 position)	 often	 fluctuates,	 which	 causes	errors	when	detecting	copy	number	variations.	Emulsifying	single	DNA	fragments	into	 droplets	 for	 their	 amplification	 reduces	 amplification	 biases	 and	 results	 in	 a	uniform	coverage	of	 genomes	even	 for	 single	 cells	 (Fu	et	 al.,	 2015).	 Furthermore,	short-read	sequencing	for	de	novo	sequencing	or	sequencing	of	mixed	populations	is	difficult,	since	short	reads	need	to	be	assembled	into	genomes.	Barcoding	of	DNA	in	 droplet	 offers	 a	 potential	 solution	 as	 shown	 by	 Lan	 and	 colleagues:	 The	encapsulation	 of	 long	DNA	 templates	 (~5	Kb)	 into	 droplets	 for	 amplification	 and	fragmentation	was	 followed	 by	 a	 barcoding	 step	 (Fig.	 1.1A).	 Droplets	 containing	barcoded	primers	were	fused	with	droplets	of	fragmented	DNA	and	in	an	overlap-extension	 PCR	 all	 fragments	 derived	 from	 one	 template	 were	 labelled	 with	 one	barcode	(Lan	et	al.,	2016).	By	sequencing	 the	barcode	and	 the	DNA	 fragments,	all	fragments	 can	 be	 assigned	 to	 their	 original	 template	 DNA,	 simplifying	 their	assembly.	 This	 method	 was	 further	 developed	 and	 applied	 to	 barcode	 genomes	from	 single	 prokaryotic	 cells	 and	 thus	 enables	 single	 cell	 genome	 sequencing	 of	diverse	bacteria	populations	(Lan	et	al.,	2017).		NGS	 is	 also	widely	 used	 as	 a	method	 to	 sequence	 all	mRNA	molecules	 present	 in	cells,	 the	 so-called	 transcriptome,	 by	 reverse	 transcribing	 them	 into	 cDNA.	Sequenced	 fragments,	 or	 reads,	 are	 subsequently	 aligned	 to	 a	 reference	 genome.	The	quantification	of	expression	levels	for	certain	genes	allows	making	statements	on	the	cellular	state.	Therefore,	RNA-Sequencing	(RNA-Seq)	has	become	extremely	popular	 for	 the	 analysis	 of	 transcriptomes	 from	 single	 cells	 (scRNA-Seq),	 since	heterogeneous	cell	populations	can	be	analysed	at	great	resolution	and	throughput.	Here,	 the	 capacity	 of	 droplet-based	 microfluidics	 for	 compartmentalizing	 single	cells	has	become	a	powerful	tool.	Single	cell	are	encapsulated	into	droplets	where	each	cell’s	transcriptome	is	labelled	with	a	unique	DNA-barcode	(Fig.	1.1B,	C).	By	paired	 sequencing	 of	 barcodes	 and	 cDNA	 fragments,	 each	 read	 is	 assigned	 to	 a	barcode	 and	 thus	 to	 a	 single	 cell	 (Klein	 et	 al.,	 2015;	Macosko	 et	 al.,	 2015).	 These	methods	(Drop-Seq	and	inDrop)	allow	high-throughput	sequencing	of	thousands	of	single	 cell	 due	 to	 randomly	 distributing	 DNA-barcodes	 together	 with	 cells	 into	droplets	
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Fig	1.1:	Barcoding	approaches	in	droplet-based	microfluidics	 	
(A)	 Barcoding	of	DNA	 templates	as	described	by	 Lan	et	al.:	 Single	DNA	 template	are	encapsulated	
into	droplets	together	with	reagents	for	their	amplification.	Droplets	containing	amplified	templates	
are	merged	with	droplets	containing	transposases	resulting	in	the	fragmentation	of	DNA	templates	
and	the	 introduction	of	constant	adapters.	Each	droplet	with	fragments	from	one	DNA	template	 is	
merged	with	a	droplet	containing	a	unique	DNA	barcode	and	PCR	reagents.	Upon	fusion,	a	constant	
part	 in	 the	 barcode	 sequence	 hybridizes	 to	 a	 constant	 adapter	 and	 fragments	 are	 barcoded	 by	
overlap-extension	PCR.	 (B)	Barcoding	of	mRNA	using	Drop-Seq:	Single	 cells	and	beads	 coated	with	
barcoded	primers	are	encapsulated	 into	droplets.	Cells	are	 lysed	and	 released	mRNA	hybridizes	 to	
poly-dT	sequences	of	the	barcoded	primers.	Droplets	are	broken	to	purify	beads	and	mRNA.	Reverse	
transcription	of	mRNA	into	cDNA	results	in	barcoding	of	all	mRNA	molecules	from	one	cell	with	a	cell	
specific	barcode	and	a	unique	molecular	identifier	(UMI).	(C)	Barcoding	of	mRNA	with	inDrop:	Single	
cells	 are	 encapsulated	 together	 with	 hydrogel	 beads	 containing	 barcodes.	 Barcodes	 are	 released	
from	 the	 hydrogels	 and	 mRNA	 from	 lysed	 cells	 hybridizes	 to	 their	 poly-dT	 sequences.	 Reverse	
transcription	is	directly	carried	out	in	droplets	resulting	in	the	barcoding	of	mRNA	from	one	cell	with	
a	 cell	 specific	 barcode	 and	UMIs.	 The	 T7	 promoter	 allows	 linear	 amplification	 of	 cDNA	 by	 in-vitro	
transcription	of	barcoded	cDNA	after	they	are	released	from	droplets.			 	
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1.6. The	biology	of	cancer		Cancer	 is	 a	 disease	 in	 which	 genomic	 changes	 result	 in	 the	 malignant	transformation	 of	 cells.	 Those	 cells	 (called	 cancer	 or	 tumor	 cells)	 are	 defined	 by	uncontrolled	cell	division	and	the	capability	to	 invade	other	tissues	(Hanahan	and	Weinberg,	 2000).	 According	 to	 the	 International	 agency	 for	 research	 on	 cancer,	14.1	million	new	cases	of	cancer	were	reported	worldwide	in	2012	and	8.2	million	people	died	 from	 cancer.	 There	 are	 several	 types	 of	 cancer,	 defined	by	 the	 tissue	they	originated	from.	Lung	cancer,	prostate	cancer,	colorectal	cancer	and	stomach	cancer	 have	 the	 highest	 prevalence	 in	 males,	 whereas	 females	 suffer	 most	frequently	from	breast	cancer,	colorectal	cancer,	lung	cancer	and	cervical	cancer.		
1.6.1. Cancer	as	a	genetic	disease		Natural	genetic	variation	is	crucial	for	any	population	since	it	provides	the	basis	for	better	adaptation.	The	fusion	of	two	gametes	(haploid	genomes)	during	fertilization	gives	 rise	 to	 an	 embryo	with	 two	 copies	of	 each	 gene,	 called	 alleles.	This	process	facilitates	natural	variation	since	two	genomes	form	a	new	one	in	which	two	alleles	can	 either	 have	 the	 same	 sequence	 (homozygosity)	 or	 two	 alleles	 show	 genetic	variation	 in	 their	 sequence	 (heterozygosity).	 Genetic	 variations	 in	 the	 germlines	affect	 the	 entire	 organism	 and	 can	 be	 passed	 on	 to	 the	 next	 generation	 (Alberts,	2015).	In	contrast,	somatic	variations	occur	outside	of	the	germlines	and	manifest	itself	 generally	 only	 in	 a	 small	 subset	 of	 cells.	 Genomes	 of	 cells	 accumulate	mutations	 (i.e.	 genetic	 variations)	 over	 their	 lifespan,	 which	 are	 passed	 on	 to	daughter	cells	during	cell	division.	There	are	different	classes	of	variations,	which	are	 defined	 based	 on	 the	 number	 of	 base	 pairs	 (bp)	 they	 are	 affecting.	 Single	nucleotide	variants	(SNVs)	are	1	bp	substitutions	and	are	the	most	common	form	of	genetic	 variations	 (Genomes	 Project	 et	 al.,	 2012).	 Insertion	 and	 deletion	 (called	Indels)	of	nucleotides	can	also	only	affect	a	single	nucleotide,	however,	 Indels	can	be	more	 severe	 since	 they	 can	 cause	 frame-shifts	 resulting	 in	 an	 altered	 reading	frame	of	a	gene.	Genomic	variations	that	affect	DNA	segments	larger	than	1	kb	are	called	 structural	 variations	 (SVs).	 Types	 of	 SVs	 include	 copy-number	 variations	(deletion,	insertions	and	duplications	of	DNA	segments),	inversions	(the	orientation	of	DNA	segment	has	changed)	and	translocations	(DNA	fragment	is	integrated	at	a	new	position)	(Feuk	et	al.,	2006).		
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Genetic	 variations	 can	 have	 an	 impact	 on	 cellular	 functions	 due	 to	 the	 central	dogma	of	molecular	biology:	Genetic	information	stored	in	genomes	is	used	by	cells	to	synthesize	proteins,	which	is	facilitated	by	the	two	processes	called	transcription	and	translation	(Crick,	1958).	The	transcription	of	a	gene	gives	rise	to	mRNA,	which	nucleotide	sequence	is	translated	into	an	amino	acid	sequence	by	decoding	always	three	nucleotides	(codons)	into	one	amino	acid.	Since	the	AS	sequence	determines	the	structure	of	a	protein	and	thus	its	function,	changes	in	the	genomic	information	can	 affect	 cellular	 processes	 carried	 out	 by	 proteins	 (Alberts,	 2015).	 Non-synonymous	 substitutions	 of	 nucleotides	 alter	 the	 AS-sequence	 of	 a	 protein	 and	thereby	 proteins	 with	 altered	 functions	 are	 produced	 (Ramensky	 et	 al.,	 2002).	Indels	with	 frame-shift	mutations	often	result	 in	premature	stop-codons	and	 thus	truncated	proteins	or	non-functional	proteins	are	produced	from	the	mutated	gene	(Lin	 et	 al.,	 2017).	 Structural	 variations	 can	 have	 more	 severe	 effects	 on	 an	organism.	 Copy	 number	 variations	 may	 cause	 the	 loss	 of	 proteins	 encoded	 by	 a	region	(deletions)	or	the	overproduction	of	a	protein	due	to	its	excess	transcription	(duplications).	 Translocations	 can	 alter	 the	 regulatory	 environment	 of	 genes	 and	thus	 cause	 losses	 as	 well	 as	 gains	 in	 expression	 (i.e.	 transcription)	 of	 the	corresponding	genes	(Rodriguez-Revenga	et	al.,	2007).		Genomic	 variations	 in	 genes	 responsible	 for	 the	 regulation	 of	 cell	 growth	 and	survival	 have	 the	potential	 to	 initiate	uncontrolled	 cell	 proliferation	 and	 thus	 can	lead	to	the	development	of	cancer.	Those	genes	are	classically	defined	as	oncogenes	or	tumor-suppressor	genes.	An	oncogene	derives	from	a	proto-oncogene	(i.e.	a	gene	with	 growth	 promoting	 functions)	 by	 a	 gain	 of	 function	 mutation,	 resulting	 in	 a	constitutively	 activated	 or	 highly	 abundant	 protein	 (Croce,	 2008).	 A	well-studied	proto-oncogene	 is	 BRAF,	 which	 is	 part	 of	 the	 mitogen-activated	 protein	 kinase	(MAPK)	pathway	that	transmits	binding	of	a	growth	factor	into	a	cellular	response	(Peyssonnaux	and	Eychene,	2001).	Oncogenic	activation	of	BRAF	is	caused	by	point	mutations	 that	 result	 in	 elevated	 kinase	 activities	 and	 growth	 factor	 independent	activation	of	MAPK	pathway	by	BRAF	(Davies	et	al.,	2002).	Proteins	derived	 from	tumor-suppressor	genes	are	 involved	 in	 the	regulation	of	 cell	 cycle	and	apoptosis	and	 balance	 growth	 promoting	 proto-oncogenes.	 A	 loss	 of	 function	mutation	 in	 a	tumor-suppressor	 gene	 (generally	 both	 alleles	 must	 be	 affected),	 promotes	uncontrolled	 growth	 of	 a	 cell	 (Weinberg,	 1991).	 The	 TP53	 gene	 is	 mutated	 in	around	 50%	of	 all	 cancer	 due	 to	 its	 central	 role	 in	 regulation	 of	 DNA	 repair,	 cell	
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senescence	 and	 apoptosis	 (Alberts,	 2015).	 More	 recently	 the	 concept	 of	 driver	mutations	and	passenger	mutation	has	been	introduced.	Driver	mutations	are	those	that	 promote	 tumor	development	 and	progression,	whereas	 passenger	mutations	are	 often	 the	 result	 of	 genomic	 instability	 and	 have	 no	 or	 only	 little	 impact	 on	tumor	progression	(Pon	and	Marra,	2015).			
1.6.2. Hallmarks	of	cancer		For	the	transformation	from	a	neoplastic	lesion	with	increased	proliferative	activity	into	 a	 malignant	 cancer,	 in	 most	 cases	 a	 gradual	 accumulation	 of	 mutations	 is	required.	 The	 presence	 of	 a	 single	 driver	 mutation	 does	 not	 result	 in	 the	development	 of	 cancer.	 Multiple	 events	 are	 necessary	 for	 cells	 to	 overcome	constraints	of	cell	growth	and	acquire	the	potential	to	invade	and	colonize	distant	tissues.	Although	different	 cancer	 types	 show	great	diversity,	 there	are	 is	 a	 set	of	properties	cells	need	to	acquire	for	their	transformation,	which	are	common	for	all	types.	These	properties	are	called	the	hallmark	of	cancer	(Hanahan	and	Weinberg,	2011):			
Sustained	Proliferative	Signalling:	Induction	of	cell	division	independent	on	growth	factors		
Evading	growth	suppression:	 Liberation	 from	mechanisms	 that	negatively	 regulate	cell	growth			
Resisting	cell	death:	Disruptions	of	mechanisms	inducing	apoptosis	in	cells		
Enabling	 replicative	 immortality:	 Unlimited	 proliferation	 by	 avoidance	 of	telelomere-shortening	induced	cell	senescence		
Inducing	 Angiogenesis:	 Ensure	 supply	 of	 nutrients	 and	 oxygen	 for	 excessive	 cell	growth	by	blood	vessel	formation	
Activating	 invasion	 and	 metastasis:	 Escape	 of	 cells	 from	 the	 primary	 tumor	 and	colonization	of	distant	tissues		
Genomic	 Instability:	 Enables	 other	 hallmarks	 by	 an	 accelerated	 acquisition	 of	mutations		
Chronic	 inflammation:	 Enables	 acquisition	 of	 hallmark	 characteristics	 by	 a	providing	a	mutagenic	and	proliferative	environment		
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Reprograming	 energy	metabolism:	 Glycolysis-dependent	 energy	 production	 under	aerobic	and	anaerobic	conditions		
Evading	 immune	 destruction:	 An	 immune	 suppressive	 microenvironment	 is	established	to	avoid	immune-based	elimination		
1.6.3. Tumor	heterogeneity		The	acquisition	of	hallmark	characteristics	is	a	sequential	process	that	ends	in	the	malignant	 transformation	 of	 cells.	 Tumor	 initiation	 and	 progression	 are	 often	stochastic	 and	 dynamic	 and	 give	 rise	 to	 cells	 with	 diverse	 mutations	 and	proliferative	 activity.	 Additionally,	 tumor	 cells	 are	 under	 continuous	 selection	pressure	 in	 order	 to	 achieve	 a	 proliferative	 advantage	 and	 avoid	 elimination	 by	control	 mechanisms.	 Together	 these	 processes	 promote	 the	 formation	 of	heterogeneous	tumors	with	genetically	distinct	subpopulations,	called	intra-tumor	heterogeneity.	This	is	in	contrast	to	inter-tumor	heterogeneity	caused	as	a	result	of	patient-specific	 factors	 (Burrell	 et	 al.,	 2013).	 A	 main	 driver	 of	 intra-tumor	heterogeneity	 is	 genomic	 instability	 that	 provides	 the	 basis	 for	 genetic	 diversity	within	a	 tumor.	 Increased	mutational	burden	due	 to	genomic	 instability	 is	 caused	by	 defects	 in	 DNA	 maintenance	 mechanisms	 (Negrini	 et	 al.,	 2010).	 However,	genomic	 instability	alone	 is	not	 sufficient	 for	establishing	a	heterogeneous	 tumor,	since	 it	 could	 also	 lead	 to	 the	 outgrowth	 of	 individual	 clones	 with	 the	 highest	proliferation	rate.	Clonal	evolution	is	necessary	to	shape	a	tumor	into	a	tissue	with	diverse	 clones	 each	 providing	 the	 possibility	 to	 adapt	 to	 changing	 environments	(e.g.	 drug	 treatment	 or	 hypoxia).	 Due	 to	 spatial	 and	 temporal	 differences	 in	 the	tumor	environment,	the	distribution	or	the	abundance	of	subclones	within	a	tumor	can	differ.	Spatial	heterogeneity	refers	 to	genetically	distinct	subclones	within	 the	primary	 tumor	 or	 across	metastasis.	 Genomic	 information	 from	 single	 cell	 nuclei	sequencing	 of	 breast	 cancer	 biopsies	 revealed	 the	 presence	 of	 three	 distinct	subpopulations,	 which	 arose	 from	 punctuated	 expansion	 of	 clones	 (Navin	 et	 al.,	2011).	On	 the	 other	 hand,	 temporal	 heterogeneity	 refers	 to	 changes	 in	 the	 clonal	composition	 of	 a	 tumor	 over	 time	 induced	 by	 changes	 in	 the	 selection	 pressure.	These	 changes	 are	 in	 most	 cases	 anti-tumor	 drug	 treatments,	 which	 provoke	adaptation	 responses	 by	 the	 tumor.	 Longitudinal	 sampling	 of	 non-small	 cell	 lung	cancer	 (NSCLC)	over	 treatment	 and	 treatment	 free	 intervals,	 showed	appearance,	loss	 and	 reappearance	 of	 resistant	 subclones	 (Sequist	 et	 al.,	 2011),	 signifying	 the	
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tumors	 adaptation	 towards	 treatments	 due	 to	 the	 presence	 of	 drug-tolerating	 or	resistant	cells.			
1.7. Drug	treatments	against	cancer			Drug	therapies	against	cancer	aim	at	targeting	properties	of	tumor	cells	that	make	them	 more	 susceptible	 than	 healthy	 cells.	 Among	 these	 properties	 are	 the	disruptions	 in	 DNA	 repair	 mechanisms	 and	 chromosomal	 maintenance	 and	 the	increased	 genetic	 instability	 and	 proliferative	 activity,	 which	 are	 exploited	 by	chemotherapeutic	drugs.	Classes	of	chemotherapeutics	are	alkylating	agents	(bind	covalently	to	DNA)	(Damia	and	D'Incalci,	1998),	antimetabolites	(inhibition	of	DNA	and	 RNA	 synthesis)	 (Parker,	 2009),	 anti-microtubule	 agents	 (inhibition	 of	microtubule	 polymerization	 and	 depolymerisation)	 (Rowinsky	 and	 Donehower,	1991)	 and	 topoisomerase	 inhibitors	 (prevent	 unwinding	 or	 replication	 of	 DNA	strands)	 (Pommier,	 2013).	 Since	 chemotherapeutic	 drugs	 only	 aim	 at	 a	 higher	susceptibility	 of	 tumor	 cells	 compared	 to	 normal	 cells,	 treatments	 are	 often	accompanied	 with	 strong	 side	 effects.	 The	 development	 of	 molecular	 target	therapies	 provides	 a	more	 specific	 therapeutic	 intervention.	 The	 dependencies	 of	tumor	 cells	 on	 specific	driver	mutations	offer	 great	 therapeutic	potential,	 such	as	inhibition	of	specific	oncogenic	proteins.	A	prominent	example	 is	 the	treatment	of	myelogenous	 leukaemia	 with	 the	 small	 molecule	 Imatinib.	 As	 a	 product	 of	 gene	translocation,	 myelogenous	 leukaemia	 cells	 express	 the	 fusion	 gene	 Bcr-Abl,	resulting	in	a	hyperactive	Abl	tyrosine	kinase	and	thus	increased	cell	proliferation.	Imatinib	 specifically	 inhibits	 the	 Bcr-Abl	 fusion	 protein	 and	 thereby	 only	 affects	tumor	cells	expressing	it	(Druker,	2008).		
1.7.1. Drug	resistance		Unfortunately,	 the	 high	 efficacies	 of	 chemotherapeutic	 and	 target	 therapies	 are	often	limited	to	short	time	windows	due	to	the	development	of	resistances.	Tumor	cells	 either	 adapt	 to	 the	 increased	 selection	 pressure	 applied	 by	 a	 drug	 or	 pre-existing	 resistant	 subclones	 evolve	 in	 the	 course	 of	 the	 treatment	 (adaptive	resistance).	 Adaptive	 responses	 include	 transcriptional	 reprogramming	 of	 tumor	cells	 to	 counteract	 drug	 damages.	 Tumor	 cells	 can	 compensate	 DNA	 damages	induced	 by	 chemotherapeutic	 drugs	 by	 up-regulating	 the	 expression	 of	 genes	
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involved	 in	 the	 DNA	 repair	 machinery	 (Kirschner	 and	 Melton,	 2010).	 A	 more	generic	resistance	mechanism	against	chemotherapeutics	is	the	expression	of	ATP-binding	 cassette	 transporters	 promoting	 drug	 efflux	 and	 thus	 resistance	(Gottesman	 et	 al.,	 2002).	 Another	 example	 is	 the	 upregulated	 expression	 of	 drug	targets,	resulting	in	more	targets	to	be	inhibited	and	consequently	a	reduced	drug	efficacy,	 as	 suggested	 for	 Imatinib	 resistance	 due	 to	 Bcr-Abl	 overexpression	(Barnes	et	al.,	2005).	Genomic	instability	favours	the	acquisition	of	new	mutations	and	thus	can	potentially	give	rise	to	resistant	cells	(acquired	resistance).	Prominent	genetic	alterations	to	escape	inhibition	of	kinases	by	small	molecules	are	so	called	gatekeeper	 mutations	 that	 reduce	 the	 accessibility	 of	 the	 binding	 pocket.	 The	inhibition	 of	 epidermal	 growth	 factor	 receptor	 (EGFR)	 by	 Gefitinib	 in	 NSCLCs	 is	often	 followed	 by	 relapses	 due	 to	 a	 secondary	 EGFR	 gatekeeper	 point	 mutation	(Kobayashi	 et	 al.,	 2005).	 Resistance	 to	 Gefitinib	 in	 NSCLCs	 was	 also	 found	 to	 be	caused	 by	 an	 amplification	 of	 the	 MET	 gene,	 resulting	 in	 the	 HER3-dependent	activation	 phosphatidylinositol-3-kinase	 (PI3K),	 which	 provides	 pro-survival	signalling	 (Engelman	 et	 al.,	 2007).	 EGFR	 inhibition	 induces	 the	 activation	 of	 an	alternative	signalling	route,	a	mechanism	called	oncogenic	bypass.		Over	the	last	decades	intra-tumor	heterogeneity	evolved	as	one	of	the	main	drivers	of	 drug	 resistance.	 Higher	 clonal	 diversity	 increases	 the	 chance	 of	 adaptation	 to	drug	treatments.	On	one	hand,	the	presence	of	pre-existing	subclones	either	being	resistance	or	capable	to	adapt	to	drug	treatment	is	more	likely.	Additionally,	genetic	diversity	increases	the	probability	of	cells	acquiring	resistance.	Resistance	to	EGFR	inhibition	 in	NSCLCs	was	described	to	either	arise	by	 the	selection	of	pre-existing	clones	 with	 a	 gatekeeper	 mutation	 or	 the	 acquisition	 of	 a	 gatekeeper	 mutation	(Hata	et	al.,	2016).	How	small	numbers	of	pre-existing	subpopulations	cause	tumor	relapse	 by	 their	 adaptive	 selection	 and	 acquired	 transcriptional	 signatures	 was	shown	 recently	 in	 the	 Navins	 Laboratory.	 Transcriptional	 and	 copy-number	evolution	 profiling	 of	 single	 cells	 from	 triple	 negative	 breast	 cancer	 (oestrogen,	progesterone	 and	HER2	 receptor	 negative)	 biopsies	 collected	 over	 the	 treatment	showed	 the	 pre-existence	 of	 primed	 resistant	 cells,	 which	 eventually	 became	resistance	 due	 to	 a	 reprogrammed	 gene	 expression.	 Taken	 together,	 tumor	heterogeneity	provides	a	selective	advantage	for	tumors	and	thus	a	basis	for	drug	resistance.		
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1.7.2. Drug	combinations	for	cancer	therapy		Treating	tumors	with	drug	combinations	offers	great	potential	to	reduce	the	risk	of	resistance,	especially	for	heterogeneous	cancers.	Targeting	multiple	subpopulations	within	the	same	tumor	can	prevent	positive	selection	of	resistant	or	drug	tolerating	clones	 and	 thereby	 prevents	 tumor	 relapse.	 Resistance	 to	 EGFR-inhibition	 in	NSCLCs	 was	 hypothesized	 to	 be	 caused	 by	 pre-existing	 cloned	 with	 MET	amplification	 and	 their	 positive	 selection	during	Gefitinib	 treatment	 (Turke	 et	 al.,	2010).	Therefore,	co-targeting	of	EGFR	and	MET	tyrosine	kinase	in	NSCLC	patients	to	 prevent	 the	 outgrowth	 of	 resistant	 cells	 is	 explored	 in	 a	 clinical	 trial	(NCT02335944).	 Furthermore,	drug	 combinations	 increase	 the	 selection	pressure	on	tumor	cells	and	thus	reduce	the	risk	of	acquired	resistances.	Allosteric	inhibition	of	Bcr-Abl	combined	with	blockage	of	 the	ATP-binding	site	has	shown	to	 improve	treatment	of	Bcr-Abl	positive	tumors	(Zhang	et	al.,	2010).	Since	the	two	compounds	have	non-overlapping	 resistance	profiles,	 a	 gatekeeper	mutation	 against	 either	 of	the	 drugs	 does	 not	 result	 in	 resistance	 against	 the	 other	 drug.	 Additionally,	adaptation	 to	 drug	 treatments	 by	 compensatory	 responses	 such	 as	 activation	 of	bypass	 signalling	may	 be	 tackled	 by	 drug	 combinations	 targeting	 both	 pathways.	Treatment	 of	 KRAS-mutant	 lung	 cancer	with	 Trametinib,	which	 inhibits	mitogen-activated	 protein	 kinase	 (MAPK)	 downstream	 of	 KRAS,	 leads	 to	 resistance	mediated	by	fibroblast	growth	factor	receptor	1	(FGFR1).	The	combined	inhibition	of	MAPK	and	FGFR1	was	found	to	improve	tumor	cell	death	in	vivo	by	nullifying	the	adaptive	response	(Manchado	et	al.,	2016).	These	examples	illustrate	the	power	of	drug	 combinations	 for	 the	 treatment	 of	 cancer	 by	 preventing	 relapses	 due	 to	adaptive	 and	 acquired	 resistance	 mechanisms.	 However,	 finding	 multiple	vulnerabilities	 of	 tumor	 cells	 and	define	 treatments	 against	 those	 is	 difficult.	One	major	 reason	 is	 the	 existence	 of	 inter-patient	 heterogeneity	 that	 leads	 to	 the	emergence	of	varying	driver	mutation	and	adaptation	mechanisms	(De	Palma	and	Hanahan,	 2012).	 Therefore,	 it	 would	 be	 beneficial	 to	 design	 personalized	 drug	combination	by	 identifying	vulnerabilities	 for	each	patient,	which	can	be	achieved	by	high-dimensional	profiling	such	as	genome	and	transcriptome	sequencing.		
1.7.3. Gene	expression	profiling	for	precision	oncology		Due	to	the	vast	heterogeneity	within	and	between	tumors	from	different	patients,	a	lot	 of	 effort	 is	 put	 into	 finding	 the	 perfect	 drug	 for	 each	 patient.	 Instead	 of	 using	
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standardized	 therapies,	 precision	 oncology	 aims	 at	 identifying	 biomarkers	 that	allow	 predictions	 on	 drug	 sensitivity.	 The	 spectrum	 of	 predictive	 biomarker	reaches	 from	 single	 genes	 to	 entire	 pathway	 networks	 and	 their	 identification	mainly	relies	on	high	dimensional	data	sets.	Gene	expression	profiles	from	various	disease	 models	 and	 patient	 biopsies	 under	 perturbed	 and	 untreated	 conditions	have	 proven	 to	 be	 powerful	 in	 understanding	 drug	 responses	 and	 predicting	efficacies.	 Detecting	 the	 expression	 of	marker	 genes	 can	 be	 used	 for	 deciding	 on	treatments	with	 target	drugs,	 such	as	Her2	overexpression	 for	EGFR-inhibition	 in	breast	 cancer	 (Nicolini	 et	 al.,	 2018).	 Gene	 expression	 data	 is	 also	widely	 used	 to	predict	pathway	activity	in	cancer	cells	by	testing	the	enrichment	of	genes	sharing	biological	 functions	 (Subramanian	 et	 al.,	 2005).	 Determining	 pathway	 signatures	for	 cancer	 cell	 lines	 was	 applied	 to	 predict	 drug	 sensitivity	 and	 thus	 therapies	decisions	 can	 be	 guided	 by	 pathway	 activity	 inferred	 from	 gene	 expression	 data	(Bild	et	al.,	2006).	By	integrating	large	data	repositories	from	hundreds	of	cell	lines	together	 with	 their	 sensitivity	 against	 hundreds	 of	 drugs,	 better	 predictions	 on	drug	 sensitivity	 can	 be	 achieved.	 Correlations	 between	 drug	 sensitivity	 and	genomic	 aberrations	 and	 gene	 expression	 were	 used	 to	 build	 models	 to	 predict	treatment	outcome	(Iorio	et	al.,	2016;	Menden	et	al.,	2018).		The	 comparative	 analysis	 of	 gene	 expression	 data	 of	 cells	 from	 before	 and	 after	drug	exposure	can	be	applied	to	understand	the	mode	of	action	(MoA)	of	drugs	and	infer	 drug	 specific	 signatures.	 The	 up-	 or	 down-regulation	 of	 pathway	 activities	upon	perturbation	gives	the	compounds’	effects	on	cells,	called	drug	signature.	The	LINCS	database	(former	cMap)	comprises	1.3	million	gene	expression	profiles	from	cell	 lines	exposed	to	42,080	different	perturbants	(Subramanian	et	al.,	2017).	The	large	 number	 of	 connection	 between	 drugs	 and	 gene	 expression	 in	 the	 database	finds	wide	application	in	drug	repositioning	by	matching	signatures	between	drugs	(Iorio	 et	 al.,	 2010;	 Keiser	 et	 al.,	 2009).	 Furthermore,	 knowledge	 about	 drug	signatures	 was	 used	 to	 predict	 drug	 treatments	 based	 on	 finding	 drugs-disease	associations.	The	underlying	hypothesis	 is	 that	 a	disease	 specific	 gene	expression	signature	 is	 reverted	 by	 a	 drug	with	 an	 opposing	 signature	 and	 thus	 the	 disease	phenotype	is	reverted	(Iorio	et	al.,	2013).	Gene	expression	data	from	100	diseases	was	used	 to	predict	new	 therapeutic	 intervention	by	 finding	drugs	with	opposing	signatures	 (Sirota	 et	 al.,	 2011).	 By	 defining	 drug	 resistance	 phenotypes	 and	querying	for	drug	signatures	that	revert	the	resistant	state,	it	was	possible	to	define	
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drug	combinations	nullifying	 the	resistance	mechanisms	 in	cancer	(Hassane	et	al.,	2010;	Wei	 et	 al.,	 2006).	 The	 comparative	 analysis	 of	 gene	 expression	 signatures	from	untreated	 and	 treated	 cells	 offer	 great	 potential	 for	 defining	 new	 treatment	strategies	 against	 cancer.	 Consequently,	 the	 development	 of	 new	 technologies,	which	 allow	 screens	 of	 high	 number	 of	 drugs	 and	 drug	 combinations	 with	 gene	expression	 based	 readout,	 is	 of	 great	 interest	 and	 one	 of	 the	 main	 goals	 of	 the	presented	work.					
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2. Objectives	and	outline				The	main	objectives	of	 this	 thesis	were	 to	establish	microfluidic	 technologies	 that	allow	 the	production	 of	 chemical	 diverse	 combinations	 in	 picolitre-sized	droplets	and	their	multiplexed	analysis	using	DNA	based	barcoding	and	RNA-Seq.			In	 order	 to	 achieve	 these	 goals,	my	 first	 objective	was	 to	 establish	 a	microfluidic	workflow	for	the	generation	of	combinations	from	injected	reagents	controlled	by	a	valve-based	module.		To	realize	the	multiplexed	analysis	of	combinations	in	droplets,	the	second	aim	was	to	integrate	a	DNA-based	barcoding	approach	into	the	pipeline	and	show	that	it	 is	applicable	for	the	identification	of	specific	droplet	populations.		The	developed	methods	 for	 the	 achievements	of	 these	 first	 aims	 are	described	 in	
Chapter	3		The	 third	 objective	 was	 to	 further	 increase	 the	 throughput	 of	 the	 valve-based	generation	 of	 combinations	 in	 droplets	 by	 establishing	 a	 system	 that	 combines	compounds	from	a	valve-module	and	a	96-well	plate	to	produce	chemically	highly	complex	droplet	libraries.		The	 fourth	objective	of	 this	 thesis	was	 to	combine	 the	microfluidic	 system	with	a	barcoding	approach	to	analyse	the	effects	of	drug	combinations	on	gene	expression	of	cancer	cells	in	a	highly	multiplexed	way.		Results	for	both	objectives	are	described	and	discussed	in	Chapter	4		Finally,	my	aim	was	to	apply	the	established	workflow	to	perform	screens	of	anti-tumor	 drug	 combinations	 and	 analyse	 their	 effects	 by	 gene	 expression.	 The	preliminary	results	of	two	screens	are	described	in	Chapter	5		 	
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3. Combinatorial	 barcoding	 of	 droplet	 content	 for	multiplexed	readouts				
3.1. Introduction		This	 chapter	describes	a	novel	microfluidic	pipeline	 for	on-demand	production	of	picolitre-sized	 droplets	 containing	 sample	 combinations	 at	 high-throughput.	Production	of	emulsions	with	high	chemical	complexity	is	of	great	interest,	since	it	will	 enable	 screening	 of	 drug	 combinations	 with	 low	 sample	 consumption	 while	having	 single	 cell	 resolution.	 A	 bottleneck	 for	 generating	 chemically	 diverse	droplets,	 however,	 is	 the	 need	 for	 changing	 the	 aqueous	 phase	 injected	 into	 a	microfluidic	 device	 for	 droplet	 production.	 The	 identification	 of	 droplet	 contents	from	 a	 chemically	 complex	 emulsion	 was	 so	 far	 achieved	 by	 fluorescence-based	barcoding	 or	 spatial	 order	 of	 droplets	 resulting	 in	 limited	 scalability	 and	throughput.	Various	approaches	 for	 the	generation	of	 chemically	diverse	droplets	have	 been	 presented,	which	 have	 been	 limited	 to	 the	 encapsulation	 of	 individual	drugs	(Brouzes	et	al.,	2009;	Clausell-Tormos	et	al.,	2010;	Gielen	et	al.,	2015;	Miller	et	 al.,	 2012).	 In	 previously	 described	 valve-based	 system,	 combinations	 were	generated	in	large	droplets	(~0.5	µl),	which	were	stored	sequentially	in	a	tubing	to	maintain	 spatial	 order	 (Eduati	 et	 al.,	 2018).	 In	 this	 chapter,	 the	 first	 part	 of	 the	study	 is	described,	where	 the	microfluidic	workflow	as	presented	by	Eduati	et	al.	was	adapted	and	integrated	into	a	new	pipeline	in	order	to	generate	combinations	in	an	emulsion	of	picolitre-sized	droplets.	For	the	identification	of	droplet	content,	we	introduced	a	DNA-barcoding	approach	to	encode	each	combination	with	a	set	of	two	barcodes	allowing	multiplexing	of	several	distinct	conditions.	We	validated	the	combinations	 generated	 with	 our	 pipeline	 using	 fluorescence	 measurements	 as	well	as	NGS	based	read-outs.	Possible	applications	of	this	system	are	combinatorial	drug	screenings	in	which	droplets	containing	potent	combinations	are	enriched	by	
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sorting	 (e.g.	based	on	an	apoptosis	assay	of	 co-encapsulated	 target	 cells)	 and	hits	are	identified	by	sequencing	of	the	corresponding	barcodes.	We	performed	a	mock	screen	 in	which	a	specific	droplet	population	was	enriched	based	on	 fluorescence	signals	and	hits	were	identified	based	on	their	barcodes.	Additionally,	we	simulated	a	 more	 realistic	 screening	 result,	 in	 which	 barcode	 containing	 droplets	 were	introduced	 at	 different	 amounts	 and	 assessed	 the	 sensitivity	 of	 the	 system	 to	differentiate	small	changes	in	droplet	abundance.		
3.2. Microfluidic	pipeline	for	generating	sample	combinations	in	droplets		In	order	to	achieve	a	continuous	and	automated	production	of	droplets	containing	distinct	 combinations	 of	 two	 components,	 a	 microfluidic	 pipeline	 consisting	 of	three	main	modules	was	established	(Fig.	 3.1):	 (1)	A	valve-module	with	16	 inlets	directing	continuously	injected	compounds	either	to	the	waste	or	the	outlet	of	the	microfluidic	chip	(Fig.	3.1A-1,	3.1B).	The	computer-controlled	Braille	valves	can	be	opened	 and	 closed	 in	 defined	 sequences	 and	 time	 intervals,	 allowing	 rapid	switching	 (approx.	 200	ms)	 between	 different	 injected	 liquids.	 The	 simultaneous	opening	of	two	valves	resulted	in	a	combination	of	the	two	components	injected	via	the	 opened	 valves.	 Thus,	 49	 combinations	 (7x7;	 samples	 A-G	 combined	 with	samples	1-7)	were	generated.	Between	individual	combinations,	two	valves	for	oil	injection	were	opened,	generating	an	oil	 spacer	 that	 separated	 two	defined	plugs.	These	 plugs	were	 then	 transferred	 via	 tubing	 to	 the	 second	module.	 (2)	 A	 drop-maker	device	where	plugs	with	combinations	from	module	1	can	be	combined	with	cells	 or	 reagents	 and	 encapsulated	 at	 a	 flow	 focusing	 junction	 into	picolitre-sized	droplets	 (Fig.	 3.1A-2,	 3.1C).	 This	 workflow	 enabled	 the	 generation	 of	 49	combinations	 and	 their	 encapsulation	 into	 droplets	 together	 with	 single	 cells	 or	further	 reagents.	 (3)	A	 third	module	was	 integrated	 into	 the	pipeline,	 in	 order	 to	prevent	 cross-contamination	 from	 remaining	 liquids	 in	 channels	 of	 the	 valve-module	and	drop-maker.	The	two	outlets	of	the	drop-maker	device	were	connected	with	 the	 two	valves	of	module	3	 such	 that	 the	produced	droplets	 could	 either	be	sent	 to	 a	 collection	 or	 waste	 tube	 (Fig.	 3.1A-3,	 3.1D).	 The	 sorting	 decision	 was	depending	on	 the	 fluorescence	 signals	of	 incoming	plugs,	monitored	on	 the	drop-maker,	and	collection	parameters	(fluorescence	threshold	and	time	windows).		
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Fig.3.1	Microfluidic	pipeline	for	generating	combinations	in	droplets	
(A)	The	valve-based	system	for	generating	droplets	containing	a	mix	of	two	compounds	comprised	
three	modules	 (microfluidic	 devices).	 (1)	 A	 valve-module	with	 16	 valves	was	made	 up	 of	 a	 braille	
display	 and	 a	 microfluidic	 chip	 that	 is	 aligned	 with	 its	 valve	 structure	 on	 top	 of	 the	 braille	 pins.	
Opening	 two	 valves	 simultaneously	 generated	 combinations	 of	 two	 injected	 solutions	 (A	 to	 G	
combined	with	 1	 to	 7).	 (2)	 Combinations	were	 transferred	 in	 a	 small	 piece	 of	 tubing	 to	 the	 drop-
maker	module	and	encapsulated	 into	droplets	along	with	cells	or	reagents.	(3)	A	sample	collection	
module	 consisting	 of	 two	 valves	 allowing	 to	 direct	 droplets	 to	 the	 waste	 or	 collection	 tube.	 The	
collection	and	waste	valve	of	module	3	was	operated	by	a	LabVIEW	software.	Fluorescence	signals	of	
injected	plugs	containing	combinations	were	processed	by	the	software	to	 initiate	a	time	series	(1.	
Delay	 Time,	 2.	 Collection	 Time,	 3.	 Waiting	 time)	 of	 different	 steps,	 required	 to	 collect	 droplets	
without	 cross-contamination.	 When	 signals	 from	 a	 sample	 plug	 were	 detected,	 the	 sequence	 of	
delay,	 collection	 and	 waiting	 time	 was	 started	 ensuring	 collection	 of	 droplets	 from	 sample	 plugs	
(green	 box)	 whereas	 droplets	 from	 washing	 plugs	 are	 discarded	 (red	 box).	 (B)	 Layout	 of	 the	
microfluidic	chip	used	for	the	valve-module.	Rectangular	channels	(red	box)	are	aligned	on	pins	of	a	
braille	 display	 to	 direct	 solution	 injected	 into	 the	 inlets	 (orange	 boxes)	 to	 the	waste	 outlets	 (blue	
box)	or	chip	outlet.	(C)	Design	of	the	drop-maker	chip	used	for	module	2.	(D)	Two	valving	channels	of	
sample	collector	chip	allowing	to	direct	drops	to	the	waste	or	collection	tube.			 	
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Measured	 fluorescence	 signals	 of	 incoming	 plugs	were	 processed	 by	 an	 in-house	LabVIEW	 software	 that	 controlled	 collection	 and	 waste	 valves.	 When	 the	fluorescence	 signal	 reached	 a	 pre-defined	 threshold	 a	 series	 of	 delay-,	 collection-	and	waiting-times	were	activated.	During	the	delay	time	(~100-500	ms,	grey	box),	droplets	 were	 sent	 to	 the	 waste	 although	 the	 set	 fluorescence	 threshold	 was	reached,	 allowing	 the	 droplet	 generation	 to	 equilibrate.	 Following	 the	 delay,	 a	collection	time	was	set	to	collect	droplets	from	the	collection	plug.	As	a	result,	the	collection	 valve	was	 open	 for	 a	 pre-defined	 collection	 time	 (2s	 to	 8s,	 green	 box).	During	 the	 waiting	 time	 the	 system	 sent	 all	 produced	 droplets	 to	 the	 waste	irrespective	of	the	fluorescence	signal	(5-8	sec,	red	box).	The	waiting	time	window	was	used	 to	 remove	 remaining	 liquids	 of	 previous	 samples	 by	 the	passage	 of	 the	washing	 plug	 generated	 from	 the	 subsequent	 sample.	 Once	 the	waiting	 time	was	over,	the	system	was	ready	for	the	collection	of	the	next	plug	by	repeating	the	cycle.		
3.2.1. Design	of	the	valve-module	and	sample	collector		The	 valve-module	 and	 sample	 collector	 described	 in	 3.1	 consisted	 of	 a	 braille	display	 and	 a	 microfluidic	 chip.	 For	 the	 valve-module	 the	 chip	 in	 Fig.	 3.1B	 was	used.	Briefly,	a	PDMS	chip	with	rounded	channels	was	bonded	to	an	elastic	PDMS	membrane.	The	wide	rectangular	structures	(valve	structures)	were	aligned	on	top	of	 the	 pins	 of	 a	 Braille	 display.	 Reagents	 connected	 to	 the	 inlet	 ports	 were	continuously	 injected	 and	 reagents	 were	 sent	 to	 the	 waste	 outlets	 in	 the	 default	mode.	In	order	to	direct	injected	reagents	to	the	drop	maker,	the	waste	channel	was	blocked	by	moving	 the	corresponding	braille	pin	upwards,	while	 the	pin	blocking	the	flow	towards	the	drop	maker	was	moved	down.	Thus,	one	valve	can	be	defined	by	a	set	of	two	pins,	which	direct	one	injected	reagent	either	to	the	waste	outlet	or	the	 chips	 outlet	 connected	 to	 the	 drop-maker.	 This	 process	 was	 automated	 by	 a	LabVIEW	software	 that	 allowed	 to	 run	defined	 series	of	 sequential	 valve	opening	times.	The	working	principle	of	the	sample	collector	was	the	same	except	that	four	pins	were	aligned	below	one	of	the	channels	of	the	chip	design	shown	in	Fig.	3.1D.	Opening	 and	 closing	 of	 channels	 was	 used	 to	 direct	 droplets	 to	 the	 collection	 or	waste	 tube.	More	 details	 can	 be	 found	 in	 the	Material	 &	Methods	 chapter	 of	 this	thesis.		
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Fig.3.2	DNA-based	barcoding	of	droplet	content		
(A)	 Biotinylated	 barcodes	 are	 hybridized	 over	 a	 ligation	 site	 with	 a	 second	 set	 of	 barcodes	 and	
subsequently	 ligated.	 This	 results	 in	 a	 barcode	 combination	 with	 two	 primer	 sites	 that	 can	 be	
amplified	by	PCR.	Fragments	are	inked	to	sequencing	adapters	during	PCR	resulting	in	Amplicon-seq	
libraries	 in	 a	 one-step	 protocol.	 (B)	 DNA	 high	 sensitivity	 Bioanalyzer	 results	 of	 ligated	 and	 non-
ligation	barcodes	after	PCR.	Ligation	and	amplification	results	in	150	bp	fragments.	(C)	Generation	of	
droplets	at	the	flow	focussing	junction	of	the	drop-maker	containing	a	combination	of	two	barcodes	
(1A,	 1B,	 1C,	…,	 7E,	 7F,	 7G)	 and	 reagents	 for	 ligation.	 Barcode	 combinations	 are	 injected	 from	 the	
valve-module	 in	 form	of	 distinct	 sample	plugs	 spaced	out	 by	oil.	 The	 volume	of	 sample	plugs	 and	
thus	the	number	of	droplets	produced	for	each	combination	depends	on	the	valve	opening	times.					
3.3. DNA-based	barcoding	of	combinations	in	droplets		A	 challenge	 in	handling	 chemically	diverse	droplet	populations	 is	 to	maintain	 the	information	 about	 droplet	 content.	 A	 possibility	 to	 overcome	 this	 limitation	 is	 to	uniquely	 label	 each	 droplet	 according	 to	 its	 content.	 This	was	 so	 far	 achieved	 by	using	 fluorescent	 dyes,	 which	 have	 limited	 multiplexing	 capabilities.	 In	 order	 to	encode	 and	 read	 out	 information	 of	 droplet	 content,	 we	 have	 established	 a	barcoding	approach	in	which	two	DNA	barcodes	(BCs)	form	one	functional	barcode	in	a	ligation	reaction.	Biotinylated	double	stranded	oligonucleotides	with	a	forward	primer	site	and	a	10	bp	barcode	 (BC-1	 to	BC-7)	were	 joined	over	single	 stranded	ligation	 sites	with	 oligonucleotides	 comprised	 of	 a	 10	bp	barcode	 (BC-A	 to	BC-G)	and	 a	 reverse	 primer	 site	 (Fig.	 3.2A).	 After	 droplet	 breakage,	 barcodes	 were	purified	and	amplified	using	primers	with	Illumina	sequencing	adapters	yielding	in	amplicon	sequencing	libraries.	Upon	ligation,	PCR	yielded	a	strong	amplification	of	the	 150	 bp	 long	 fragments,	 whereas	 non-ligated	 barcodes	 did	 not	 result	 in	 any	detectable	 amplification	 (Fig.	 3.2B).	 The	barcoding	 approach	was	 integrated	 into	the	microfluidic	pipeline	by	injecting	BC-1	to	BC-7	and	BC-A	to	BC-G	into	the	valve-
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module	 and	 combining	 the	 barcode	 species	 with	 each	 other.	 Plugs	 containing	barcode	combinations	were	subdivided	into	picolitre-sized	droplets,	together	with	reagents	 for	 ligation,	 using	 a	 flow-focusing	 junction	on	 the	drop-maker	 chip	 (Fig.	
3.2C).		
3.4. Pipeline	generates	droplets	with	uniform	size	and	contents		For	 demonstrating	 the	 working	 principle	 and	 robustness	 of	 the	 microfluidic	pipeline,	 a	 valve-module	 with	 16	 inlets	 was	 used	 and	 generated	 droplets	 were	analysed	by	fluorescence	signals.	Cascade	Blue	(A-G)	injected	over	seven	valves	was	combined	 with	 injected	 fluorescein	 (1-7)	 in	 order	 to	 measure	 how	 the	 modules	combine	the	 two	compounds.	An	 important	parameter	 for	droplet	generation	 in	a	microfluidic	 device	 is	 the	 monodispersity	 since	 a	 uniform	 size	 reflects	 a	 stable	droplet	production	with	uniform	content.	To	assess	the	monodispersity	of	droplets	generated	 from	 sample	 plugs,	we	measured	 the	width	 of	 the	 fluorescence	 signals	from	droplets	of	49	combinations	generated	by	the	valve-module	(Fig.	 3.3A),	and	no	major	fluctuation	in	droplet	size	was	observed.	This	observation	was	quantified	by	 calculating	 the	 coefficients	 of	 variation	 for	 each	 group	 of	 seven	 combinations,	which	 yielded	 values	 ranging	 from	 5.3%	 to	 6.5%	 (Fig.	 3.3B).	 Measuring	 the	fluorescence	signal	of	droplets	allowed	us	 to	determine	whether	both	compounds	from	 the	 valve-module	were	mixed	 at	 equal	 ratios	 and	 if	 they	were	 encapsulated	homogeneously	 with	 the	 other	 reagents	 injected	 into	 the	 drop	 maker.	 Blue	fluorescence	 intensities	 of	 droplet	 generated	 from	 always	 combining	 green	 dye	(inlets	 1-7)	 with	 blue	 dye	 (inlets	 A-G)	 showed	 variations	 ranging	 from	 6.6%	 to	12.7%	for	groups	of	seven	combinations	(Fig.	3.3C).	The	observed	variation	of	the	median	 fluorescence	 intensities	 between	 all	 seven	 groups	 was	 3.3%.	 In	 order	 to	further	 evaluate	 the	 valve-based	 mixing	 of	 two	 components,	 syringes	 were	supplemented	with	DNA	barcodes.	All	barcode	combinations	of	1-7	with	A-G	were	generated,	 collected	 separately	 and	 ligated.	 The	 quantification	 of	 barcode	combinations	 by	 qPCR	 showed	 a	 low	 level	 of	 variation	 (CVs	 between	 2.2%	 and	5.1%)	except	combinations	of	BC-1	with	BC-A	to	BC-G	(CV	of	7.7%)	most	likely	due	to	 pipetting	 errors.	 These	 results	 imply	 a	 stable	 and	 uniform	 encapsulation	 of	 all	components	into	picolitre-sized	droplets	(Fig.	3.3D).		
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Fig.3.3	Generation	of	combinations	in	droplets	using	braille	valves		 	
(A)	Measured	 fluorescence	 signal	 width	 in	milliseconds	 [ms]	 over	 49	 combinations	with	 each	 dot	
representing	 a	 droplet	 and	 the	 coloured	boxes	 indicating	 a	 set	 of	 7	 combinations.	 (B)	Boxplots	 of	
signal	width	 grouped	by	 seven	 combinations	 according	 to	 the	 colour	 scheme	 in	A.	Numbers	 show	
coefficient	 of	 variations	 (CV)	 of	 signal	 width.	 (C)	 Blue	 peak	 fluorescence	 intensities	 of	 droplets	
generated	 from	 combinations	 (1-7	 +	 A-G).	 Combinations	 were	 grouped	 according	 to	 the	 colour	
scheme	 in	 A	 and	 CVs	 were	 calculated	 for	 each	 group.	 (D)	 Ct-values	 of	 49	 barcode	 combinations	
produced	from	the	valve-module.	Barcodes	were	collected	separately	and	then	amplified.	Ct-values	
were	grouped	into	seven	combinations	to	calculate	CV	values.			
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3.5. Sample	collector	and	washing	steps	The	 microfluidic	 pipeline	 included	 a	 sampler	 collector	 module,	 which	 was	integrated	 to	 collect	 specific	 subsets	 of	 droplets.	 It	 was	 necessary	 to	 perform	washing	 steps	between	each	 combination	 to	prevent	 cross-contamination.	After	 a	combination	was	generated,	valves	to	produce	the	next	combination	were	opened	for	3	sec	 resulting	 in	a	waste	plug	 (as	 it	 could	contain	remains	 from	the	previous	combination),	which	was	followed	by	an	oil	spacer.	Once	the	waste	plug	flushed	the	channels,	 the	 same	 valves	 were	 opened	 to	 produce	 the	 actual	 collection	 plug,	without	any	contamination	from	the	previous	sample	composition.	This	resulted	in	alternating	 sample	 and	waste	 plugs	 spaced	 out	 by	 oil.	 The	 sample	 collector	was,	thus,	 set	 to	 only	 collect	 droplets	 produced	 from	 sample	 plugs	 by	 applying	 time	windows	for	opening	collection	or	waste	valves.	To	test	the	collection	and	disposal	of	distinct	droplet	populations,	sample	plugs	with	fluorescein	(Green	channel)	and	Cascade	blue	(UV	channel)	followed	by	waste	plugs	additionally	labelled	with	Alexa	594	 (Orange	 channel)	 were	 generated	 using	 the	 valve-module	 (Fig.	 3.4A).	 We	aimed	to	collect	only	the	droplets	generated	from	green	sample	plugs	and	discard	droplets	generated	from	orange	plugs	by	setting	time	windows	for	delay,	collection	and	 waste	 (coloured	 boxes	 in	 Fig.	 3.4A).	 Droplets	 from	 the	 collection	 and	 waste	tube	were	re-injected	into	a	microfluidic	device	to	measure	fluorescence	intensities	of	the	two	fractions.	Droplets	from	the	collection	tube	were	negative	in	the	orange	channel,	 whereas	 droplets	 from	 the	waste	were	 positive,	 signifying	 a	 robust	 and	efficient	 collection	 of	 desired	 droplets	 generated	 from	 sample	 plugs	 (Fig.	 3.4B).	The	waste	 contained	additionally	orange	negative	droplets,	due	 to	 the	disposal	of	droplets	 from	 collection	plugs	 during	delay	 times.	 To	 assess	 the	purity	 of	 sample	plugs,	we	generated	combinations	 from	seven	 inlets	containing	Cascade	blue	with	six	inlets	containing	water	and	one	inlet	containing	fluorescein.	Thus,	by	combining	one	Cascade	blue	inlet,	six	blue	washing	and	sample	plugs	and	one	double	positive	(green	 and	 blue)	 washing	 and	 sample	 plug	 was	 produced	 (Fig.	 3.4D).	 The	summarized	 fluorescence	 intensities	 of	 all	 plugs	 showed	 strong	 green	 signals	 for	the	plugs	expected	 to	be	positive,	whereas	 the	subsequent	washing	plugs	and	 the	plugs	 expected	 to	 be	 negative	 showed	 only	 slightly	 increased	 or	 background	signals,	respectively	(Fig.	3.4C).	This	demonstrates	that	a	washing	step	of	3	sec	was	sufficient	 to	 remove	 all	 residual	 liquids	 that	 remain	 from	 the	 previous	 sample	composition	in	the	channels.		
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Fig.	3.4:	Validation	of	the	sample	collector		
(A)	 Fluorescence	 peaks	 of	 green	 positive	 (Fluorescein	 +	 Cascade	 Blue)	 and	 orange	 green	 double	
positive	 (Alexa594	 +	 Fluorescein	 +	 Cascade	 Blue)	 plugs.	 Collection	 parameters	were	 set	 to	 collect	
droplets	 generated	 from	 green	 plugs	 (green	 box)	 and	 discard	 droplets	 from	 orange	 plugs	 (orange	
box).	(B)	Histogram	of	droplet	intensities	in	the	orange	channel.	Green	and	red	counts	correspond	to	
measured	 intensities	 of	 droplets	 from	 the	 collection	 tube	 and	 waste	 tube,	 respectively.	 (C)	
Quantification	of	green	fluorescence	intensities	of	pos.	green	peaks,	the	subsequent	washing	peaks	
and	the	remaining	peaks	(neg.	peaks).	(D)	Representative	fluorescence	peaks	of	sample	(green	box)	
and	washing	 (orange	box)	plugs	and	green	peaks	every	 fourth	plug.	 Shown	peaks	 correspond	 to	a	
cycle	of	seven	combinations.		
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Fig.	3.5:	Barcode	combinations	generated	in	droplets		
(A)	Median	fluorescence	intensities	of	sample	plugs	from	49	barcode	combinations	over	3	replicates.	
(B)	 Normalized	 read	 counts	 of	 49	 barcode	 combinations	 for	 3	 replicates.	 Read	 counts	 were	
normalized	by	the	total	library	size	per	replicate.			
3.6. Generation	of	barcode	combinations	in	droplets		For	generation	of	droplets	 containing	distinct	 combinations,	we	used	a	 set	of	7x7	DNA-barcodes,	resulting	in	49	combinations	of	barcodes	which	were	read-out	using	NGS.	 Syringes	 filled	 with	 BC-A	 to	 BC-G	 were	 labelled	 with	 Cascade	 Blue	 for	measuring	 plugs	 and	 triggering	 the	 collection	 of	 droplets.	 Since	 only	 one	 set	 of	barcodes	 was	 labelled	 with	 a	 blue	 dye,	 measuring	 fluorescence	 signals	 was	 also	used	as	a	quality	control	for	a	mixing	at	constant	ratios	between	labelled	and	non-labelled	barcodes.	Valves	to	generate	one	barcode	combination	were	opened	for	5	sec	and	droplets	containing	barcodes	and	ligation	reagents	were	collected	for	4	sec,	resulting	in	a	total	production	time	of	12.25	min	for	49	combinations	with	~2100	droplets	per	combination	(for	droplets	of	800	pl	 in	size).	The	fluorescence	data	of	barcode	 combinations	 showed	 that	 the	 median	 intensities	 of	 plugs	 for	 all	
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combinations	were	stable	between	the	three	replicates.	The	median	intensities	over	all	 the	 plugs	 within	 each	 of	 the	 three	 technical	 replicates	 were	 6.5%,	 6.6%	 and	6.5%,	indicating	that	the	ratios	at	which	two	barcodes	were	mixed	were	stable	over	the	 experiments.	 Barcode	 combinations	 were	 sequenced	 and	 reads	 were	demultiplexed	based	on	the	input	sequences	from	the	barcode	library.	Read	counts	for	each	barcode	were	normalized	by	 the	 total	number	of	reads	per	replicate.	For	the	 majority	 of	 barcode	 combinations	 only	 low	 level	 of	 variation	 was	 observed	between	 replicates	 (Median	 CV=3.9%),	 conforming	 reproducibility	 between	replicates	(Fig.	3.5B).	However,	the	abundances	of	different	barcode	combinations	showed	 an	 almost	 2-fold	 difference	 in	 the	 read-count	 medians.	 This	 can	 be	circumvented	 by	 comparing	 barcode	 abundances	 to	 a	 reference	 like	 the	 barcode	numbers	before	sorting-based	enrichment	(see	chapter	3.7).			
3.6.1. Collection	 of	DNA	barcodes	 of	 varying	 collection	 times	 to	mimic	differences	in	barcode	abundance		In	order	to	assess	the	sensitivity	of	detecting	barcodes	at	different	abundances,	we	performed	experiments	with	varying	collection	times	for	different	barcodes.	For	a	set	 of	 seven	 barcode	 combinations	 the	 collection	 times	 were	 lowered	 manually	from	8	 sec	 to	 2	 sec	 by	 increments	 of	 1	 sec	 in	 the	 sample	 collector	 software	(Fig.	
3.6B).	 Apart	 from	 fluorescence	 intensities	 of	 sample	 plugs,	 the	 sample	 collector	software	recorded	the	time	windows	of	droplet	collection	(Fig.	3.6A).	The	number	of	 data	 points	 in	 each	 collection	 time	 window	 reflects	 the	 number	 of	 droplets	collected	 for	each	combination.	Since	droplets	were	produced	at	520	Hz	and	data	points	 for	 sample	 plugs	 were	 acquired	 at	 100	 Hz	 (upstream	 of	 the	 droplet	production),	 one	 data	 point	 corresponds	 to	 5.2	 collected	 droplets.	 Hence	 the	number	of	data	points	was	used	 to	verify,	 if	 correct	numbers	of	droplet	 for	all	49	barcode	combinations	over	3	replicates	were	collected	(Fig.	3.6B).	Only	in	one	case	(Barcode	 combination	 D7)	 we	 observed	 a	 strong	 deviation	 in	 the	 number	 of	collected	 droplets,	most	 likely	 being	 caused	 by	 a	 false	 activation	 of	 the	 collection	time.	The	reduced	droplet	collection	was	also	reflected	by	a	reduced	read-count	in	the	sequencing	data	and	hence	this	data	point	was	excluded	from	the	analysis.		
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Fig.	3.6:	Decreasing	collection	times	for	pairs	of	seven	barcode	combinations		
(A)	Fluorescence	signals	of	plugs	containing	barcode	combinations	and	collection	time	windows	(red	
lines)	applied	by	the	sample	collector	software.	 (B)	Number	of	droplets	collected	during	each	time	
window	 for	 all	 49	barcode	 combinations	 (n=3).	 The	number	of	droplets	 for	each	 combination	was	
determined	 from	 the	number	of	 recorded	data	points	 for	 each	 combination	 and	 the	 frequency	of	
droplet.					
3.6.2. Read-counts	in	barcode	libraries	recapitulate	number	of	collected	droplets	Barcode	 libraries	of	varying	abundances	were	sequenced	to	determine	 if	different	amounts	of	barcoded	droplets	could	be	quantified	using	DNA-based	barcoding	and	NGS.	 From	 each	 replicate	 two	 samples	 were	 prepared	 and	 sequenced.	Demultiplexed	read-counts	for	each	replicate	were	normalized	by	total	read-counts.	To	assess	whether	the	number	of	generated	droplets	correlated	with	read-counts,	a	set	of	seven	barcode	combinations	(A1-A7,	B1-B7	etc.)	was	normalized	by	the	read-counts	 for	 barcodes	 collected	 for	 5	 sec.	 Fold	 changes	 of	 barcode	 abundances	compared	to	a	collection	of	5	sec	was	in	good	agreement	with	the	collection	times	for	most	of	the	barcode	combinations	(Fig.	3.7A).	Only	in	three	cases	a	reduction	in	the	collection	time	did	not	result	 in	a	reduced	fold	change	(D1	and	D2,	E3	and	E4	and	C6	and	C7).	The	good	agreement	between	collected	droplets	and	read-counts	was	confirmed	by	the	fold	changes	for	each	collection	time	summarized	across	all	
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barcodes,	 which	 consistently	 showed	 an	 increased	 read-count	 for	 increasing	amounts	of	collected	droplets,	apart	 for	 increasing	the	collection	time	 from	5	to	6	sec.	 (Fig.	 3.7B).	 Nonetheless,	 these	 results	 signify	 a	 good	 sensitivity	 since	differences	of	approximately	520	droplets	were	detected	 in	most	cases	with	good	confidence.	
	
	
	
Fig.	3.7:	Barcode	libraries	collected	at	varying	collection	time		 	
(A)	 Log	 fold	 change	 of	 read	 counts	 for	 varying	 collection	 times	 over	 6	 technical	 replicates	 from	 3	
different	 samples.	 Barcoded	 droplets	 were	 collected	 for	 different	 time	 periods	 decreasing	 from	
barcode	1	(8s)	to	barcode	7	(2s).	Read	counts	were	normalized	by	the	mean	read	count	at	5	sec	for	
each	set	of	7	combinations	(B)	Summary	of	the	fold	changes	 in	read	counts	for	different	collection	
times,	compared	to	5s	collection.	Statistical	significance	for	every	increase	in	the	collection	time	was	
determined	 using	 pairwise	 Wilcox	 test	 and	 p-values	 were	 adjusted	 according	 to	 Benjamini	 &	
Hochberg	(ns:	not	significant,	*:	p<0.05,	**:	p≤0.01,		***:	p≤0.001,	****:	p≤0.0001).	 	
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3.7. Enrichment	 of	 specific	 droplets	 encoded	 by	 barcode	combinations		Fluorescence	 activated	 droplet	 sorting	 (FADS)	 can	 be	 applied	 to	 enrich	 specific	droplet	populations	based	on	their	fluorescence	signals	and	thereby	select	the	ones	with	 specific	 phenotypes	 (e.g.	 droplets	 containing	 apoptotic	 cells).	 Sorting	experiments	 with	 chemically	 diverse	 droplets	 encoded	 by	 DNA-barcodes	 would	allow	 highly	 multiplexed	 enrichment	 of	 all	 rather	 than	 only	 one	 sample	combination	(e.g.	drug	combination)	fulfilling	the	selection	criteria.	For	testing	the	ability	to	enrich	specific	phenotypes	and	to	determine	the	corresponding	droplets	composition	by	sequencing,	49	barcode	combinations	were	generated	 in	droplets.	Apart	 from	 the	 syringes	 containing	 BC-A	 to	 BC-G	 labelled	with	 Cascade	 Blue,	 we	labelled	 the	 syringe	 containing	BC-3	with	 fluorescein.	As	 a	 result,	 7	 out	 of	 the	49	combinations	 (3A	 to	 3G)	 were	 stained	 with	 a	 green	 dye,	 mimicking	 a	 particular	phenotype	(Fig.	3.8A).	The	generated	droplets	from	49	combinations	were	injected	into	 a	 droplet-sorting	 device	 and	 sorted	 based	 on	 their	 fluorescence	 signal	 (Fig.	
3.8B).	 Since	we	aimed	 for	enriching	green	positive	droplets,	we	applied	a	 sorting	gate	 around	 droplets	with	 high	 green	 fluorescence	 signal	 (Fig.	 3.8C).	 In	 order	 to	determine	the	level	of	enrichment	in	the	sorted	population,	we	sequenced	barcode	libraries	prepared	from	droplets	before	sorting	and	after	sorting	and	compared	the	read	counts.	The	fold	change	in	barcodes	between	the	unsorted	and	sorted	samples	showed	 an	 increase	 for	 barcode	 combinations	 3A	 to	 3G	 (FDR<0.05)	 whereas	 all	other	 barcode	 combinations	 were	 depleted	 (Fig.	 3.8D).	 On	 average,	 barcode	combinations	 encoding	 green	 positive	 droplets	 were	 significantly	 enriched	compared	 to	 green	 negative	 droplets	 (Δ𝑙𝑜𝑔2 = 5.3;  𝑝 < 2.2𝑒!!",	 Student’s	 t-test).	This	demonstrates	that	the	described	workflow	can	be	applied	to	specifically	enrich	all	sample	combinations	fulfilling	particular	phenotypic	selection	criteria	(i.e.	hits)	by	 sorting	 based	 on	 fluorescence	 and	 these	 hits	 can	 subsequently	 be	 identified	based	on	DNA-barcodes.		
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Fig.	3.8:	Enrichment	and	demultiplexing	of	specific	droplet	populations	 	
(A)	 Sequence	 of	 fluorescence	 signals	 for	 49	 barcode	 combinations.	 Plugs	 containing	 BC-3	 were	
additionally	labelled	with	a	green	dye	resulting	in	green	positive	peaks	for	every	7th	combination.	(B)	
Microfluidic	 setup	 for	 the	 enrichment	 of	 specific	 droplet	 populations	 encoded	 by	 barcode	
combinations.	 (1)	Each	barcode	combination	was	encapsulated	together	with	 ligation	reagents.	 (2)	
Droplets	 were	 re-injected	 into	 a	 sorting	 device	 and	 fluorescence-based	 sorting	was	 performed	 to	
enrich	droplets	positive	in	the	green	channel.	(3)	Green	positive	droplets	were	collected	and	used	to	
prepare	 barcode	 libraries	 for	 sequencing.	 (C)	 Fluorescence	 data	 acquired	 during	 sorting	 of	 green	
positive	 droplets.	 Red	 square	 indicates	 the	 gating	 applied	 for	 sorting	 green	 positive	 droplets.	 (D)	
Log2	 fold-changes	 in	 barcode	 abundances	 comparing	 read-counts	 from	 before	 and	 after	 sorting.	
Read	counts	were	normalized	by	the	corresponding	means	from	the	unsorted	samples.	Adjusted	p-
values	(False	discovery	rate)	are	shown	next	every	bar	in	italic.			 	
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3.8. Discussion	on	DNA-barcoding	based	multiplexing	of	droplet	content				The	 above	 described	 microfluidic	 workflow	 enables	 on-demand	 generation	 of	combinations	 in	 droplets	 using	 a	 valve-based	 system.	 This	 was	 achieved	 by	integrating	previously	described	Braille	valves	into	a	newly	developed	microfluidic	pipeline	including	a	drop-maker	and	a	sample	collector.	The	pipeline	facilitates	the	production	of	droplets	from	sample	plugs	containing	combinations	of	two	samples,	each	 encoded	 by	 a	 distinct	 DNA-barcode	 combination.	 Additionally,	 the	 sample	collector	 enables	 the	 selective	 collection	 of	 droplets	 and	 thereby	 allows	washing	between	 consecutive	 combinations	 ensuring	 purity	 of	 produced	 droplets.	 The	modularity	of	the	described	system	has	the	advantage	that	individual	components	can	be	easily	exchanged	for	different	purposes	(e.g.	more	inlets	on	the	drop-maker).	Furthermore,	malfunctions	in	one	of	the	modules	can	be	fixed	by	only	replacing	the	affected	device,	resulting	in	a	workflow	that	is	easy	to	maintain.		
3.8.1. Validation	based	on	fluorescence	signals	and	qPCR	By	using	two	fluorescent	dyes,	the	ability	of	the	valve-module	and	the	drop-maker	to	 combine	 two	 injected	compounds	and	 to	encapsulate	 those	 into	droplets	along	with	 other	 reagents	 was	 tested.	 The	 signal	 width	 of	 the	 generated	 droplets	 was	used	to	determine	the	level	of	monodispersity.	According	to	literature,	an	emulsion	is	generally	considered	monodisperse	if	the	size	of	droplet	diameter	varies	by	a	CV	less	 than	 5%	 (Roberts	 et	 al.,	 2012),	 although,	 monodispersity	 has	 also	 been	attributed	 to	emulsions	with	CVs	 in	droplet	width	of	8%	(Abate	et	al.,	2011).	The	measured	 size	 distribution	 of	 droplets	 generated	 from	 sample	 plugs	 had	 a	 CV	 of	6%,	 thus	 exceeding	 the	 general	 criteria	 of	monodispersity	 and	 therefore	 droplets	can	be	considered	quasi-monodisperse.	The	increased	variation	in	droplet	size	was	caused	by	high	numbers	of	outliers	(see	Fig.	3.3A),	which	mainly	fall	below	the	1st	quartile	(3%	of	all	droplets	compared	to	0.9%	above	the	4th	quartile).	This	is	likely	caused	 by	 the	 need	 for	 spacing	 out	 individual	 combinations	with	 oil,	 resulting	 in	short	 intervals	of	droplet	production	 from	aqueous	phases	 injected	 into	 the	drop-maker.	 Therefore,	 the	 aqueous	 flow	needs	 to	 re-equilibrate	 for	 each	 combination	causing	 short	 periods	 of	 flow	 instability.	 Additionally,	 the	 variation	measured	 for	the	fluorescence	intensities	of	the	droplets	affects	the	apparent	signal	width	(higher	
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peaks	cause	a	greater	signal	width)	and	thereby	contributed	to	the	measured	quasi-monodisperse	size	distribution	(Clausell-Tormos	et	al.,	2008).	As	a	consequence	the	true	monodispersity	of	 the	generated	droplets	might	be	better	than	the	measured	size	 distribution.	 The	 dilution	 of	 a	 fluorescence	 dye	 was	 used	 as	 a	 measure	 to	determine	the	mixing	of	reagents	by	the	valve-module.	In	some	cases	we	observed	strong	variations	 in	 the	 fluorescence	 intensities	of	droplets	 from	49	combinations	(CV	 >	 10%,	 Fig.	 3.3C).	 However,	 the	 median	 intensities	 of	 each	 group	 of	 seven	combinations	were	stable	over	all	seven	groups	(CV	of	3.3%).	This	suggests	that	the	mixing	 of	 two	 components	 in	 the	 valve-module	 was	 comparable	 for	 all	combinations,	 but	 the	 droplet	 production	was	 not	 stable	 over	 time.	 This	 again	 is	likely	to	be	caused	by	unstable	flow	regimes	at	the	beginning	of	each	collection	plug	and	 could	 potentially	 be	 overcome	 by	 increasing	 the	 droplet	 collection	 times	 for	each	combination.	Furthermore,	fluctuation	in	the	trajectory	of	droplets	within	the	channel	 can	 affect	 their	 position	 relative	 to	 the	 focused	 laser	 beam	 used	 for	 the	readout,	 potentially	 causing	 signal	 variation	 that	 does	 not	 correspond	 to	 varying	contents	or	sizes.	Since	droplets	were	produced	from	a	laminar	flow	and	no	mixing	of	droplet	content	was	performed	before	measuring,	this	can	additionally	affect	the	fluorescence	 intensities.	Taken	together,	 the	 true	variation	of	droplet	composition	and	size	might	be	smaller	than	indicated	by	the	fluorescence	signals.	The	accuracy	of	mixing	two	components	was	therefore	also	measured	by	qPCRs	of	two	DNA-fragments	combined	into	droplets.	The	Ct-values	of	barcode	combinations	were	comparable	for	sets	of	seven	combinations,	demonstrating	a	stable	and	robust	mixing	of	two	components	by	the	described	pipeline.	Since	no	internal	reference	for	the	normalization	of	Ct-values	was	present,	the	high	level	of	variation	observed	for	Ct-values	 of	 combinations	 from	 valve	 1	 with	 valves	 A	 to	 G	 is	 likely	 to	 reflect	pipetting	errors.	For	the	pipeline	described	in	this	chapter	we	used	a	sample	collector	ensuring	the	collection	 of	 only	 those	 droplets	 containing	 sample	 combinations	 without	significant	 cross-contaminations.	 Washing	 the	 microfluidic	 devices	 by	 opening	valves	 for	 the	 next	 combination	 and	 flushing	 residual	 liquids	 of	 the	 previous	combinations	 away,	 primed	 the	 channels	 for	 collection	 of	 an	 uncontaminated	subsequent	combination.	Discarding	droplets	created	during	the	washing	step	was	possible	with	a	 simple	valve-based	unit	 that	directed	 these	droplets	 to	 the	waste.	The	 implementation	 of	 a	 computer	 guided	 droplet	 collection	 unit	 allows	
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fluorescence-	 and	 time-based	 collection	 of	 droplets	 into	 different	 tubes.	 The	established	droplet	collection	module	 is	a	useful	 tool	 for	droplet	production	were	cross-contaminations	 between	 chemically	 different	 samples	 is	 an	 issue	 (Clausell-Tormos	et	al.,	2010).	The	sample	collector	module	can	be	further	envisioned	as	an	application	 such	as	automated	droplet	 collection	 to	 selectively	distribute	droplets	into	different	wells	(Utharala	et	al.,	2018)	for	more	complex	downstream	analyses.		
3.8.2. Multiplexing	of	droplets	using	deterministic	barcoding		In	 order	 to	 show	 that	 the	 presented	 microfluidic	 workflow	 can	 generate	 truly	distinct	combinations,	we	generated	49	DNA-barcode	combinations	in	droplets	for	sequencing.	Using	 constant	 collection	 times	 for	each	 combination,	we	expected	 to	obtain	even	read	counts	 for	each	barcode	combination.	However,	we	observed	an	almost	2-fold	difference	between	the	lowest	and	highest	median	read	count	(Range:	0.0137	 to	 0.0263).	 The	 observed	 variation	 in	 read-counts	 made	 it	 crucial	 to	normalize	 values	 and	 compare	 relative	 barcode	 abundances.	 Since	 we	 envision	performing	 combinatorial	 drug	 screenings	 with	 the	 presented	 technology,	 we	anticipate	 comparisons	 between	 barcode	 abundances	 before	 and	 after	 a	 droplet	sorting	 based	 enrichment	 step.	 Thereby	 we	 can	 neglect	 differences	 in	 barcode	abundance	 before	 sorting,	 as	 we	 will	 only	 consider	 the	 enrichment	 of	 barcodes	between	 unsorted	 and	 sorted	 samples.	 Additionally,	 the	 moderate	 variation	between	replicates	will	ensure	reproducibility	over	several	experiments	enabling	a	more	 robust	detection	of	barcode	abundances.	The	observed	variation	 in	barcode	abundance	 was	 potentially	 caused	 by	 amplification	 biases	 during	 library	preparation.	 Consequently,	 the	 integration	 of	 unique	molecular	 identifiers	 (UMIs)	into	the	barcoding	system	could	help	to	improve	the	readout	of	barcode	abundance	since	absolute	numbers	of	barcodes	would	be	counted	(Islam	et	al.,	2014).	In	 a	 setting	 where	 droplets	 containing	 diverse	 drug	 combinations	 are	 enriched	based	 on	 their	 potency	 to	 induce	 apoptosis,	 we	 would	 imagine	 an	 increase	 in	number	 of	 droplets	 with	 different	 drug	 combinations	 that	 correlate	 with	 their	apoptotic	potency.	To	mimic	such	a	case	and	to	test	the	sensitivity	of	our	setup	to	detect	subtle	differences	in	droplets	numbers	by	sequencing	barcode	combinations,	we	collected	droplets	containing	barcode	combinations	with	varying	time	windows.	A	 change	 in	 collection	 time	 for	 droplets	 with	 a	 specific	 barcode	was	 reflected	 in	most	cases	by	a	corresponding	change	in	the	read-counts.	An	increase	in	collection	
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time	 from	 7s	 to	 8s	 corresponded	 to	 a	 1.14	 fold	 increase	 in	 number	 of	 collected	droplets,	 that	 was	 overall	 detected	 with	 statistical	 confidence,	 implying	 a	 good	sensitivity	in	discriminating	the	potencies	of	potential	“hits”.	Only	in	three	cases	the	read-count	data	did	not	correspond	to	 the	number	of	collected	droplets.	Since	we	did	not	observe	a	deviation	in	the	number	of	collected	droplets	for	these	cases	(Fig.	3.6B),	we	assume	that	amplification	biases	caused	the	observed	deviation	in	read-counts.	Furthermore,	 by	 sorting	 specific	 droplet	 phenotypes,	 we	 illustrated	 the	applicability	of	 the	presented	pipeline	 for	combinatorial	screenings	of	compounds	with	 fluorescence-based	 detection	 of	 hits	 and	 their	 sequencing-based	demultiplexing.	 We	 showed	 that	 49	 potential	 conditions	 could	 be	 screened	simultaneously	in	a	single	droplet-based	sorting	experiment	by	sorting	droplets	of	interest	 and	 identifying	 their	 contents	 by	 sequencing.	 The	 high	 specificity	 of	 the	presented	 approach	 was	 reflected	 in	 significant	 increase	 of	 the	 desired	 barcode	combinations	(FDR<0.01)	and	strong	depletion	of	all	other	barcodes.			 	
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4. Development	 of	 a	 microfluidic	 workflow	 for	 gene	expression	based	profiling	of	drug	combinations				
4.1. 	Introduction		In	this	chapter,	an	expanded	version	of	the	introduced	microfluidic	and	barcoding	systems	is	described,	that	allows	the	multiplexed	readout	of	gene	expression	from	cells	exposed	to	combinatorial	droplet	contents.	Since	the	number	of	combinations	increase	 exponentially	 with	 the	 number	 of	 drugs,	 conventional	 approaches	 for	screening	 combinations	 can	 often	 exceed	 feasibility,	 especially	 when	 the	biomaterial	is	limited	(e.g.	screening	tumor	biopsies).	Additionally,	various	studies	have	 shown	 the	 great	 potential	 of	 drug	 combinations	 for	 the	 treatment	 of	 cancer	(Dietlein	et	al.,	2015;	Manchado	et	al.,	2016)	and	bacterial	(Brochado	et	al.,	2018)	or	viral	 infections	 (Gulick	 et	 al.,	 1997).	 Together,	 it	 implies	 that	 the	 development	 of	new	approaches	for	combinatorial	drug	screenings	can	be	beneficial.	Droplet-based	microfluidics	 would	 allow	 drug	 screenings	 in	 a	 miniaturized	 format,	 reducing	sample	 volumes	 by	 several	 orders	 of	 magnitude	 compared	 to	 multi-titre	 plate	approaches	 (Sackmann	 et	 al.,	 2014).	 Such	 a	 decrease	 in	 volumes	 can	 result	 in	 an	increased	 throughput	 and	 scale	 since	 small	 amounts	 of	 reagents	 are	handled	 and	required.	Additionally,	a	reduction	of	input	material	allows	screenings	with	low	cell	numbers	and,	therefore,	could	enable	testing	drug	combinations	on	tumor	biopsies	to	 define	 personalized	 treatments.	 Conventional	 drug	 screens	 focus	 on	 singular	readouts	(e.g.	cell	viability)	to	determine	efficacies	of	drugs.	These	readouts	do	not	provide	insights	into	the	molecular	responses	a	drug	or	drug	combination	evokes	in	tumor	cells.	However,	a	deeper	characterization	of	drug	responses	could	be	of	great	interest	to	decipher	working	principles	of	synergistic	drug	pairs	and	to	determine	potential	causes	of	resistance	towards	drugs.		
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In	 order	 to	 perform	 combinatorial	 drug	 screenings	 in	 a	miniaturized	 setting,	 the	microfluidic	workflow	described	in	the	previous	chapter	was	improved	in	terms	of	scale	 and	 readout.	 By	using	 the	previously	 described	 valve-based	 system	with	 an	increased	number	of	 valves	 and	pairing	 it	with	 an	autosampler-based	 system,	we	can	 produce	 hundreds	 of	 combinations	 in	 picolitre-sized	 droplets.	 In	 order	 to	achieve	a	more	comprehensive	characterization	of	effects	drug	combinations	have	on	cellular	phenotypes,	we	used	an	advanced	barcoding	approach	to	perform	highly	multiplexed	profiling	gene	expression.			
4.2. Microfluidic	workflow	for	a	combinatorial	drug	screening	in	droplets		The	 generation	 of	 chemically	 complex	 droplets	 was	 achieved	 by	 combining	 the	valve-based	 technology	with	 a	 commercially	 available	 autosampler	device	 (AS).	A	modular	 workflow	 with	 two	 microfluidic	 devices	 and	 an	 autosampler	 was	established	 to	 enable	 rapid,	 automated	 and	 robust	 production	 of	 droplets	 with	large	numbers	of	 compound	combinations	 (Fig.	 4.1).	 (1)	A	valve-module	with	24	inlets	 directed	 20	 injected	 compounds	 either	 to	 the	 waste	 outlets	 or	 the	 sample	outlet.	 The	 two	 outermost	 valves	 on	 both	 sides	 of	 the	 device	 were	 used	 for	 oil	injection	to	space	out	individual	compounds	with	an	immiscible	phase.	Opening	of	a	single	valve	to	generate	a	compound	plug	was	followed	by	oil	injection	from	all	four	oil	 valves	(Fig.	 4.1A-1).	 The	outlet	of	 the	valve-module	was	 connected	 to	 a	delay	tubing	long	enough	to	be	filled	with	one	cycle	of	20	compound	plugs.	Once	the	delay	tubing	was	filled	with	all	20	compound	plugs,	two	oil	valves	were	opened	to	inject	all	 compound	 plugs	 into	 the	 drop-maker	 chip.	 (2)	 The	 drop-maker	 combined	compound	plugs,	cells	and	compounds	injected	from	the	autosampler	into	picolitre-sized	 droplets	 at	 a	 flow-focusing	 junction.	 The	 autosampler	was	 used	 to	 aspirate	one	compound	at	a	time	from	a	96-well	plate,	which	was	then	combined	with	one	cycle	of	20	compound	plugs	coming	from	the	valve-module	(Fig.	4.1A-2).	Produced	droplets	 containing	 a	 combination	 of	 two	 compounds	 and	 cells,	 were	 directly	collected	 in	 a	 single	 tube.	 No	washing	 steps	were	 required	 as	 dead	 volumes	 and	plug	 break-up	 at	 the	 inlet	 and	 outlet	 of	 the	 delay	 tubing	 were	 minimized	 (see	below).		
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Fig.	4.1:	Workflow	for	large-scale	production	of	combinations	in	droplets	
(A)	 Microfluidic	 pipeline	 used	 in	 this	 work	 to	 generate	 up	 to	 420	 drug	 combinations	 in	 droplets	
together	with	RNA-Seq	based	readout.	The	pipeline	consisted	of	two	microfluidic	devices	(B	and	C)	
and	an	autosampler.	(1)	A	valve-module	controlling	20	compound	inlets	and	4	oil	inlets	connected	to	
syringes.	Opening	of	one	 compound	valve	 results	 in	 the	 injection	of	 a	particular	drug	 into	 a	delay	
tubing	used	to	transfer	a	cycle	of	20	compounds	from	the	valve-module	into	the	drop-maker.	(2)	On	
the	drop-maker	compound	plugs	were	combined	with	cells	and	compounds	 from	the	autosampler	
before	encapsulation	into	droplets,	which	were	subsequently	stored	in	a	single	tube.	(B)	Chip	layout	
used	 for	 the	valve-module	with	24	 inlets	and	valve	units.	 (C)	Chip	 layout	of	 a	drop-maker	used	 to	
generate	droplets	 from	3	aqueous	 inlets	 (compound	plugs,	 cells	 and	 compounds	 coming	 from	 the	
autosampler).	
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For	 the	 valve-module,	 a	 microfluidic	 chip	 bound	 to	 an	 elastic	 membrane	 was	aligned	with	its	valve	structures	on	pins	of	a	braille	display	(Fig.	4.1B).	The	outlet	was	a	funnel-like	structure	that	allows	horizontal	insertion	of	the	delay	tubing.	The	delay	 tubing,	 on	 the	 other	 end,	was	 connected	 via	 a	 funnel-like	 inlet	 to	 the	drop-maker	device	(Fig.	4.1C).	The	drop	maker	was	bound	to	an	elastic	membrane	and	glass	slide	enabling	the	side-wards	insertion	of	the	delay	tubing	(Fig.	4.2A).		
Determining	 the	 level	 of	 cross-contaminations	 between	compound	plugs	In	order	to	avoid	washing	steps	between	individual	compound	plugs,	the	injection	of	compound	plugs	into	the	drop-maker	was	performed	over	a	horizontal	inlet.	As	compared	 to	 conventional	 vertical	 inlets,	 horizontal	 connection	 ports	 prevent	cross-contamination	 between	 injected	 compound	 plugs	 due	 to	 plug	 breakup	 in	dead	 volumes	 of	 the	 punched	 inlet	 (Clausell-Tormos	 et	 al.,	 2010).	 We	 injected	compound	plugs	containing	 trypan	blue	dye	 to	visualize	 the	complete	 injection	of	plugs	(Fig.	4.2A).	The	individual	frames	of	a	video	sequence	showed	that	the	entire	compound	plug	was	injected	into	the	channel	of	the	drop-maker.	To	further	assess	the	 purity	 of	 compound	 plugs	 injected	 for	 droplet	 generation,	 we	 supplemented	syringes	with	Cascade	blue	or	fluorescein	and	injected	the	compound	dye	mixtures	in	an	alternating	fashion	(blue	->	green	->	blue	etc.)	(Fig.	4.2B).	The	representative	cycle	of	compound	plugs	illustrates	that	the	level	of	cross-contaminations	between	plugs	 was	 below	 the	 detection	 limit	 as	 the	 fluorescence	 signal	 of	 a	 positive	 plug	dropped	 to	 background	 level	 in	 the	 subsequent	 plug	 (one	 valve	was	not	working	resulting	in	19	peaks).	The	level	of	cross-contaminations	over	all	compound	plugs	(n=418)	were	analysed	by	comparing	 the	median	 intensities	of	positive	peaks	 for	one	 dye	 (e.g.	 green	 positive	 peaks)	 and	 the	median	 intensities	 of	 this	 dye	 in	 the	negative	peaks	(e.g.	green	signal	 in	blue	peaks)	(Fig.	 4.2C).	Over	all	22	cycles,	we	only	 observed	 cross	 contamination	 in	 four	 compound	 plugs.	 The	 summarized	median	green	and	blue	intensities	of	green	and	blue	peaks	confirmed	the	low	level	of	 cross-contamination	 between	 compounds	 (Fig.	 4.2D,	 E).	 The	 level	 of	 cross-contamination	 was	 determined	 by	 comparing	 the	 median	 intensity	 of	 negative	peaks	to	positive	peaks.	The	overall	cross-contamination	of	blue	(by	the	green	dye)	and	green	(by	the	blue	dye)	peaks	was	0.72%	and	2.32%,	respectively.		
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Fig.	4.2:	Generation	of	compound	plugs	from	the	valve-module		
(A)	Horizontal	injection	of	compound	plugs	from	the	valve-module	into	the	inlet	of	the	drop-maker.	
(B)	Representative	cycle	of	compound	plugs	injected	into	the	drop-maker,	each	spaced	out	with	oil.	
Compounds	 were	 supplemented	 with	 either	 green	 or	 blue	 dye	 and	 produced	 in	 an	 alternating	
fashion.	 (C)	Median	green	 intensities	of	green	positive	plugs	and	subsequent	negative	 (blue)	plugs	
over	 22	 injection	 cycles.	 (D)	 Summarized	median	 green	 intensities	 from	 all	 green	 and	 blue	 peaks.	
Percentage	 of	 cross-contamination	was	 calculated	 by	 comparing	 the	median	 of	 green	 intensity	 of	
negative	(blue)	peaks	with	positive	(green)	peaks	(0.72%).	(E)	Cross	contamination	of	the	blue	dye	in	
the	green	plugs.	Median	blue	intensities	of	blue	peaks	and	green	peaks	with	the	percentage	of	cross-
contamination	given	for	green	peaks	(2.32%).	
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4.3. Principle	of	generating	chemical	complexity	in	droplets		With	the	aforementioned	approach,	we	produced	combinations	of	compounds	from	the	valve-module	with	compounds	from	a	96-well	plate	and	encapsulated	them	into	picolitre-sized	droplets.	Here	a	sequence	of	20	compound	plugs	was	combined	with	one	 compound	 injected	 by	 the	 autosampler,	 before	 repeating	 the	 cycle	 with	 the	next	compound	coming	from	the	autosampler.	The	workflow	started	with	injection	of	 plugs	 containing	 a	 single	 compound	 spaced	 out	 by	 an	 oil	 phase	 into	 a	 delay	tubing	(Fig.	4.3A-1).	The	length	of	the	delay	tubing	was	adjusted	to	the	volume	of	all	 20	 compound	 plugs	 plus	 oil	 spacer	 so	 that	 one	 entire	 cycle	 of	 20	 plugs	 was	stored	in	it.	The	arrival	of	the	compound	plugs	from	the	valve-module	via	the	delay	tubing	 and	 the	 compound	 from	 the	 autosampler	 at	 the	 drop	maker	 needed	 to	 be	synchronized.	 Therefore,	 after	 the	 first	 5	 compound	 plugs	were	 injected	 into	 the	delay	tubing	by	the	valve-module,	the	autosampler-based	injection	of	a	compound	was	 started,	 since	 it	 took	 about	 2	 min	 until	 the	 compound	 reached	 its	 peak	concentration	 in	 the	drop-maker.	During	 this	 time,	all	 remaining	compound	plugs	were	injected	into	the	delay	tubing	(Fig.	4.3A-2).	Once	all	plugs	were	produced,	the	two	outer	most	oil	valves	from	both	sides	of	the	valve-module	were	opened	and	all	plugs	were	 injected	 into	 the	drop-maker,	 guaranteeing	 a	 stable	 and	uniform	 flow	rate	 for	 all	 compounds	 during	 their	 encapsulation	 into	 droplets.	 Each	 cycle	 of	 20	compound	plugs	was	combined	with	one	compound	 injected	 from	a	96-well	plate	by	the	autosampler	(Fig.	4.3B).	We	matched	the	injection	time	for	each	compound	by	 the	 autosampler	 to	 the	 overall	 time	 of	 one	 cycle	 from	 the	 valve-module	(generation	 and	 injection	 of	 compound	 plugs),	 thereby	 ensuring	 that	 all	 20	compound	 plugs	 were	 combined	 with	 the	 specific	 compound	 injected	 from	 the	autosampler.	 For	 cell-based	 screenings,	 we	 injected	 a	 single-cell	 suspension	 into	the	drop-maker	at	a	 concentration	 resulting	 in	a	 single	 cell	being	encapsulated	 in	approximately	 every	 fourth	 droplet	 (Clausell-Tormos	 et	 al.,	 2008).	 By	 combining	several	 cycles	 of	 20	 compound	 plugs	with	 compounds	 from	 the	 autosampler,	we	were	able	to	produce	high	numbers	of	combinations	at	high	throughput	(Fig.	4.3C).	The	overall	time	depends	on	the	number	of	droplets	(i.e.	number	of	cells)	screened	for	each	combination	and	the	number	of	compounds	injected	by	the	autosampler.	In	this	 study	we	 combined	21	 compounds	 from	a	 96-well	 plate	 and	 aimed	 for	 1000	cells	per	combination.	In	this	case	the	time	for	one	combination	was	16	sec	and	the	total	time	for	420	combinations	was	112	min.		
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Fig.	4.3:	Principle	of	combining	compound	plugs	and	compounds	from	the	
autosampler	in	droplets		
(A)	Plugs	containing	a	single	compound	were	produced	by	the	valve-module	and	injected	into	a	delay	
tubing,	each	spaced	out	by	oil	(1).	The	length	of	the	delay	tubing	was	adjusted	to	fit	all	20	compound	
plugs.	 (2)	Once	 all	 20	 compound	 plugs	were	 produced	 and	 stored	 in	 the	 delay	 tubing	 (3),	 two	 oil	
valves	were	opened	to	 inject	all	plugs	 into	the	drop	maker.	 (B)	 Injection	of	compound	plugs	 into	a	
drop-maker	 along	 with	 cells	 and	 compound	 from	 the	 autosampler.	 All	 three	 streams	 formed	 a	
laminar	flow	before	they	were	encapsulated	together	into	droplets	at	constant	ratios,	giving	rise	to	
20	combinations	 in	a	single	cycle.	 (C)	Compound	plugs	combined	with	1	to	n	compounds	 from	the	
autosampler	results	in	a	chemical	complexity	of	20n.			
	
4.4. Combining	 compounds	 from	 the	 autosampler	 with	 sample	plugs	yields	highly	complex	droplet	libraries		The	described	principle	of	generating	combinations	from	the	valve-module	and	an	autosampler	 was	 validated	 using	 fluorescence	 dyes.	 The	 autosampler	 was	 first	loaded	with	a	96-well	plate	containing	fluorescein	and	Cascade	blue	samples	in	an	
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alternating	 fashion,	 which	 were	 injected	 into	 a	 drop-maker	 device.	 An	 injection	time	of	5	min	for	each	round	of	injection	was	set	and	fluorescence	intensities	were	measured	 downstream	 of	 the	 inlet	 (Fig.	 4.4A).	 We	 observed	 clear	 separation	 of	green	and	blue	peaks	with	 low	dispersion	 into	 the	carrier	 fluid	(PBS).	The	overall	cycle	for	one	injection	round	was	6	min	(1	min	for	the	aspiration	of	one	sample	and	1	min	for	the	signal	to	reach	its	plateau/max.	concentration)	leaving	a	time	window	of	~4	min	during	which	one	sample	coming	from	the	autosampler	can	be	combined	with	all	20	compound	plugs	from	the	valve-module.	Testing	the	performance	of	the	pipeline	 to	 generate	 combinations	 in	 the	 described	 manner,	 compound	 plugs	 of	Cascade	blue	were	combined	with	 fluorescein	 injected	by	 the	autosampler	on	 the	drop-maker	 device	 and	 co-encapsulated	 into	 droplets.	 Successful	 mixing	 was	confirmed	 by	 measuring	 double-positive	 fluorescence	 signals	 of	 droplets	 from	 9	cycles	 (Fig.	 4.4B).	 We	 observed	 one	 main	 population	 indicating	 that	 both	compounds	 were	 encapsulated	 at	 constant	 ratios.	 This	 was	 confirmed	 by	 the	median	 intensities	 of	 individual	 combinations,	 which	 were	 stable	 over	 all	combinations	with	a	CV	of	2.9%	and	3%	for	blue	and	green	intensities,	respectively	
(Fig.	4.4E).	The	blue	fluorescence	intensity	distributions	of	droplets	from	9	cycles	strongly	overlapped	and	thus	further	indicated	a	stable	co-encapsulation	of	the	two	dyes	 (Fig.	 4.4C).	 However,	 the	 blue	 fluorescence	 distributions	 were	 relatively	broad	 and	 showed	 a	 high	 number	 of	 outliers	 (Fig.	 4.4C,	 E).	 To	 rule	 out	 that	 the	observed	 variations	 in	 fluorescence	 intensities	 were	 caused	 by	 instable	 laminar	flow	regimes	due	to	the	oil	spacer	between	each	compound	plug,	we	compared	the	density	distributions	of	blue	fluorescence	intensities	from	droplets	generated	with	or	 without	 oil	 spacer	 (Fig.	 4.4D).	 Since	 the	 observed	 variations	 of	 both	distributions	 were	 comparable	 (CV	 spacer	 13	 %	 vs.	 CV	 no	 spacer	 15%),	 we	concluded	 that	 the	 variation	 did	 not	 derive	 from	 re-equilibrating	 flows	 between	each	 sample	 plug	 but	 is	 likely	 to	 be	 a	 measurement	 artefact.	 Overall,	 this	 data	demonstrated	that	mixing	of	compound	plugs	together	with	compounds	from	a	96-well	 plate	 into	 droplets	 can	 be	 achieved	 at	 constant	 ratios	 and	 thus	 this	 pipeline	presents	 a	 novel	 approach	 for	 the	 fast	 and	 large-scale	 production	 of	 chemically	diverse	droplet	libraries.			
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Fig.	4.4:	Validations	of	large-scale	production	of	combinations	in	droplets	 	
(A)	 Fluorescence	 intensities	 of	 compounds	 injected	by	 the	 autosampler	 labelled	 alternatingly	with	
fluorescein	and	Cascade	blue.	Grey	box	represents	time	window	during	which	no	combinations	were	
produced	with	compound	plugs.	Blue	box	 indicates	time	window	during	which	combinations	made	
of	 compound	 plugs	 and	 autosampler	 compound	 can	 be	 generated.	 (B)	 Scatterplot	 of	 droplets	
produced	 from	 compound	 plugs	 labelled	with	 Cascade	 blue	 and	 autosampler	 compounds	 labelled	
with	 fluorescein.	Droplets	 from	180	combinations	 (9	cycles)	were	plotted.	 (C)	Distributions	of	blue	
intensities	from	droplets	over	9	cycles	(180	combinations).	Colour	code	for	cycles	identical	to	colour	
code	 in	 E.	 (D)	 Mean	 normalized	 distributions	 of	 blue	 fluorescence	 intensities	 from	 droplets	
generated	 with	 oil	 spacer	 or	 without	 oil	 spacer.	 (E)	 Blue	 fluorescence	 intensities	 of	 all	 individual	
combinations,	colour	coded	according	to	cycles	with	each	box	corresponding	to	droplets	generated	
from	one	combination.			 	
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4.5. Barcoding	 approach	 for	 gene	 expression	based	profiling	 of	compound	combinations		In	order	 to	deconvolve	diverse	droplet	 contents	we	 implemented	a	 combinatorial	barcoding	approach	that	barcodes	the	transcriptome	according	to	the	compounds	a	cell	 was	 exposed	 to.	 Thereby,	 we	 can	 achieve	 the	 simultaneous	 detection	 of	treatment	conditions	(i.e.	droplet	contents)	and	their	effects	on	gene	expression	by	RNA-Seq.	In	this	approach,	two	barcode	species	were	joined	in	a	ligation	reaction	to	form	one	functional	barcode	(Fig.	4.5A).	BC-1	to	BC-22	(BC-bio)	were	biotinylated	and	had	a	common	primer	site	followed	by	a	10	bp	barcode	and	a	single-stranded	ligation	site.	BC-A	to	BC-S	(BC-dT)	consisted	of	a	complementary	ligation	site,	a	10	bp	 barcode	 and	 a	 poly-dT	 sequence.	 The	 ligation	 of	 barcodes	 took	 place	 within	droplets	 together	 in	 parallel	 with	 cell	 lysis	 and	 mRNA	 release.	 These	 mRNA	molecules	 then	 hybridized	 to	 the	 polydT	 sequences	 of	 BC-dT.	 After	 ligation	 and	hybridization,	droplet	contents	were	released	and	purified	via	the	biotinylation	site	of	 BC-bio	 capturing	 only	 mRNA	 hybridized	 to	 ligated	 barcode	 combinations.	Purified	mRNA	was	reverse	transcribed	to	cDNA	and	amplified	using	the	common	primer	site	on	BC-bio	and	a	template-switching	oligonucleotide	(TSO)	as	described	in	 the	 Smart-Seq2	 protocol	 (Picelli	 et	 al.,	 2013).	 Since	 only	 mRNA	 bound	 to	combinations	of	two	barcodes	was	purified	and	amplified,	the	barcoding	approach	was	highly	dependent	on	ligation	(Fig.	4.5B).	This	ensured	depletion	of	mRNA	with	single	 barcodes	 and	 prevented	 formation	 of	 barcode	 combination	 during	subsequent	 library	 preparation	 steps.	 We	 implemented	 the	 combinatorial	barcoding	approach	for	RNA-Seq	based	read-outs	with	the	microfluidic	pipeline	by	injecting	 drugs	 with	 unique	 barcodes	 (e.g.	 compounds	 injected	 into	 the	 valve-module	 were	 encoded	 by	 BC-dT	 (A-T)	 and	 21	 compounds	 injected	 by	 the	autosampler	from	96-well	plates	were	encoded	by	BC-1	to	BC-21	(BC-22	was	used	for	 separate	 untreated	 controls).	 Thereby,	 combinations	 generated	 by	 mixing	compounds	 from	 the	 valve-module	 and	 the	 autosampler	 were	 encoded	 by	 two	barcodes	that	were	ligated	to	one	functional	barcode	in	droplets.		
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Fig.	4.5:	Combinatorial	barcoding	of	transcriptomes		
(A)	Deterministic	barcoding	of	transcriptomes	by	a	combination	of	two	barcode	species.	Biotinylated	
barcodes	 (BC	1	 -22)	with	 a	 terminal	 primer	 site	 are	 ligated	with	barcodes	having	 a	 3’-end	poly-dT	
sequence	 (BC	 A-T).	 Hybridized	 mRNA	 is	 isolated	 by	 streptavidin-coated	 beads	 and	 reverse	
transcribed	 (RT)	 into	cDNA.	Template	switching	oligonucleotides	 (TSOs)	 introduce	a	5’-end	priming	
site	 allowing	 whole	 transcriptome	 amplification.	 (D)	 Fragment	 length	 analysis	 of	 barcoded	
transcriptomes	after	amplification.	The	observed	average	peak	size	 in	the	 ligated	sample	was	2000	
bp.			
4.6. Combinatorial	barcoding	of	cells	in	droplets	for	multiplexed	RNA-Seq	experiments		For	 RNA-Seq	 based	 read-outs	 of	 compound	 combinations	 in	 droplets,	 20	compounds	supplemented	with	the	assigned	barcodes	were	injected	into	the	valve-module	 and	 combined	 with	 21	 barcode-compound	 mixtures	 injected	 from	 the	autosampler.	Both	were	encapsulated	together	with	K562	cells	into	picolitre-sized	droplets	 (Fig.	 4.6A-1).	 Since	 each	 droplet	 corresponds	 to	 one	 reaction	 vessel,	uniquely	barcoded	according	to	its	content	by	a	set	of	two	barcodes,	we	were	able	to	pool	all	droplets	in	a	single	tube.	After	incubation,	droplets	were	re-injected	into	a	microfluidic	 device	 for	 pico-injection	 to	 add	 reagents	 for	 cell	 lysis	 and	 barcode	ligation	 into	each	droplet	(Fig.	 4.6A-2).	Subsequently,	 the	sets	of	 two	barcodes	 in	
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each	droplet	were	ligated	to	form	one	functional	barcode,	and	mRNA	released	from	cells	 was	 hybridized	 to	 their	 poly-dT	 tails.	 Only	 after	 ligation	 of	 barcodes	 and	hybridization	of	mRNA	to	the	barcodes,	droplets	were	broken	and	released	droplet	contents	 were	 used	 for	 preparation	 of	 the	 sequencing	 library	 (Fig.	 4.6A-3).	 The	libraries	 comprised	 cDNA	 barcoded	 according	 to	 the	 droplet	 contents	 cells	 were	exposed	 to,	which	 in	 this	 case	were	 399	 distinct	 treatment	 conditions	 (one	 valve	was	not	working).	After	paired-end	sequencing	of	barcodes	and	mRNA,	reads	were	demultiplexed	 based	 on	 their	 barcode	 combinations,	 each	 encoding	 a	 specific	droplet	 condition,	and	subsequently	aligned.	During	demultiplexing	6	mismatches	per	barcode	combination	were	allowed.	We	observed	a	high	level	of	correlation	of	read	 counts	 per	 gene	 (R2	 ≥	 0.94)	 between	 three	 replicates,	 implying	 good	reproducibility	of	 combinatorial	barcoding	of	 cells	 in	droplets	 generated	with	 the	described	 approach	 (Fig.	 4.6B).	 Out	 of	 all	 reads	 assigned	 to	 the	 three	 replicates	(2.5x108),	 78%	 of	 reads	 were	 unambiguously	 demultiplexed	 to	 barcode	combinations	 showing	 a	 low	 level	 of	 read	 losses.	 However,	 between	 individual	samples	 (i.e.	 barcode	 combinations)	 we	 observed	 a	 wide	 range	 of	 read	 counts	(2199	 to	864845)	and	number	of	detected	genes	with	more	 than	one	read	 (42	 to	5092)	(Fig.	4.6C	and	Fig.	4.6D).	To	test	whether	the	number	of	detected	genes	was	sample	 (i.e.	 barcode)	 dependent,	 hierarchical	 clustering	 of	 scaled	 gene	 counts	 (Z-scores)	was	performed	(Fig.	4.6E).	We	found	two	main	clusters	based	on	barcodes	from	the	valve-module	(BC-A	to	BC-T)	and	one	outlier	cluster	of	samples	with	BC-O	reflecting	 the	 low	number	of	genes	 (42	 to	566	genes)	detected	 for	 these	samples.	We	 expected	 the	 number	 of	 genes	 detected	per	 sample	 to	 be	 associated	with	 the	number	 of	 droplets	 generated	 per	 sample.	However,	we	 did	 not	 find	 correlations	between	 the	 lengths	 of	 the	 compound	 plugs,	 which	 determined	 the	 number	 of	droplets	 generated	 per	 sample,	 and	 the	 number	 of	 genes	 detected.	 Thus,	 the	variation	in	gene	counts	is	likely	to	be	caused	by	varying	demultiplexing	efficiency	of	the	barcode	combinations	or	amplification	biases	during	library	preparation.		
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Fig.	4.6	Combinatorial	barcoding	for	highly	multiplexed	RNA-Seq		
(A)	 Illustration	of	the	workflow	used	for	combinatorial	barcoding	of	transcriptomes.	(1)	Single	cells	
were	 encapsulated	 into	 droplets	 along	with	 a	 set	 of	 two	 barcodes	 and	 the	 corresponding	 pair	 of	
drugs.	All	droplets	were	stored	in	a	single	tube	and	after	incubation	droplets	(2)	were	injected	into	a	
device	for	pico-injection.	Reagents	for	cell	lysis	and	barcode	ligation	were	added	to	each	droplet.	(3)	
RNA-Seq	libraries	from	cDNA	with	barcode	combinations	were	prepared.	(B)	Pairwise	correlations	of	
read-counts	 per	 gene	 between	 three	 replicates	 after	 demultiplexing	 of	 reads	 according	 to	 their	
barcodes.	(C)	Read	counts	for	 individual	samples	(i.e.	barcode	combinations);	the	red	line	 indicates	
the	median	read	count	(126000).	(D)	Counts	of	genes	for	 individual	samples	covered	by	more	than	
one	 read.	 The	 red	 line	 indicates	 the	 median	 gene	 count	 (1863).	 (E)	 Heatmap	 and	 hierarchical	
clustering	of	scaled	gene	counts.	Each	box	represents	a	combination	of	two	barcodes.		
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4.7. Discussion		The	 introduced	 workflow	 used	 a	 valve-based	 system	 and	 an	 autosampler	 to	produce	 high	 numbers	 of	 drug	 combinations	 in	 picolitre	 sized	 droplets.	 Starting	from	the	setup	described	in	the	first	chapter,	we	significantly	increased	the	number	of	generated	combinations,	as	well	as	the	throughput	of	the	pipeline,	as	the	washing	steps	became	unnecessary.	Identification	of	each	combination	was	achieved	by	the	deterministic	barcoding	of	transcriptomes	from	cells	encapsulated	with	a	particular	combination.	 Thereby,	 highly	 multiplexed	 gene	 expression	 experiments	 of	compound	combinations	can	be	performed	using	droplet-based	microfluidics.	
4.7.1. Validation	of	compound	plug	purity	We	 designed	 a	 microfluidic	 device	 for	 the	 valve-module	 that	 prevented	 cross-contamination	 between	 compounds	 on	 the	 device	 by	 avoiding	 dead	 volumes.	Additionally,	horizontal	ports	were	used	to	connect	the	delay	tubing	with	the	outlet	of	 the	 valve-module	 and	 the	 inlet	 of	 the	 drop-maker	 to	 reduce	 plug-breakup	 at	inlets	due	to	dead	volumes.	By	measuring	compound	plugs	alternately	labelled	with	a	green	or	a	blue	dye,	we	could	show	that	for	the	majority	of	compound	plugs,	no	contamination	was	 detected.	 The	median	 intensity	 of	 green	 signals	 in	 blue	 peaks	was	reduced	to	0.72%	compared	to	green	positive	plugs,	whereas	the	blue	signals	in	 green	 positive	 peaks	 was	 only	 reduced	 to	 2.32%.	 This	 discrepancy	 in	 the	contamination	 levels	 could	 arise	 from	 the	 fact	 that	 we	 observed	 more	 cross-contaminating	 green	 peaks	 in	 blue	 positive	 plugs	 (8	 peaks	 in	 total)	 than	 blue	positive	 peaks	 in	 green	 plugs	 (4	 peaks	 in	 total).	We	 also	 observed	 higher	 cross-contamination	at	the	beginning	of	contaminated	plugs,	that	declined	exponentially	and	only	caused	contamination	of	the	first	generated	droplets.	This	was	caused	by	plugs	 breaking	 while	 entering	 the	 drop-maker	 device,	 and	 the	 subsequent	 plug	picking	up	the	residual	 liquids.	By	making	use	of	 the	previously	described	sample	collector	 (Section	3.5),	we	could	prevent	 collection	of	 the	 first	droplets	by	 setting	the	 delay	 time	 for	 collection	 accordingly.	 However,	 this	 would	 need	 further	optimization	of	the	sample	collector,	since	it	was	not	applicable	to	high	flow	rates	and	caused	high	backpressures	in	the	delay	tubing.		
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4.7.2. Generating	 combinations	 from	 valve-module	 and	 autosampler	based	compound	injections		In	 order	 to	 generate	 high	 numbers	 of	 combination	we	made	 use	 of	 autosampler-based	 injection	 of	 compounds	 from	 96-well	 plates	 into	 the	 drop	 maker	 chip.	 By	combining	 one	 compound	 from	 the	 autosampler	 with	 20	 compounds	 from	 the	valve-module,	 it	 became	 possible	 to	 generate	 20	 different	 combinations,	 which	could	 be	 increased	 multiplicatively	 with	 the	 number	 of	 compounds	 from	 the	autosampler.	 We	 used	 a	 delay	 tubing	 for	 the	 valve-module	 based	 injection	 of	compounds	into	the	drop-maker.	This	setup	has	the	advantage	that	one	cycle	of	20	compounds	 is	 first	 produced	 and	 then	 injected	 at	 a	 uniform	 flow	 rate	 since	 the	same	two	oil	valves	are	continuously	open	for	the	time	of	plug	injection.	As	a	result,	no	 valves	 are	 switched	 during	 droplet	 production	 ensuring	 a	 stable	 droplet	formation	over	 time.	Due	 to	waiting	 times	between	 compounds	 injected	 from	 the	autosampler	(~2min),	the	increase	in	time	of	using	a	delay	tubing	was	only	~20	sec	as	compared	to	when	the	delay	tubing	is	not	used.	The	compound	injection	by	the	autosampler	 resulted	 in	 uniform	 peaks	 as	 shown	 by	 the	 fluorescence	 data.	 Each	compound	 was	 combined	 with	 compound	 plugs	 to	 form	 droplets	 containing	combinations.	 It	was	 important	 to	 validate	 that	 compound	 plugs	 and	 compounds	from	the	autosampler	were	encapsulated	at	a	constant	ratio	in	order	to	ensure	that	both	 compounds	were	 encapsulated	 at	 the	 right	 concentration.	 The	 validation	 of	the	pairing	between	blue	positive	compound	plugs	and	green	positive	compounds	from	 the	 autosampler	 showed	 that	 one	major	 double	 positive	 droplet	 population	was	 generated	 (Fig.	 4.4B).	 We	 found	 the	 median	 intensities	 over	 all	 generated	combinations	to	be	stable	with	a	CV	of	2.9%	and	3%	for	the	blue	and	green	signal,	respectively	(Fig.	4.4E).	This	indicates	that	both	compounds	were	encapsulated	into	droplets	at	a	highly	constant	ratio.	Since	both	dyes	were	encapsulated	at	a	constant	ratio,	 the	 concentrations	 of	 compounds	 encapsulated	 into	 droplets	 correspond	 to	injected	concentrations	diluted	by	a	factor	given	by	the	flow	rate	ratios	between	all	injected	 aqueous	 phases	 (valve-module:	 0.5;	 autosampler:	 0.25;	 cells:	 0.25).	However,	the	observed	intensity	distributions	over	all	cycles	were	broad	indicating	variations	between	individual	droplets.	We	anticipated	that	this	observation	might	be	explained	by	unstable	 laminar	 flows	of	 the	 two	dyes	 caused	by	 the	oil	 spacers	between	 each	 compound	 plug.	 However	 we	 found	 the	 same	 level	 of	 variation	 in	fluorescence	 intensities	 when	 measuring	 droplets	 produced	 without	 oil	 spacers	
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(Fig.	 4.4D).	 Therefore,	we	 concluded	 that	 the	 variation	 of	 fluorescence	 intensities	around	 a	 constant	 median	 intensity	 was	 caused	 by	 recoding	 droplets	 generated	from	 a	 laminar	 flow	 of	 three	 aqueous	 phases	 and	 the	 fluctuation	 of	 the	 droplet	trajectory	within	the	channel	(as	discussed	in	3.8.1).	Taken	together,	the	discussed	results	of	the	presented	microfluidic	workflow	is	applicable	to	generate	up	to	420	chemically	 distinct	 combinations,	 each	 present	 in	 around	 2500	 droplets,	 in	 less	than	2h.		
4.7.3. Barcoding	of	transcriptomes	according	to	droplet	contents	To	 characterize	 effects	 on	 gene	 expression	 caused	 by	 a	 combination	 of	 two	compounds,	we	established	a	barcoding	approach	in	which	each	cells	transcriptome	was	 labelled	 according	 to	 the	 compounds	 it	 was	 exposed	 to	 within	 a	 droplet.	Ligation	of	two	barcodes	was	used	to	encode	a	combination	but	additionally	mRNA	was	 hybridized	 to	 the	 barcodes	 and	 allowed	 its	 reverse	 transcription.	Consequently,	it	became	possible	to	barcode	transcriptomes	from	cells	according	to	combinatorial	drug	treatments,	using	a	combination	of	two	barcodes.	The	designed	approach	was	highly	dependent	on	 the	 ligation	of	 two	barcode	species	since	both	were	crucial	for	later	library	preparations,	ensuring	an	RNA-Seq	library	containing	only	 cDNA	 fragments	 with	 two	 barcodes.	 Additionally,	 biotin-streptavidin	 based	purification	was	used	to	avoid	PCR-based	joining	of	non-ligated	fragments,	as	seen	by	 the	 lack	of	amplified	 fragments	 in	 the	no	 ligation	control	 (Fig.	4.5B).	Thus,	 the	approach	can	be	used	to	perform	deterministic	barcoding	of	cells	in	droplets,	since	we	assigned	each	barcode	 to	 a	 specific	 treatment	 condition.	This	 is	 in	 contrast	 to	widely	applied	random	barcoding	in	droplets	used	for	single	cell	sequencing	(Klein	et	 al.,	 2015;	 Macosko	 et	 al.,	 2015).	 Here,	 thousands	 of	 droplets	 (i.e.	 cells)	 are	uniquely	barcoded,	however,	without	knowing	the	barcode	sequence.	Our	approach	does	not	aim	at	single	barcodes	 for	each	cell,	but	barcoding	each	condition	with	a	unique	set	of	barcodes.	 In	a	 screen	we	combined	19	compound-barcode	mixtures	from	 the	 valve-module	 (one	 valve	was	 not	 working)	 with	 21	 compound-barcode	mixtures	from	the	autosampler,	resulting	in	a	total	of	399	combinations	of	barcodes	(i.e.	 drugs).	 The	 integration	 of	 barcoding	 mRNA	 from	 cells	 encapsulated	 into	droplets,	made	it	necessary	to	perform	pico-injection	to	add	reagents	for	cell	 lysis	and	 ligation.	 Although	 each	 droplet	 was	 processed	 individually	 in	 this	 step,	 high	frequencies	 (~300	 droplets/sec)	 allowed	 processing	 all	 droplets	 in	 approx.	 1h,	
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which	 reduced	 biases	 in	 the	 incubation	 times	 over	 the	 course	 of	 pico-injections.	Within	each	droplet,	barcodes	were	ligated	and	released	mRNA	hybridized	to	their	poly-dT	 tail.	 Since	 the	 emulsion	 was	 broken	 in	 a	 volume	 much	 larger	 than	 the	volume	 of	 droplets	 (a	 ~3.125x107	 fold	 increase),	 the	 chance	 of	 unbound	 mRNA	hybridizing	 randomly	 to	 barcodes	 was	 reduced	 ensuring	 a	 high	 level	 of	 specific	barcoding.	 However,	 to	 determine	 the	 level	 of	 cross-hybridized	 mRNA,	 artificial	mRNA	 species	 could	 be	 spiked	 into	 the	 supernatant.	 The	 pairwise	 correlation	between	 read	 counts	 per	 gene	 for	 all	 replicates	 was	 comparable	 to	 described	correlations	of	3’-end	RNA-Seq	libraries	(Hennig	et	al.,	2018),	demonstrating	a	high	degree	 of	 reproducibility	 between	 replicates.	 Although,	 the	 read	 loss	 due	 to	demultiplexing	reads	according	 to	 their	barcodes	 (78%	of	 reads	were	assigned	 to	barcode	combinations)	was	low,	we	observed	only	a	median	of	1863	genes	covered	by	 more	 than	 one	 read.	 The	 total	 amount	 of	 reads	 for	 all	 samples	 from	 three	replicates	was	2.5x108,	leaving	only	approx.	2x105	reads	for	each	sample.	This	is	a	sequencing	depth	generally	considered	 for	high-throughput	single	cell	 sequencing	methods	(Hwang	et	al.,	2018)	and	thus,	detections	of	~2000	genes	per	sample	are	comparable	to	counts	expected	from	single	cell	sequencing	experiments	(Macosko	et	 al.,	 2015;	 Torre	 et	 al.,	 2018).	 This	 indicates	 towards	 a	 comparable	 sequencing	efficiency	 of	 the	 presented	 combinatorial	 barcoding	 approach.	 An	 increase	 in	 the	number	of	genes	per	sample	can	be	achieved	by	increasing	the	sequencing	depth	as	indicated	 by	 samples	 sequenced	 at	 a	 higher	 coverage	 (average	 of	 7.7x106	 reads),	which	 resulted	 on	 average	 in	 12216	 detected	 genes	 per	 sample.	 We	 analysed	 if	variations	 in	 gene	 counts	 are	 due	 to	 different	 amounts	 of	 droplets	 generated	 per	combination.	However,	the	length	of	compound	plugs	failed	to	explain	the	number	of	 detected	 genes	 since	 no	 correlation	 between	 plug	 length	 and	 gene	 counts	was	observed.	 Additionally,	 cluster	 analysis	 of	 gene	 counts	 did	 not	 reveal	 barcode	dependent	clustering	for	the	majority	of	barcodes.	We	observed	two	main	clusters	based	on	BC-A	to	BC-T,	which	again	did	not	show	barcode	specificity.	Therefore,	we	concluded	that	the	observed	variation	was	likely	due	to	biases	in	the	amplification	efficiency	between	different	fragments.	Furthermore,	differences	in	the	efficiency	of	demultiplexing	 reads	 on	 barcode	 combinations	 could	 explain	 the	 observed	variations	 in	 gene	 counts	 per	 sample.	 Taken	 together,	 deterministic	 barcoding	 of	combinations	was	applicable	 for	 the	demultiplexing	of	RNA-Seq	data	according	 to	combinatorial	drug	treatments	in	droplets.		 	
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5. Highly	 multiplexed	 gene	 expression	 profiling	 of	 drug	combinations	in	droplets				
5.1. Introduction		In	the	following	chapter	we	applied	the	microfluidic	pipeline	introduced	in	chapter	4	to	perform	combinatorial	screens	using	ant-tumor	drugs	in	droplets	and	analysed	their	 effects	on	gene	expression	 in	K562	 cells.	Gene	expression	based	profiling	of	drugs	 was	 proven	 to	 be	 powerful	 in	 determining	 the	 mode	 of	 action	 and	repositioning	of	drugs	(Subramanian	et	al.,	2017;	Woo	et	al.,	2015).	As	compared	to	singular	readouts	in	conventional	high-throughput	drug	screens,	such	as	apoptosis	or	 enzyme	 activity,	 gene	 expression	 of	 cells	 under	 perturbation	 enables	 more	comprehensive	 readouts	 of	 the	 drugs’	 effect	 on	 cells,	 which	 can	 be	 useful	 to	improve	 models	 aiming	 at	 predicting	 drug	 response	 or	 understanding	 of	 drug	resistance	 and	 sensitivity.	 Since	 RNA-Seq	 experiments	 are	 expensive,	 several	 low	cost	 approaches	 have	 been	 developed	 to	 combine	 high-throughput	 drug	 screens	with	gene	expression	profiling.	 Increased	sequencing	throughput	was	achieved	by	focusing	only	on	gene	panels	(Subramanian	et	al.,	2017)	or	by	multiplexed	RNA-Seq	experiments	(Bush	et	al.,	2017;	Ye	et	al.,	2018).	However,	these	approaches	aim	at	studying	 the	 effects	 of	 single	 drugs	 on	 gene	 expression	 and	 screens	 were	 still	performed	 in	plate-based	setups.	The	 translation	of	drug	screens	 from	plates	 into	droplets	 harbours	 the	 potential	 to	 further	 increase	 the	 multiplexing	 capacity	 of	RNA-Seq	based	analysis	of	drug	responses.	By	applying	the	described	microfluidic	pipeline	 for	 gene	 expression	based	profiling	of	 drug	 combinations,	 their	 effect	 on	the	transcriptome	can	be	studied	in	a	highly	multiplexed	manner.	Gene	expression	data	 from	 tumor	 cells	 treated	with	 drug	 combinations	 can	 be	 used	 to	 determine	drug	 synergy	 based	 cell	 death	 signatures	 (Szalai	 et	 al.,	 2018).	 Subsequently,	 the	datasets	 can	 be	 used	 to	 decipher	 the	 underlying	 mechanisms	 of	 the	 observed	
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synergism	 based	 on	 perturbation	 responses	 in	 gene	 expression	 (Schubert	 et	 al.,	2018).	Furthermore,	using	droplets	results	in	a	strong	reduction	of	sample	volume	and	allows	screening	high	numbers	of	drug	combinations	(420)	with	low	numbers	of	 cells	 (~2x106).	 Low	 amounts	 of	 input	 material	 can	 facilitate	 drug	 screens	 on	tumor	 biopsies	 to	 determine	 personalized	 treatments	 (Eduati	 et	 al.,	 2018).	Additionally,	encapsulating	single	cancer	cell	together	with	drug	combinations	into	droplets	 provides	 a	 potential	 platform	 for	 single	 cell	 characterization	 of	 drug	sensitivity,	 and	 thus,	 to	 study	 the	effect	of	 tumor	heterogeneity	on	drug	 response	using	gene	expression	profiling.		
5.2. Drug	library	used	for	RNA-Seq	based	screens	Screening	drugs	 in	 surfactant-stabilized	droplets	 can	potentially	 result	 in	micelle-mediated	 exchange	 of	 drugs	 between	 droplets	 (Gruner	 et	 al.,	 2016).	 The	distribution	(LogD	value)	or	partitioning	coefficient	(LogP	value)	can	be	used	as	a	measure	 to	 assess	 the	 probability	 of	 a	 drugs’	 retention	 in	 a	 water	 droplet	surrounded	by	oil.	A	compound	with	a	negative	LogD-value	has	a	higher	solubility	in	water	than	in	octanol	and	thus	has	a	higher	probability	to	be	retained	in	a	water	droplet.	Therefore,	we	selected	drugs	based	on	 two	criteria:	First,	drugs	 from	 the	ChEMBL	database	were	selected	based	on	a	 low	LogD	value	and	 then	drugs	were	further	selected	by	their	potential	relevance	for	cancer	(Tab.	5.1).	The	majority	of	the	 selected	40	drugs	have	negative	 LogD-values	 or	 smaller	 than	one,	 apart	 from	Imatinib	and	Trametinib	(2.49	and	2.54).	Targets	of	the	selected	drugs	were	used	to	generate	 a	 network	 based	 on	 protein-protein	 associations	 using	 STRING	 (Fig.	
5.1A).	We	obtained	a	dense	network	with	strongest	enrichments	for	cancer	related,	PI3K-Akt	 and	 Ras	 signalling	 pathways	 (FDR	 of	 2.6e-24,	 3.68e-24	 and	 1.29e-22,	respectively).	To	determine	the	sensitivity	of	K562	cells	towards	the	selected	drugs,	the	 growth	 reductions	 after	 48h	 over	 hundred	 fold	 concentration	 ranges	 were	measured.	Growth	reduction	curves	were	used	to	calculate	GR20	values	(Hafner	et	al.,	2016),	which	were	used	in	all	later	drug	screenings	(Fig.	5.1B).	For	drugs	where	no	effect	on	the	growth	of	K652	cells	was	measured,	a	concentration	of	100	µM	was	used.	Taken	together,	despite	the	restriction	to	drugs	with	low	logD	values,	a	cancer	relevant	drug	 library	was	selected	out	of	which	the	majority	of	drugs	reduced	the	growth	 of	 K562	 cells.	 Therefore,	 the	 selected	 drug	 library	 was	 used	 to	 generate	drug	combinations	exploiting	the	pipeline	described	in	chapter	4.2.		 	
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Tab.	4.1:	Drug	library		
Drug	 Targets	 LogD	pH	7.4	 GR20	[µM]	
10Z-Hymenialdisine	 MEK1	 0.20	 6.085	
5-Fluorouracil	 TYMS	 -1.64	 0.571	
5-Iodotubercidine	 ADK/INSR/	PKA/CK1	 0.20	 5.705	
AT9283	 AURKA/AURKB/JAK2/JAK3	 -0.99	 0.147	
Baricitinib	 JAK1/JAK2	 0.46	 0.387	
Blebbistatin	 MYH2	 1.09	 77.16	
Clofarabine	 RRM1	/	DNA	Polymerase	 0.45	 0.455	
Cytarabine	 DNA	/	RNA	Polymerase	 -0.81	 100	
Dacarbazine	 DNA	Animetabolite	 0.03	 1,867	
Decitabine	 DNMT1	 -1.87	 0.206	
Dexrazoxane	 TOP2	 -0.91	 11.842	
Dovitinib	 FLT3/c-Kit/FGFR1/FGFR3	 0.80	 0.034	
Doxorubicin	 TOP2	 -1.47	 0.322	
Epirubicin	 TOP2	 -1.47	 0.100	
Fludarabine	Phosphate	 DNA	Animetabolite	 -7.62	 6.737	
Gemcitabine	 DNA	Animetabolite	 -2.22	 0.00292	
Gimeracil	 DPYD	 -2.56	 100	
H-7	dihydrochloride	 PKC/PKG/PKA	 NA	 64.89	
Hematoxylin	 EGFR/ERBB2/c-MET/c-KIT/SRC*	 -0.18	 0.625	
Imatinib	 BCR-ABL	 2.49	 0.039	
Methodextrat	 DHFR	 -5.10	 100	
Mitomycin	C	 DNA	Synthesis	 -0.30	 0.815	
Nelarabine	 DNA	Animetabolite	 -0.26	 100	
NMS-1286937	 PLK1	 -1.19	 0.105	
Olomoucine	 CDK2/ERK1	 -0.2	 112.1	
Oxaliplatin	 DNA	 -0.47*	 8.699	
PF-562271	 FAK	 -0.75	 7.059	
Pomalidomide	 TNF-alpha	 -0.71	 100	
Sangivamycin	 PKC	 -2.28	 100	
SB-747651	 MSK1/MSK2	 -2.24	 0.285	
SF-1126	 PI3K/mTOR	 -2.87**	 0.257	
Sonolisib	 PI3K	 -0.95	 1.460	
Streptozotocin	 DNA	 -1.25	 100	
Sunitinib	Malate	 VEGFR2/PDGFRb	 0.44	 6.702	
Tabloid	/	Thioguanine	 DNMT1	 -1.50	 0.813	
Thiostrepton	 FOXM1	 0.60	 5.932	
Trametinib	 MEK1/2	 2.54	 0.0977	
Triciribine	 AKT1/AKT2/AKT3	 -7.22	 1.992	
Wortmannin	 PI3K	 -1.64	 0.223	
YM155	 BIRC5	 -1.45	 0.00041	
Targets	according	to	the	manufactures	information		
LogD	pH	7.4:	ACD_LogD	pH	7.4	values	at	given	by	ChEMBL	database	using	ACD	software	v12.01	
*	LogP	value	from	DrugBank	
**	ALogP	value	ChEMBL:	Atomic	LogP	value	(Ghose	and	Crippen,	1987)		 	
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Fig.	5.1:	Network	analysis	and	growth	reduction	of	drugs		
(A)	STRING-based	network	of	associations	between	proteins	targeted	by	the	drugs	used	in	this	work.	
Each	 node	 represents	 all	 proteins	 that	 can	 be	 produced	 from	 a	 single	 protein-coding	 gene.	 Edges	
illustrate	 protein-protein	 association	 and	 their	 thickness	 indicates	 confidence	 of	 their	 association.	
Drug	targets	were	strongly	enriched	for	cancer	related	signalling	pathways.	(B)	Log10	values	of	drug	
concentrations	at	which	the	growth	of	K562	cells	was	inhibited	by	20%	(GR20)	after	an	incubation	of	
48h.			
5.3. Screening	of	drug	combinations	in	droplets	and	detection	of	their	effects	on	gene	expression		For	combinatorial	drug	screenings	19	drugs	from	the	drug	library	(Tab.	5.1)	and	a	DMSO	 sample	 were	 assigned	 to	 20	 BC-dTs	 (BC-A	 to	 BC-T)	 and	 mixtures	 were	injected	into	the	valve-module	of	the	microfluidic	pipeline	described	in	chapter	4.2.	A	remaining	set	of	20	drugs	and	a	DMSO	sample	were	assigned	to	21	biotinylated	BCs	 (BC-1	 to	 BC-21)	 and	 mixtures	 were	 aspirated	 from	 96-well	 plates	 by	 the	autosampler.	 Combinations	 of	 drug-barcode	mixtures	 from	 the	 valve-module	 and	autosampler	were	encapsulated	into	droplets	along	with	K562	cells	and	incubated	for	 12h.	 For	 each	 replicate	 an	 additional	 emulsion	 of	 untreated	 control	 droplets	(DMSO	 control)	 was	 prepared	 and	 incubated	 separately.	 Subsequently,	 the	emulsion	 comprising	 420	 drug	 combinations	 was	 mixed	 with	 the	 DMSO	 control	
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emulsion	 and	 droplets	 were	 processed	 for	 library	 preparation	 according	 to	 the	workflow	 described	 in	 chapter	 4.7.	 To	 test	 potential	 biases	 based	 on	 the	 drug	source	(valve-module	or	autosampler)	or	barcode	fragments	used	to	encode	drugs,	we	run	two	screens	with	420	combinations	generated	from	four	sets	of	drugs:	Out	of	 the	 four	 sets	 always	 two	 sets	 were	 either	 used	 on	 the	 valve-module	 or	 the	autosampler	and	either	encoded	with	BC-dT	or	BC-bio	barcodes,	respectively	(Tab.	
5.2).	In	screen	1	the	drug	sets	1	and	3	from	the	valve-module	were	combined	with	the	drug	sets	2	and	4	from	the	autosampler.	In	screen	2	the	drug	sets	1	and	4	from	the	valve-module	were	combined	with	the	drug	sets	2	and	3	from	the	autosampler.	In	total	840	drug	combinations	were	generated	in	droplets	out	of	which	630	were	unique.	 Out	 of	 the	 210	 combinations	 that	 were	 generated	 in	 both	 screens,	 110	combinations	 were	 produced	 in	 the	 same	 order	 and	 were	 encoded	 by	 the	 same	barcode	 combinations	 (e.g.	 Drug-A	 BC-dT	 +	 Drug-B	 BC-bio	 and	 Drug-A	 BC-dT	 +	Drug	B	BC-bio).	100	drug	combinations	were	shared	between	screen	1	and	2,	but	generated	 in	 a	 different	 order,	 and	 thus,	 were	 encoded	 by	 the	 opposite	 order	 of	barcodes	(e.g.	Drug-A	BC-dT	+	Drug-B	BC-bio	and	Drug-B	BC-dT	+	Drug-A	BC-bio).			
Tab.	5.2:	Drug	combinations	screen	1	and	screen	2	
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Fig.	5.2:	Dimensional	reduction	of	gene	expression	data	from	drug	combinations	 	
Normalized	gene	expression	data	of	drug	combinations	from	screen	1	(A	and	B)	and	2	(C	and	D)	was	
visualized	 using	 t-distributed	 stochastic	 neighbourhood	 embedding	 (tSNE).	 (A)	 Clustering	 of	 gene	
expression	 data	 from	 420	 treatment	 conditions	 generated	 in	 screen	 1	 coloured	 based	 on	 the	 19	
drugs	and	DMSO	from	the	valve-module	encoded	by	barcodes	BC-dT.	Each	data	point	represents	a	
treatment	condition	encoded	by	a	barcode	combination	and	triangular	shaped	data	points	refer	to	
separately	 incubated	 DMSO	 controls.	 (B)	 Cluster	 analysis	 of	 drug	 combinations	 from	 (A)	 coloured	
according	to	the	20	drugs	and	DMSO	injected	by	the	autosampler.	(C)	tSNE-based	clustering	of	gene	
expression	data	 from	399	 treatment	 conditions	 generated	 in	 screen	2.	Clustered	data	points	were	
colour	 coded	 according	 to	 drugs	 from	 the	 valve-module	 encoded	 by	 BC-dT	 with	 each	 data	 point	
representing	 a	 treatment	 condition.	 Triangular	 shaped	 data	 points	 refer	 to	 DMSO	 controls.	 (D)	
Clustering	 of	 gene	 expression	 data	 from	 screen	 2	 coloured	 according	 to	 21	 drugs	 from	 the	
autosampler	encoded	by	BC-bio.			Sequenced	libraries	from	three	replicates	per	screen	were	demultiplexed	according	to	 their	 barcode	 combinations	 and	 gene	 expression	 profiles	 for	 all	 drug	combinations	were	obtained.	Data	was	preprocessed	and	normalized	to	account	for	differences	in	library	size	and	batch	effects.	In	order	to	illustrate	expression	profiles	from	 all	 420	 drug	 combinations,	 we	 performed	 dimensional	 reduction	 using	 t-distributed	 stochastic	 neighbourhood	 embedding	 (tSNE)	 of	 the	 normalized	 gene	
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expression	data	(Fig.	5.2).	In	both	screens	we	observed	strong	clustering	based	on	drugs	from	the	valve-module,	which	were	encoded	by	barcodes	BC-A	to	BC-T	(Fig.	
5.2	A,	C).	Apart	from	a	few	exceptions,	we	observed	one	main	cluster	for	each	drug	injected	 from	 the	 valve-module	 encoded	 by	 a	 particular	 BC-dT.	 Additionally,	 all	samples	 containing	 DMSO	 from	 the	 valve-module	 fall	 into	 one	 cluster	 that	additionally	contains	the	DMSO	control	samples.	However,	we	did	not	observe	any	clustering	based	on	drugs	injected	from	the	autosampler	encoded	by	BC-bio	(BC-1	to	BC-22)	 in	 both	 screens	 (Fig.	 5.2	 B,	 D).	 The	dominant	 effect	 of	 drugs	 from	 the	valve-module	on	gene	expression	was	further	confirmed	by	spearman	correlations	of	 drug	 signatures	 for	 screen	 2	 (Fig.	 5.3).	 We	 observed	 the	 highest	 degree	 of	correlation	 between	 combinations	 of	 the	 same	 two	 drugs.	 However,	 the	correlations	 between	 signatures	 where	 drugs	 from	 the	 valve-module	 were	 the	same,	showed	much	stronger	correlations	as	compared	to	signatures	of	drugs	from	the	 autosampler.	 Since	 the	 degree	 of	 correlation	 was	 comparable	 to	 signatures	between	different	drugs,	we	concluded	that	effects	of	drugs	from	the	autosampler	on	gene	expression	were	undetectable	in	the	screens.				
	
	
Fig.	5.3:	Correlations	between	drug	signatures		 	
Distributions	 of	 spearman	 correlations	 between	 drug	 signatures	 from	 screen	 2.	 Signatures	 were	
determined	 by	 z-scores	 of	 gene	 expression	 for	 each	 sample.	 Correlations	 between	 the	 same	
combinations	(red,	n=3),	all	combinations	containing	the	same	drug	from	the	valve-module	(green,	
n=21),	 all	 combinations	 containing	 the	 same	 drug	 from	 the	 autosampler	 (blue,	 n=19),	 and	
combinations	containing	different	drugs	(purple,	n=378	or	n=380).	Analysis	and	plots	by	Bence	Szalai	
(Julio	Saez-Rodriguez	Group;	BioQuant,	University	Heidelberg).		
Same combination 
Only drug valve module, the same
Only drug autosampler, the same 
Different drugs 
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5.4. Improved	 detection	 of	 drug	 combinations	 by	 diminishing	residual	non-ligated	barcodes		Since	 the	 observed	 clustering	 was	 dependent	 on	 position	 and	 barcode	 (Valve-module	and	BC-dT),	we	excluded	any	biological	relevant	reason.	We	hypothesized	that	 the	 barcoding	 protocol	 was	most	 likely	 the	 cause	 of	 the	 observed	 dominant	effects	 by	 drugs	 from	 the	 valve-module.	 In	 particular,	 non-ligated	 biotinylated	barcodes	(BC-bio)	were	purified	on	beads	together	with	barcode	combinations	and	mRNA.	 The	 common	 primer	 site	 on	 non-ligated	 BC-bio	 fragments	 caused	 their	linear	amplification	during	PCR	and	products	were	likely	to	function	as	primers	on	ligated	 barcode	 combinations.	 This	 would	 result	 in	 the	 loss	 of	 gene	 expression	information	 encoded	 by	 BC-bio,	 since	 free-floating	 BC-bio	 fragments	 could	randomly	 bind	 to	 barcoded	 cDNA,	 resulting	 in	 a	 PCR	 product	 with	 new	 barcode	combinations.	To	avoid	priming	by	non-ligated	BC-bio	fragments	we	improved	the	library	 preparation	 protocol	 by	 cleaving	 all	 fragments	 off	 the	 streptavidin	 coated	beads	and	size	selecting	fragments	longer	than	300	bp.	We	prepared	new	libraries	using	 the	 improved	protocol	 from	cDNA	of	 screens	1	and	2	and	re-sequenced	 the	samples.	Cluster	analysis	based	on	normalized	gene	expression	data	from	screen	1	(see	 appendix	 Fig.	 9.1)	 and	 2,	 demonstrated	 an	 improvement	 since	 no	 dominant	effects	of	drugs	from	the	valve-module	were	observed	anymore	(Fig.	5.4).	Instead,	no	strong	clustering	based	neither	of	drugs	from	the	valve-module	(Fig.	5.4A)	nor	of	drugs	from	the	autosampler	(Fig.	5.4B)	was	observed.	We	again	compared	gene	expression	drug	signatures	from	both	screens	by	Spearman	correlation	and	found	the	level	of	correlations	for	drugs	from	the	valve-module	and	the	autosampler	to	be	comparable	 (Fig.	 5.4	 C,	 D).	 Gene	 expression	 signatures	 of	 the	 same	 drug	combinations	showed	 in	both	cases	 the	highest	degree	of	correlations.	This	result	implied	 an	 improved	 detection	 of	 drug	 effects	 by	 gene	 expression	 for	 drugs	encoded	 by	 BC-bio	 in	 both	 screens.	 Finally,	 we	 performed	 cross-validations	between	 combinations	 from	 screen	 1	 and	 2.	 We	 compared	 signatures	 from	 the	same	 drug	 combinations	 generated	 in	 the	 same	 order	 and	 encoded	 by	 the	 same	barcode	 combination	 and	 observed	 a	 good	 level	 of	 correlation	 between	 drug	signatures	 (Fig.	 5.4E).	 However,	 when	 comparing	 signatures	 of	 the	 same	 drug	combinations	generated	 in	a	different	order	(e.g.	Drug	A	autosampler	BC-bio	with	BC-B	valve-module	BC-dT),	the	observed	correlation	between	drug	signatures	from	the	two	screens	was	low.		
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Fig.	5.4:	Analysis	of	re-sequenced	libraries	after	removal	of	non-ligated	BC-bio.	 	
(A)	 Clustering	 of	 gene	 expression	 data	 from	 399	 combinations	 generated	 in	 screen	 2	 coloured	
according	 to	 17	 drugs	 and	 DMSO	 from	 the	 valve-module	 encoded	 by	 barcodes	 BC-dT.	 Each	 data	
point	 represents	 a	 treatment	 condition	 encoded	 by	 a	 barcode	 combination	 (B)	 Cluster	 analysis	 of	
drug	 combinations	 from	 (A)	 coloured	 according	 to	 the	 20	 drugs	 and	 DMSO	 injected	 by	 the	
autosampler	encoded	by	BC-bio.	(C)	Spearman	correlations	between	drug	signatures	from	screen	2,	
calculated	from	z-scores	of	gene	expression	in	each	sample.	Signatures	from	combinations	with	the	
same	drugs	(red,	n=3),	combinations	where	only	drugs	from	the	valve-module	(green,	n=19)	or	the	
autosampler	 (blue,	 n=21)	 were	 the	 same	 and	 combinations	 with	 different	 set	 of	 drugs	 were	
compared	 (D)	 Spearman	 correlations	 between	 drug	 signatures	 for	 screen	 1	 as	 in	 (C).	 (E)	 Cross	
validation	of	drug	signatures	between	screen	1	and	2	by	spearman	correlations.	Correlations	of	gene	
expression	 profiles	 from	 the	 same	drug	 combinations	 generated	 in	 the	 same	order	 (purple	 curve;	
Drug	 A	 BC-dT	 +	 Drug	 B	 BC-bio	with	 Drug	 A	 BC-dT	 +	 Drug	 B	 BC-bio),	 the	 same	 drug	 combinations	
generated	in	different	order	(yellow	curve;	Drug	A	BC-dT	+	Drug	B	BC-bio	with	Drug	B	BC-dT	+	Drug	A	
BC-bio),	the	combinations	containing	the	same	drug	form	the	valve-module	(bright	blue	curve,	Drug	
A	 BC-dT	 with	 Drug	 A	 BC-dT),	 the	 combinations	 containing	 the	 same	 drug	 form	 the	 autosampler	
(green	 curve,	 Drug	 A	 BC-bio	 with	 Drug	 A	 BC-bio),	 the	 combinations	 containing	 the	 same	 drug	
generated	 in	 different	 order	 (blue	 curve,	 Drug	 A	 BC-dT	 with	 Drug	 A	 BC-bio)	 and	 combinations	
containing	 two	 different	 drugs	 (red	 curve).	 Analysis	 and	 plots	 of	 spearman	 correlations	 by	 Bence	
Szalai	(Julio	Saez-Rodriguez	Group;	BioQuant,	University	Heidelberg).			Comparably,	the	correlations	between	signatures	of	the	same	drugs	encoded	by	BC-dT	in	both	screens	were	good,	but	correlations	between	the	same	drugs	encoded	by	BC-dT	 in	 one	 screen	 and	BC-bio	 in	 the	 other	 screen	were	 as	 low	 as	 comparisons	between	 different	 drugs.	 Therefore,	we	 concluded	 that	we	 still	 observed	 barcode	
12
10
8
6
4
2
0
0.00 0.05 0.10 0.15 0.20-0.15 -0.10 -0.05
12
10
8
6
4
2
0
0.00 0.05 0.10 0.15 0.20-0.15 -0.10 -0.05 0.0 0.1 0.2-0.2 -0.1
10
8
6
4
2
0
De
ns
ity
Spearman Correlations 
Same combination
Only drug valve module (BC-dT), the same
Only drug autosampler (BC-bio), the same
Different drugs
Same combination, same order
Same combination, different order
Same drug, different order
Different drugs
Spearman Correlations Spearman Correlations 
Same combination
Different drugs
A B
C D E
Only drug valve module (BC-dT), the same
Only drug autosampler (BC-bio), the same
Only drug valve module (BC-dT), the same
Only drug autosampler (BC-bio), the same
5Iodotubercidine
Baricitinib
Blebbistatin
DMSO
Doxorubicin
Gimeracil
H7
Hematoxylin
Hymenialdisine
Methodextrate
Nelarabine
Olomucine
PF562271
Razoxane
Thiostrepton 
SB747651
SF116
Sonolisib
Streptozotocin
Triciribine
WortmanninAT9283
Clofarabine
Dacarbazine
Decitabine
DMSO
Dovitinib
Epirubicin
FludarabinePho
Fluorouracil
Gemcitabine
Imatininb
Mitomycin
NMS1286937
Oxaliplatin
SunitinibMalate
Tabloid
Trametinib
YM155
-10
10
0tS
NE
2
-10
10
0tS
NE
2
-2.5 2.5
tSNE1
0-5.0 5.0 -2.5 2.5
tSNE1
0-5.0 5.0
DMSO ctrl.
Drugs Valve module (BC-dT) Drugs Autosampler (BC-bio) 
R	E	S	U	L	T	S	
94	
(i.e.	injection	position)	dependent	effects	in	the	gene	expression	data.	Nonetheless,	removing	residual	non-ligated	barcode	fragments	resulted	in	improved	detection	of	effects	 from	 both	 drugs	 in	 individual	 experiments,	 indicating	 that	 successful	barcoding	of	drug	combination	can	be	achieved.		 	
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5.5. Discussion		In	 the	 presented	work	we	 aimed	 at	 generating	 the	 first	 gene	 expression	 data	 set	from	 cells	 perturbed	 with	 hundreds	 of	 drug	 combinations.	 We	 envisioned	determining	synergistic	drug	pairs	 from	gene	expression	data	based	on	cell	death	signatures.	 Additionally,	 analysing	 pathway	 activities	 in	 cells	 under	 perturbation	would	 allow	 finding	 potential	 mechanisms	 of	 the	 observed	 synergistic	 effects.	However,	 we	 did	 not	 detect	 robust	 effects	 of	 drug	 combinations	 in	 the	 collected	gene	 expression	 data.	 Initially,	 we	 only	 observed	 strong	 clustering	 of	 the	 gene	expression	 data	 based	 on	 one	 set	 of	 drugs	 (encoded	 by	 BCs-dT)	 but	 no	 clusters	were	formed	based	on	perturbation	with	drugs	from	the	autosampler	(encoded	by	BCs-bio).	 The	 observed	 clusters	 in	 both	 screens	 demonstrate	 that	 the	 applied	microfluidic	approach	was	able	to	pick	up	drug	specific	effects,	since	the	majority	of	the	20	treatment	conditions	in	both	screens	form	single	defined	clusters	(Fig.	5.2).	The	distinct	clustering	observed	for	all	29	drugs	from	both	screens	indicate	that	no	detectable	responses	based	on	drug	exchange	were	observed.	This	conclusion	was	confirmed	by	the	 formation	of	one	defined	cluster	of	all	DMSO	samples	generated	from	the	valve-module	and	the	DMSO	control	samples.		We	hypothesized	that	the	dominant	effects	of	drugs	encoded	by	BC-dT	were	caused	by	 residual	 BC-bio	 functioning	 as	 primers	 during	 whole	 transcriptome	amplifications.	An	optimized	protocol	for	library	preparation	in	which	we	managed	to	remove	remaining	non-ligated	BC-bio	from	the	cDNA	libraries	indeed	resulted	in	improved	 sequencing	 results.	 Compared	 to	 the	 initial	 results	we	 did	 not	 observe	cluster	formation	in	the	tSNE	analysis	neither	by	drugs	from	the	valve-module	nor	the	drugs	 from	the	autosampler	 (Fig.	5.3A,	B).	The	previously	observed	dominant	effects	of	drugs	encoded	by	BC-dT	were	undetectable	or	diminished	for	screen	1	or	screen	 2,	 respectively,	 as	 shown	 by	 correlations	 between	 drug	 signatures	 from	drugs	 encoded	 by	 BC-dT	 or	 BC-bio	 (Fig.	 5.3C,	 D).	 Correlations	 between	combinations	containing	only	one	specific	drug	from	the	valve-module	or	only	one	specific	 drug	 from	 the	 autosampler	 are	 comparable,	 while	 correlations	 between	drug	 signatures	 from	 the	 same	 combinations	were	 increased.	 Comparison	within	the	 individual	 screens	 indicated	 towards	 a	 detection	 of	 both	 drugs.	 Since	 we	exchanged	 half	 the	 drugs	 between	 screen	 1	 and	 2,	 we	 could	 compare	 drug	signatures	 of	 the	 same	 combinations	 across	 two	 experiments,	 either	 prepared	 in	the	 same	 or	 in	 the	 opposite	 order.	 Order	 in	 this	 case	 refers	 to	 injection	 position	
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(valve-module	 or	 autosampler)	 and	 barcode	 species	 (BC-dT	 or	 BC-bio)	 used	 for	demultiplexing	 gene	 expression	 data	 to	 each	 treatment	 condition.	 Since	 we	observed	only	a	high	degree	of	 correlations	between	drug	 signatures	of	 the	 same	combinations	 generated	 in	 the	 same	 order	 but	 not	 for	 the	 one	 generated	 in	 a	different	 order,	 the	 data	 was	 still	 biased	 by	 the	 barcoding	 position.	 Despite	 the	initial	 improvements,	we	 could	not	 fully	overcome	 the	positional	bias	 in	 the	gene	expression	 data.	 However,	 removing	 residual	 non-ligated	 BC-bio	 diminished	 the	strong	 clustering	 of	 drugs	 encoded	 by	 BC-dT	 and	 resulted	 in	 an	 improved	correlation	 between	 signatures	 of	 drugs	 encoded	 with	 BC-bio	 in	 the	 individual	experiments.	Therefore,	it	is	likely	that	the	positional	bias	between	drug	signatures	across	 two	 experiments	 was	 still	 caused	 by	 remaining	 non-ligated	 barcodes.	Potential	 solutions	 offer	more	 stringent	 purification	 protocols	 in	 order	 to	 ensure	the	 complete	 removal	 of	 unbound	 and	 non-ligated	 barcodes.	 Additionally,	increasing	 the	 sequencing	 depth	 could	 improve	 the	 detection	 of	 drug	 effects.	 For	screen	 1	 and	 2	 each	 treatment	 conditions	 was	 sequenced	 approximately	 with	 a	depth	of	2.4x105	and	2x105	reads,	respectively.	Considering	that	these	are	the	target	sequencing	depth	 for	 single	cell	 sequencing	experiment	 (Hwang	et	al.,	2018),	 it	 is	not	surprising	that	the	number	of	detected	genes	(genes	>	1	read)	are	comparably	low	(median	of	1863	genes	per	sample	in	screen	2)	as	for	droplet	based	single	cell	sequencing	methods	(Zhang	et	al.,	2018).	From	spiked-in	DMSO	control	samples	we	know	 that	 the	 detection	 of	 higher	 gene	 numbers	 is	 possible	 with	 the	 developed	pipeline.	DMSO	control	 samples	were	 sequenced	at	a	higher	 coverage	 (average	of	7.7x106	 reads),	 since	 the	 number	 of	 droplets	 per	 experiment	 was	 higher.	Accordingly,	the	number	of	detected	genes	(genes	>	1	read)	was	on	average	12216.	The	 number	 of	 detected	 genes	 at	 the	 given	 coverage	 is	 comparable	 to	 the	performance	of	previously	reported	high-throughput	RNA-Seq	based	drug	screens	in	plates	(Ye	et	al.,	2018).	Taken	together,	an	increased	sequencing	depth	per	drug	combinations	would	allow	the	detection	of	higher	gene	numbers	and	subsequently	give	a	higher	sensitivity.	A	possible	consequence	is	an	improved	detection	of	effects	induced	by	drugs	encoded	by	BC-bio.	This	is	likely	to	improve	correlations	between	drug	 signatures	 independent	 on	 the	 barcoding	 order,	 since	we	would	 expect	 the	data	 across	different	 screens	 to	be	 less	noisy.	 For	 this	purpose	we	 recently	 run	a	control	experiment	using	only	4x4	combinations,	resulting	in	16	combinations	out	of	 which	 10	 are	 unique	 treatment	 conditions	 and	 the	 remaining	 6	 samples	were	
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repetitions	 encoded	 with	 a	 different	 barcode	 combination	 (Tab.	 5.3).	 To	additionally	 control	 for	 biases	 introduced	 by	 injection	 positions,	we	 repeated	 the	experiment	with	a	changed	order	of	barcodes,	meaning	BC-dT	barcodes	were	used	for	the	autosampler	and	BC-bio	barcodes	for	the	valve-module.	From	the	results	we	expect	 to	 draw	 conclusions	 on	 whether	 an	 increased	 coverage	 improves	 the	detection	of	 effects	 from	both	drugs	of	 combinations	 and	whether	we	 are	 able	 to	exclude	biases	in	the	observed	effects	based	on	whether	drugs	are	injected	from	the	valve-module	or	autosampler.			
Tab.	5.3:	Combination	control	screen	 	
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6. General	discussion	and	perspective				Finding	 the	 right	 combination	 is	 a	 challenging	 task	when	 the	 number	 of	 possible	choices	 is	 tremendous.	That	 is	clearly	the	case	when	considering	all	possible	drug	like	molecules	(1x1030)	present	 in	 the	chemical	space	(Macarron	et	al.,	2011),	but	yet	 a	 challenging	 task	 for	 all	 1500	drugs	 approved	by	 the	FDA	 (Sun	 et	 al.,	 2013).	Nevertheless,	 the	 financial	 (stating	 from	 clinical	 phase	 2)	 and	 biomedical	 (higher	efficacies,	 reduced	 toxicity	 and	 fewer	 side	 effects)	 advantages	 of	 defining	 new	treatment	 strategies	 based	 on	 combinations	 of	 approved	 drugs,	 gives	 their	discovery	 great	 potential.	 Due	 to	 the	 high	 numbers	 of	 possible	 combinations,	 the	development	 of	 new	 approaches	 enabling	 the	 discovery	 of	 potential	 drug	combinations	is	of	great	relevance.	Massive	sample	reduction	and	increased	storage	capacity	 combined	 with	 a	 higher	 throughput,	 could	 potentially	 allow	 unbiased	screens	 of	 drug	 combinations.	Droplet-based	microfluidics	 fulfils	many	 criteria	 to	push	 the	 boundaries	 for	 combinatorial	 drug	 screens.	 We	 believe	 that	 innovative	new	 methods	 for	 combinatorial	 drug	 screens	 are	 of	 great	 potential	 for	 cancer	research	due	to	the	emerging	hallmark	of	inter	and	intra	tumor	heterogeneity	and	its	impact	on	treatment	strategies.	The	promise	of	combinatorial	targeted	therapies	to	prevent	resistance	has	already	led	to	several	clinical	trials	and	approvals	for	drug	combinations	(Al-Lazikani	et	al.,	2012).	However,	limitations	in	defining	new	potent	drug	 combinations	 do	 not	 only	 arise	 from	 the	 high	 number	 of	 potential	combinations,	but	also	the	intertumour	heterogeneity.	The	heterogeneity	observed	between	 tumors	 from	 different	 patient	 is	 mainly	 caused	 by	 genetic	 mutations	within	 the	 tumor	 and	 can	 cause	 different	 susceptibility	 towards	 therapies	(Vogelstein	 et	 al.,	 2013).	 Studies	 testing	 drug	 sensitivities	 directly	 on	 models	derived	from	biopsies	of	solid	tumors,	such	as	patient	derived	cell	lines	(Crystal	et	al.,	 2014)	 or	 patient	 derived	 tumor	 xenograft	 mouse	 models	 (Gao	 et	 al.,	 2015)	observed	 heterogeneous	 drug	 responses.	 Additionally,	 studies	 performing	micro-titer	based	screens	directly	on	blood	cancer	samples	were	performed	to	determine	
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patient	 tailored	 treatments	 (Pemovska	 et	 al.,	 2013)	 and	 to	 decipher	 genetics	underlying	drug	responses	(Dietrich	et	al.,	2018).	Patient	derived	models	present	a	powerful	tool	to	study	drug	responses	on	patient	material,	however,	to	what	extent	these	models	represent	the	full	intratumour	heterogeneity	is	difficult	to	assess.	Pre-existing	 subclones	 responsible	 for	 tumor	 relapse	 due	 to	 drug	 resistance	 were	described	to	be	present	at	very	 low	frequencies	 in	pre-treated	tumors	(Kim	et	al.,	2018)	 and	 therefore	 can	 be	 missed	 in	 genetic	 comparisons	 between	 primary	tumors	 and	 their	 derived	models.	 In	 order	 to	 enable	 drug	 screenings	 directly	 on	patient	 material	 from	 solid	 as	 well	 as	 blood	 tumors	 a	 reduction	 in	 the	 required	number	of	cells	per	screen	could	be	beneficial	and	was	shown	to	be	achievable	by	the	use	of	droplet	based	microfluidics	(Eduati	et	al.,	2018).	Besides	the	possibility	of	studying	 interpatient	 heterogeneity,	 droplet-based	microfluidics	 has	 the	 potential	to	enable	better	characterization	of	intratumour	heterogeneity	by	screening	drugs	and	drug	combinations	at	the	single	cell	level.	The	encapsulation	of	single	cell	into	droplet	 along	 with	 drug	 combinations	 can	 be	 exploited	 to	 select	 individual	 cells	based	on	their	phenotype	(e.g.	resistance)	followed	by	their	characterization	based	on	gene	expression	profiling.	Implementation	such	as	direct	single	cell	sequencing	on	treated	cells	in	droplets	has	the	potential	to	give	deep	insights	into	the	impact	of	heterogeneity	 on	 sensitivity	 towards	 large	 sets	 of	 drug	 combinations.	 In	 order	 to	pave	 the	 way	 for	 such	 types	 of	 experiments,	 we	 developed	 novel	 microfluidic	workflows	 for	 the	 generation	 of	 hundreds	 of	 combinations	 in	 picolitre-sized	droplets,	enabling	screens	on	low	input	materials.	In	the	presented	work,	up	to	420	treatment	conditions	were	tested	on	tumor	cells	encapsulated	into	droplets	on	the	single	cell	level.	Additionally,	we	provide	the	first	framework	for	highly	multiplexed	gene	 expression	 readout	 of	 cells	 perturbed	 by	 drug	 combinations	 using	 drug	specific	barcoding	of	transcriptomes.		
6.1. Indexing	 of	 droplets	 with	 barcode	 combinations	 for	multiplexed	droplet	experiments	In	chapter	3	we	presented	a	novel	approach	to	generate	combinations	in	picolitre-sized	droplets	by	using	a	valve	based	microfluidic	pipeline.	The	control	of	injected	reagents	 by	 valves	 allowed	 rapid	 switching	 between	 14	 sample	 inlets	 and	 their	mixing.	 Combinations	 of	 two	 reagents	 were	 encapsulated	 into	 droplets	 on	 a	
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separate	 drop-maker	 chip	 and	 a	 valve	 based	 sample	 collector	 controlled	 their	collection.	We	 implemented	 a	 novel	 DNA-based	 barcoding	 approach	 that	 enables	the	identification	of	each	combination	and	therefore	all	droplets	could	be	stored	in	the	same	tube.	The	generation	and	the	DNA-barcoding	of	combinations	in	droplets	overcame	 the	 limitation	 of	 other	 valve-based	 approaches	 to	 store	 combinations	sequentially	in	large	droplets,	which	is	not	fully	scalable	(Eduati	et	al.,	2018;	Rane	et	 al.,	 2015).	 Furthermore,	 it	 enables	 the	 integration	 of	 single-cell	 phenotypic	screens,	 e.g.	 to	 isolate	and	characterize	 resistant	 cells	 in	a	multiplexed	 fashion.	 In	contrast	 to	 previous	 approaches,	 in	 the	 presented	 work,	 combinations	 were	generated	 in	 picolitre-sized	 droplets	 and	 stored	 in	 a	 single	 tube.	 As	 compared	 to	fluorescence-based	barcoding	used	for	encoding	single	compounds	(Brouzes	et	al.,	2009)	 or	 drug	 concentration	 (Miller	 et	 al.,	 2012),	 the	 presented	 DNA-based	barcoding	 approach	 can	 be	 scaled	 up	 to	 encode	 millions	 of	 conditions.	 The	generation	 of	 combinations	 from	 the	 valve-module	 allowed	 production	 of	 49	combinations	with	2100	droplets	per	condition	in	around	12	min	and	thus	presents	a	 fast	 way	 to	 test	 several	 conditions	 in	 droplets.	 Since	 each	 condition	 can	 be	demultiplexed	by	 its	barcode	combinations,	all	droplets	with	diverse	contents	can	be	 processed	 in	 a	 single	 emulsion.	 Multiplexed	 screens	 increase	 the	 throughput	compared	 to	 conventional	 droplet-based	 screening	 approaches	 by	 processing	 all	conditions	 in	 a	 single	 run.	 Furthermore,	 the	 possibility	 to	 multiplex	 several	conditions	has	the	advantage	that	less	input	material	is	required	since	only	several	thousand	droplets	per	conditions	can	be	processed.	As	an	example	we	performed	one	 droplet	 sorting	 experiment	with	 a	 pool	 of	 49	 conditions	 (only	 different	 DNA	barcodes)	 instead	 of	 sorting	 for	 individual	 49	 conditions,	 providing	 a	 method	 to	increase	 throughput	 of	 droplet	 based	 sorting	 screens.	 A	 subset	 of	 droplets	 with	barcode	combinations	was	additionally	 labelled	with	a	 fluorescence	dye.	Droplets	of	interest	were	sorted	based	on	their	fluorescence	signal	and	the	enrichment	was	measured	 by	 comparing	 sequenced	 barcodes	 obtained	 from	 sorted	 droplets	 and	unsorted	 droplets.	 In	 future,	 this	 setup	 can	 be	 applied	 to	 screen	 for	 potent	combinations	of	perturbants,	such	as	anti-cancer	drugs.	Sorting	based	on	reporter	signals	would	allow	the	enrichments	of	combinations	showing	the	desired	effects.	By	exposing	cancer	cells	to	drug	combinations	and	subsequent	sorting	of	droplets	based	on	fluorescence	apoptosis	readouts,	potent	combinations	against	cancer	can	
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workflow	 described	 in	 chapter	 4,	 would	 allow	 to	 separate	 heterogeneous	 cell	populations	into	responding	and	non-responding	populations		As	 a	 strategy	 to	 increase	 the	 chemical	 diversity	 in	 droplets,	 compounds	 injected	into	 the	 valve-module	 could	 be	 diluted.	 One	 possibility	 is	 to	 generate	 multiple	discrete	concentrations	of	drug	combinations	by	diluting	each	sample	plug	with	a	defined	 volume	 injected	 from	 a	 third	 valve.	 Additionally,	 by	 using	 different	 valve	opening	 times,	 the	 ratio	 in	which	 two	 reagents	 are	 combined	 can	be	 altered.	 In	 a	more	advanced	approach,	the	increased	diffusion	due	differences	of	flow	velocity	in	a	 tube	 (Taylor-Aris	 dispersion)	 could	 be	 exploited	 to	 generate	 dilutions	 of	compound	 plugs	 as	 described	 by	 Miller	 et	 al.	 Here,	 the	 use	 of	 a	 miscible	 carrier	phase	 was	 used	 to	 dilute	 compounds,	 resulting	 in	 bell-shaped	 concentration	profiles.	More	complex	dilution	patterns	could	be	generated	by	opening	two	valves	in	 different	 sequential	 orders	 and	 the	 use	 of	 an	 additional	 valve	 for	 dilution.	 The	generation	of	 continuous	dilution	 curves	 could	help	 to	 increase	 the	 sample	 space	and	 could	 serve	 as	 a	 powerful	 tool	 to	 find	 synergistic	 drug	pairs.	However,	more	challenging	to	implement	is	a	readout	for	each	concentration	using	DNA-barcoding	approach.	A	possible	solution	could	be	the	ligation	of	three	barcodes	where	two	are	used	to	encode	a	combination	and	one	is	used	to	encode	a	concentration.	However,	this	would	need	one	barcode	for	each	concentration,	which	would	again	be	limited	by	 the	 number	 of	 available	 valves.	 A	 second	 approach	 could	 be	 to	 implement	fluorescence	 dye	 based	 readout	 to	 encode	 dilutions	 of	 compounds	 as	 shown	 by	Miller	and	colleagues	(Miller	et	al.,	2012).	We	could	moreover	increase	the	number	of	combinations	by	the	generation	of	all	possible	pairs	(91	pairwise	combinations	from	14	valves)	from	the	valve-module.	For	this	purpose	each	compound	could	be	encoded	by	one	barcode	sequence	present	as	a	mixture	of	two	barcode	species	so	that	all	barcodes	become	compatible	with	each	other	and	such	that	all	valves	can	be	combined	 with	 each	 other.	 A	 pipeline	 that	 additionally	 provides	 the	 option	 to	generate	all	possible	 combinations	out	of	 three	 compounds	would	generate	up	 to	364	 combinations	 without	 increasing	 the	 number	 of	 sample	 inlets.	 Along	 with	implementations	 of	 the	 discussed	 improvements,	 the	 pipeline	 will	 exceed	multiplexing	 capacities	 for	 droplets	 in	 emulsions	 of	 previously	 presented	 work.	Therefore,	 the	 valve-based	 approach	 together	 with	 DNA	 based	 barcoding	 of	samples,	 presents	 a	 powerful	 technology	 for	 screening	 drug	 combinations	 using	droplet-based	microfluidics.		
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A	 long	 lasting	 limitation	 for	 drug	 screens	 in	 emulsion	 is	 the	 exchange	 of	 drugs	based	 on	 micellular	 transport	 (Gruner	 et	 al.,	 2016).	 In	 order	 to	 exploit	 the	 full	potential	 of	 droplet-based	 microfluidics	 for	 combinatorial	 drug	 screen,	 a	 crucial	step	 is	 to	 develop	 technologies	 preventing	 exchange	 of	 compounds	 between	droplets.	A	potential	 solution,	we	 tried	 to	 integrate	 into	 the	pipeline,	 is	 the	use	of	droplet	 arrays	 in	which	 droplets	 are	 stored	 individually	 in	 traps.	 This	 allows	 the	removal	of	surfactant	since	droplets	are	spaced	out	and	thus	do	not	coalesce.	The	advantage	of	this	approach	was	exploited	in	a	recently	published	work	to	perform	large-scale	combinatorial	drug	screens	in	droplets	(Kulesa	et	al.,	2018).	However,	it	requires	high	number	of	microfluidic	devices	for	droplet	storage	and	processing	of	droplets	after	 incubation	is	challenging	since	droplets	stick	to	traps	 in	the	droplet	array.	 We	 also	 tested	 the	 so-called	 pickering	 emulsions	 to	 prevent	 surfactant	mediated	exchange	between	droplets.	Here,	 fluorinated	amphiphilic	nanoparticles	are	used	to	stabilize	the	water-oil	interface	(Pan	et	al.,	2015).	By	use	of	fluorinated	nanoparticles	 the	 formation	 of	 micelles	 and	 consequently	 exchange	 can	 be	prevented.	Until	now,	we	did	not	manage	to	synthesize	nanoparticles	that	stabilize	water	in	oil	droplets	over	a	long	time	period.	Since	long	incubation	times	can	result	in	 an	 exchange-mediated	 equilibrium	 of	 drug	 concentrations	 between	 droplets	(Gruner	et	al.,	2016),	we	focused	on	drug	screens	using	RNA-Seq	readouts.	Here,	as	compared	 to	 cell	 viability	 readouts,	 shorter	 incubations	 are	 sufficient	 (6h)	 to	determine	 the	 effects	 of	 drugs	 on	 gene	 expression	 (Subramanian	 et	 al.,	 2017).	Another	advantage	in	this	context	is	that	gene	expression	readouts	allow	detection	of	 drug	 exchange	 by	 comparing	 expression	 patterns	 between	 different	 treatment	conditions,	especially	of	untreated	controls.		
6.2. Gene	expression	based	profiling	of	drug	combinations	using	droplet-based	microfluidics	The	following	section	discusses	the	results	and	conclusions	drawn	from	chapter	4	and	 chapter	 5.	 Here	 we	 introduced	 a	 microfluidic	 pipeline	 to	 generate	 drug	combinations	 from	an	extended	version	of	 the	valve-module	 and	an	autosampler.	As	 compared	 to	 an	 approach	 previously	 described	 by	 our	 group	 (Eduati	 et	 al.,	2018),	we	 could	 significantly	 increase	 the	 number	 of	 possible	 combinations	 (420	instead	of	55).	Moreover,	in	the	presented	work	all	420	combinations	were	stored	
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in	a	single	tube,	which	reduces	screening	costs	and	increases	the	storage	capacity.	Another	 advantage	 is	 the	 possibility	 to	 process	 droplets	 after	 incubation	 by	standard	methods	used	for	droplet-based	microfluidics,	such	as	droplet	sorting	or	pico-injection,	 which	 allows	 selection	 of	 droplets	 or	 addition	 of	 reagents,	respectively.	 This	 is	 particularly	 interesting	 considering	 that	 the	 use	 of	 picolitre-sized	droplets	allows	the	encapsulation	of	single	cells	along	with	drug	combinations	and	 thus	 processing	 of	 droplets	 allows	 single	 cell	 phenotypic	 readouts	 (e.g.	apoptosis).	 Pooling	 of	 all	 compound	 combinations	 in	 a	 single	 tube	 was	 again	facilitated	 by	 DNA-based	 barcoding	 of	 each	 combination.	 In	 this	 case,	 we	 used	barcode	 combinations	 additionally	 functionalized	 with	 poly-dT	 sequences	facilitating	barcoding	of	transcriptomes	according	to	the	combination	of	drugs	cells	were	 exposed	 to.	 Sequencing	 of	 barcoded	 transcriptomes	 was	 applied	 to	 assign	gene	 expression	 data	 to	 each	 treatment	 condition.	 The	 barcoding	 approach	 is	deterministic,	meaning	each	barcode	identifies	a	specific	treatment	condition.	This	is	in	contrast	to	random	barcoding	as	used	for	droplet-based	single	cell	sequencing	approaches	 (Klein	 and	 Macosko,	 2017).	 Therefore,	 the	 presented	 work	 has	 the	potential	 to	 perform	 highly	 multiplexed	 gene	 expression	 experiments	 from	 420	treatment	 conditions	 using	 a	 semi-automated	 workflow.	 To	 the	 best	 of	 our	knowledge,	 the	 presented	 approach	 is	 the	 first	 one	 allowing	 the	 on-demand	generation	of	such	high	numbers	of	combinations,	which	can	be	stored	in	a	single	emulsion	 of	 picolitre-sized	 droplets.	 Additionally,	 the	 integration	 of	 a	 RNA-Seq	compatible	barcoding	strategy	with	the	developed	droplet-based	screening	pipeline	is	 the	 first	 approach	 that	 aims	 at	 a	 highly	 multiplexed	 gene	 expression	 based	readouts	of	drug	combinations.	This	is	in	contrast	to	a	recently	published	work	by	Kulesa	 and	 colleagues	 (Kulesa	 et	 al.,	 2018),	 where	 drug	 combinations	 were	generated	in	stationary	droplet-arrays	by	fusion	of	two	droplets.	All	droplets	were	stored	in	the	droplet-arrays	over	the	time	of	incubation	after	which	growth	rates	of	bacteria	 were	 measured	 by	 a	 single	 fluorescence	 raedout.	 In	 order	 to	 screen	100,800	drug	combinations	126	microarray	chips	were	used	with	only	13	droplets	per	combinations.		The	 translation	 from	 micro-titer	 plate	 screens	 towards	 emulsion-based	 screens	harbours	great	potential	 for	several	 future	applications.	The	relative	low	numbers	of	cells	necessary	for	420	combinations	with	maximal	1000	cells	per	sample	may	be	exploited	 to	 perform	 functional	 screens	 directly	 on	 patient	 material.	 Due	 to	 low	
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incubation	time	necessary	to	obtain	gene	expression	profiles	from	drug	treatments,	no	long	term	culturing	would	be	required.	Gene	expression	profiles	from	the	LINC	database	were	 prepared	 from	 cells	 exposed	 to	 drugs	 for	 6h	 (Subramanian	 et	 al.,	2017).	 Additionally,	 we	 detected	 drug-specific	 clustering	 of	 gene	 expression	 data	prepared	from	cells	exposed	to	drugs	for	only	6h	(data	shown	in	appendix	Fig.	9.2)	and	12h	(Fig.	5.3).	Consequently,	 incubation	times	of	only	12h	or	even	6h	may	be	sufficient	 to	 draw	 conclusions	 about	 drug	 sensitivity	 based	 on	 gene	 expression	data.	Fast	prediction	on	drug	sensitivity	of	primary	tumor	cells	can	be	beneficial	to	prevent	selection	of	specific	subclones	and	to	preserve	their	phenotypes	in	terms	of	drug	sensitivity	(Montero	et	al.,	2015).	The	possibility	to	use	gene	expression	under	perturbation	to	predict	anti-cancer	drug	sensitivity	was	recently	demonstrated	by	the	 integration	 of	 perturbation	 signatures	 from	 the	 LINCS	 database	 and	 cell	viability	 screens	 (Szalai	 et	 al.,	 2018).	 Szalai	 et	 al.	 defined	 consensus	 cell	 death	signatures,	which	were	used	to	predict	cell	viability.	This	may	turn	out	as	a	useful	method	to	additionally	predict	synergistic	drug	pairs	based	on	cell	death	signatures	scores	exceeding	the	additive	scores	of	the	two	compounds	alone.	Taken	together,	gene	expression	data	obtained	from	cells	after	short	 incubation	times	can	be	used	to	 determine	 potent	 drug	 combinations,	 which	 eventually	 will	 improve	 drug	screens,	 in	particular	 for	primary	tumor	cells.	Moreover,	 the	gene	expression	data	of	perturbed	cells	is	a	more	informative	readout	of	drug	sensitivity	as	compared	to	reporter-based	 readouts,	 such	 as	 cell	 viability	 or	 apoptosis	 alone.	 Besides	 the	possibility	 to	 determine	 cell	 death	 signatures	 of	 drug	 combinations,	 the	 gene	expression	 data	 can	 be	 used	 to	 define	 underlying	 signalling	 pathway	 activities	(Schubert	et	al.,	2018).	Knowledge	on	the	pathway	activity	of	perturbed	cells	can	be	informative	 to	 make	 associations	 between	 synergistic	 actions	 of	 drug	 pairs	 and	pathway	activity.		In	 the	 presented	 work,	 cell	 suspensions	 were	 used	 at	 densities	 suitable	 for	obtaining	single	cells	in	droplets.	The	generation	of	droplets	harbouring	single	cells	provides	 the	 possibility	 to	 introduce	 droplet-processing	 methods	 for	 functional	single	 cell	 characterization.	We	believe	 that	 this	 is	 of	 great	 potential	 for	 studying	the	 impact	 of	 tumor	 heterogeneity	 on	 drug	 sensitivity,	 since	 effects	 of	 individual	subpopulations	 can	 be	 studied.	 Quantifying	 the	 number	 of	 non-responding	 cells	towards	 drug	 combinations	 could	 allow	 prediction	 on	 resistance	 subpopulations.	Such	 screens	 can	be	performed	by	 encapsulating	 cells	with	 fluorescence	 reporter	
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assays	 for	 apoptosis	 (e.g.	 Caspase	 3/7	 substrates)	 followed	 by	 sorting	 of	 droplet	containing	 viable	 cells	 (i.e.	 apoptosis	 negative).	 Enrichment	 of	 surviving	 cells	 and	their	characterization	by	gene	expression	can	provide	interesting	insights	on	non-responding	or	drug	resistance	phenotypes	in	a	highly	multiplexed	fashion.	We	have	demonstrated	 in	section	3.7	 the	possibility	 to	enrich	a	specific	droplet	population	and	determine	their	content	by	sequencing	the	enriched	barcode	combinations.	In	a	next	 step,	 sorting	 of	 droplets	 can	 be	 combined	 with	 the	 later	 drug	 screening	 to	enrich	for	non-responding	cells.	However,	to	fully	exploit	the	use	of	the	presented	pipeline	for	screens	on	biopsies	from	solid	tumors	and	to	sort	those	cells	based	on	apoptosis,	 we	 would	 need	 to	 implement	 strategies	 to	 prevent	 programmed	 cell	death	 induced	 by	 the	 loss	 of	 adhesion	 (Frisch	 and	 Screaton,	 2001).	 To	 overcome	this	 limitation,	 a	 possibility	 could	 be	 cell	 encapsulation	 into	 droplets	 along	 with	polymers	 used	 in	 3-D	 cell	 culture	 techniques	 as	 previously	 reported	 (Sart	 et	 al.,	2017;	Yu	et	al.,	2010).		Furthermore,	 the	 encapsulation	 of	 single	 cells	 along	with	 drug	 combinations	 and	their	 corresponding	barcodes	 can	be	 exploited	 in	 single	 cell	 sequencing	methods.	Our	 current	 pipeline	 would	 in	 principle	 allow	 the	 co-encapsulation	 of	 barcoded	beads	 and	 cells	 as	 described	 in	 the	 Drop-Seq	 protocol	 (Macosko	 et	 al.,	 2015).	Instead	 of	 lysing	 the	 cells	 directly,	 we	 could	 apply	 pico-injection	 as	 described	 in	section	 2.7	 to	 lyse	 cells	 after	 their	 incubation	 together	 with	 drug	 combinations.	Hence,	we	 could	 sequence	 the	 transcriptome	 of	 each	 cell	 individually	 and	 obtain	single	 cell	 resolution	 of	 responses	 to	 drug	 combinations.	 To	 additionally	 barcode	each	cells	transcriptome	according	to	the	drug	combination	it	was	exposed	to	in	the	droplet,	 we	 would	 need	 to	 adapt	 our	 combinatorial	 barcoding	 approach.	 One	possibility	to	encode	the	drug	information	together	with	single	cell	transcriptomes,	is	 to	 apply	 hybridization	 of	 barcodes	 harbouring	 poly-dA	 sequences	 to	 barcoded	beads	as	it	is	already	described	by	for	single	cell	multi-omics	methods	(Stoeckius	et	al.,	2017).		Using	 single	 cell	 sequencing	 together	 with	 the	 introduced	 microfluidic	 pipeline	would	 additionally	 allow	 the	 implementation	 of	 a	 new	 barcoding	 strategy	 for	encoding	 drug	 concentrations.	 We	 could	 dilute	 compound	 plugs	 by	 opening	 an	additional	valve	to	 inject	a	DMSO	control	at	a	certain	ratio.	However,	determining	the	 concentrations	 by	 sequencing	 RNA-Seq	 is	 challenging	 since	 we	 would	 only	determine	the	number	of	reads	with	a	particular	barcode	combination.	Introducing	
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an	additional	barcode	 for	each	droplet	 (i.e.	 cells),	 as	 it	 is	done	 in	Drop-Seq,	 could	potentially	 be	 exploited	 to	 count	 the	 numbers	 of	 drug	 barcodes	 assigned	 to	 each	cell	barcode.	Extending	drug	barcodes	with	unique	molecular	 identifiers	(Islam	et	al.,	 2014)	 would	 allow	 the	 quantification	 of	 drug	 barcodes	 assigned	 to	 a	 cell	barcode.	As	a	result,	concentration	of	drug	barcodes	could	potentially	be	measured	by	 sequencing	 and	 consequently	 the	 concentration	 of	 drugs	 and	 its	 influence	 on	gene	 expression	 could	 be	 assessed.	 Diluting	 compound	 plugs	 from	 the	 valve-module	 would	 increase	 the	 overall	 number	 of	 possible	 combinations	 without	expanding	 the	 current	 setup.	 Screen	 over	 five	 different	 distinct	 concentrations	would	 already	 result	 in	 2100	 treatment	 conditions	 using	 the	 current	 drug	 panel.	Performing	 single	 cell	 sequencing	 from	 hundreds	 of	 drug	 combinations	will	 be	 a	powerful	 tool	 to	 elucidate	 their	 effects	 on	 gene	 expression.	 We	 envision	 that	implementations	 of	 such	 technologies	 will	 provide	 information	 of	 why	subpopulations	 do	 not	 respond	 to	 drug	 treatments	 and	 allow	 definition	 of	 drug	combination	that	overcome	resistance	mechanisms.			
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7. Material	and	Methods				
7.1. Methods	in	Microfluidics	
7.1.1. Mask	design		Photo-masks	are	necessary	in	the	process	of	standard	photolithography.	The	design	of	a	photo-mask	was	drawn	in	AutoCAD	(Autodesk	Inc.,	USA).	Designs	were	printed	(Selba	 S.A.	 Versoix	 Switzerland)	 on	 transparent	 plastic	 slides	 at	 25400	 dpi.	Depending	 on	 the	 later	 application	 designs	 were	 either	 printed	 as	 positives	 or	negatives.	Positives	were	used	for	mould	manufacturing	from	positive	photoresist	for	the	production	of	microfluidic	devices	used	in	the	valve-module.	Negative	prints	of	designs	were	used	for	producing	moulds	from	negative	photoresists	(see	below).	
7.1.2. Photolithography	for	mould	manufacturing		
Negative	Photoresists		Silicon-wafers	 (Siltronix,	 Silicon	Materials,	 Germany,	 3”	 or	 4”)	 were	 first	 cleaned	using	an	air	gun	and	then	placed	on	a	hot	plate	at	140	˚C	for	10	min.	In	the	next	step	wafers	 were	 coated	 with	 a	 layer	 of	 SU-8	 2075	 photoresist	 (MicroChem	 Corp.,	Newton	 MA):	 A	 wafer	 was	 placed	 on	 a	 spin	 coater	 (Laurell	 Technologies	 Corp.,	North	Wales	PA),	photoresist	was	poured	on	 the	wafer	and	evenly	distributed	by	spinning	the	wafer	at	a	given	speed.	The	time	and	speed	of	spinning	determined	the	thickness	and	thereby	the	channel	height	of	the	mould	and	these	parameters	were	adapted	according	to	the	manufacturer’s	instructions.	Coated	wafers	were	baked	at	65	 ˚C	 and	 95	 ˚C	 for	 times	 given	 by	 the	 manufacturer	 for	 a	 given	 photoresist	thickness.	A	negative	of	a	photo-mask	was	placed	on	the	wafer	and	exposed	to	UV-light	in	a	mask	aligner	(Karl	Suss	MA45).	Wafers	were	again	baked	at	65	˚C	and	95	
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˚C	 followed	by	the	development	with	mr-Dev-600	(micro	resist	 technology	GmbH,	Berlin)	in	order	to	remove	all	areas	that	were	not	exposed	to	UV-light.	After	a	last	baking	 step	at	150	 ˚C	 the	moulds	were	 ready	 for	microfluidic	 chip	manufacturing	(see	below).		
Positive	Photoresist	Positive	photoresists	were	used	 to	obtain	 rounded	channels	used	 for	 chips	 in	 the	valve-module.	Silicon-wafers	were	cleaned	and	baked	at	140	˚C	for	10	min.	AZ	40XT	photoresist	 (MicroChemicals	 GmbH,	 Ulm)	 was	 poured	 on	 a	 wafer,	 which	 was	distributed	 in	a	spin	coater	at	1300	rpm	for	40	sec.	After	a	soft-baking	step	(Tab.	
7.1)	 a	 positive	 photo-mask	 was	 placed	 on	 top	 of	 photoresist	 layer,	 which	 was	exposed	to	UV-light	for	150	sec.	Wafers	were	left	at	RT	for	5	min	followed	by	a	post-exposure	 baking	 step	 (see	 Tab.	 7.1).	 Moulds	were	 developed	 using	 AZ	 726	MIF	Developer	 (MicroChemical	 GmbH,	Ulm)	 to	 remove	 all	 UV-exposed	 areas	 from	 the	wafer.	 In	 order	 to	 obtain	 rounded	 channels,	wafers	were	 baked	 according	 to	 the	round	 bake	 step	 (see	 Tab.	 7.1).	 Subsequently	 moulds	 were	 ready	 to	 produce	microfluidic	chips	used	for	valve-modules	(see	below).		
Tab.	7.1:	Baking	times	for	positive	photoresist	
Time	[min]	 4	 2	 2	 1	 2	 2	 2	 4	
Soft	bake	 55	°C	 65	°C	 75	°C	 85	°C	 95	°C	 105	°C	 115	°C	 	
Post-exposure	bake	 55	°C	 65	°C	 75	°C	 85	°C	 95	°C	 	 	 	
Round	bake	 55	°C	 65	°C	 75	°C	 85	°C	 95	°C	 105	°C	 115	°C	 125	°C	
7.1.3. PDMS	Membranes		Polydimethylsiloxane	(PDMS)	and	curing	agent	(Sylgard	184	silicone	elastomer	kit,	Dow	 Corning	 Corp.,	 USA)	 were	 mixed	 at	 a	 ratio	 of	 10:1	 w/w	 and	 placed	 in	 a	desiccator	 until	 all	 air	 bubbles	 were	 removed.	 The	 mix	 was	 distributed	 on	transparency	 slides	 using	 a	 spin	 coater	 at	 500	 rpm	 for	 19	 sec.	Membranes	were	cured	over	night	at	65	˚C.		
7.1.4. Microfluidic	chip	manufacturing	Moulds	were	placed	in	petri	dishes	and	filled	with	a	10:1	mix	of	PDMS	and	curing	agent.	After	desiccation,	moulds	were	baked	over	night	at	65	˚C.	On	the	next	day	the	PDMS	was	cut	and	peeled	off	the	mould.	Inlets	to	insert	tubing	or	electrodes	were	
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punched	using	biopsy	punches	with	a	diameter	of	0.75	mm.	The	PDMS	was	cleaned	using	 air	 pressure	 and	 adhesive	 tape	 and	 then	 plasma	 bonded	 (Femto,	 Diener	electronic	GmbH	+	Co.	KG,	Germany)	either	to	glass	slides	(negative	photoresist)	or	PDMS	membranes	(for	all	chips	with	valves).	Subsequently,	devices	were	kept	at	65	˚C	 for	 5	min.	 Chips	 for	 the	 valve-module	were	 additionally	 bound	 to	 a	 glass	 slide	only	covering	 the	 inlet	and	outlet	ports.	This	was	necessary	 to	prevent	rupture	of	the	membrane	and	thus	leakage	when	inserting	tubings	into	the	ports.	In	order	to	obtain	 hydrophobic	 channel	 surfaces,	 Aquapel	 (Autoserv,	 Germany)	 was	 flushed	through	the	channels	and	subsequently	removed	using	an	air	filled	syringe.		
7.1.5. Preparation	of	microfluidics	chips	with	horizontal	inlets	Valve-module	 chips	 and	 drop-makers	 used	 for	 producing	 high	 numbers	 of	combinations,	were	connected	by	a	delay	tubing	which	was	inserted	from	the	side	allowing	 reagent	 injection	 parallel	 to	 the	 channels.	 This	 minimizes	 cross-contamination	due	to	plug	breakage	(Clausell-Tormos	et	al.,	2010).	Holes	for	valve-module	 outlets	were	 punched	 from	 the	 side	 using	 a	 0.5	mm	 biopsy	 punch.	 After	plasma-bounding	the	chip	to	a	PDMS	membrane,	a	piece	of	Polytetrafluoroethylene	(PTFE)	tubing	(UT3,	Adtech	Polymer	Engineering	LtD,	UK)	with	an	outer	diameter	of	0.4	mm	was	inserted	into	the	side	inlet	until	it	reached	the	funnel	structure	of	the	outlet	 channel.	 Chips	 were	 bound	 to	 glass	 slides	 big	 enough	 to	 cover	 parts	 with	inlets	 and	 outlets,	 preventing	membrane	 rupture	 by	 the	 insertion	 of	 tubing.	 The	tubing	 inserted	 into	 the	 outlet	 channel	 was	 bound	 to	 the	 chip	 using	 UV	 curing	adhesive	 (Loctite,	 Henkel	 AG	 &	 Co.	 KGaA,	 Germany).	 Drop-maker	 chips	 were	produced	by	first	punching	holes	with	a	0.75	mm	biopsy	punch	for	oil	and	cell	inlets	and	the	outlet.	Insertion	ports	for	the	autosampler	were	punched	using	a	1.25	mm	punch	and	 inlets	 for	 the	delay	 tubing	using	0.5	mm	punch	Holes	 for	 inserting	 the	delay	 tubing	 were	 punched	 from	 the	 side	 to	 prevent	 plug	 break-up.	 The	 drop-maker	devices	were	 first	 bonded	 to	 a	 PDMS	membrane	 and	 then	 to	 a	 glass	 slide.	After	aquapel	treatment	chips	were	ready	to	use.		
7.1.6. Injection	of	fluids	into	microfluidic	devices		The	 injection	of	 fluids	 into	channels	of	a	microfluidic	device	was	performed	using	syringes	mounted	on	syringe	pumps.	PTFE	tubings	with	 in	outer	diameter	of	0.76	mm	(HW30,	Adtech	Polymer	Engineering	LtD,	UK)	were	connected	with	Luer-Lok	
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syringes	 (Becton	 Dickinson,	 USA)	 using	 27G	¾	 gauge	 needles	 (Becton	 Dickinson,	USA).	 Syringes	 were	 filled	 with	 reagents	 and	mounted	 on	 PHD	 22/2000	 Syringe	Pumps	 (Harvard	 Apparatus,	 USA).	 In	 the	 pumps’	menu	 the	 syringe	 diameter	 and	flow	rates	were	 set	 accordingly.	The	 free	end	of	 the	 tubing	was	 connected	with	a	microfluidic	device	via	the	punched	tubing	inlet	and	thereby	reagents	were	injected	at	a	defined	flow	rate	into	the	channels	of	the	device.		
7.1.7. Braille	display	operations	A	 SC-9	braille	 display	with	64	pins	 (KGS	Corporation,	 Japan)	was	 connected	over	communication	port	to	a	computer.	The	sample	on	demand	software	(Eduati	et	al.)	was	 used	 to	 control	 the	 pins	 of	 the	 braille	 display.	 All	 pins	 were	 automatically	moved	down	once	the	braille	display	was	connected.	For	using	the	braille	display	to	direct	injected	fluids	into	different	channels	of	the	microfluidic	device,	always	two	pins	 were	 operated	 at	 the	 same	 time.	 In	 the	 default	 mode	 the	 outer	 pins	 were	moved	upwards	 and	 the	 two	 lines	of	pins	 in	 the	middle	were	moved	downwards	
(Fig.	7.1A).	In	this	mode,	all	liquids	injected	into	the	chip	are	directed	towards	the	waste	 outlet	 since	 pins	 blocked	 the	 channels	 directing	 fluids	 the	 outlet	 for	 plug	production.	 Injected	 fluids	 were	 directed	 to	 the	 outlet	 for	 plug	 production	 by	closing	the	waste	valve	(pin	in	the	middle	row)	and	by	opening	the	corresponding	pin	 in	 the	outer	row	(Fig.	 7.1A).	This	process	was	automated	by	uploading	a	CVS	file	 in	 the	 sample	 on	 demand	 software,	 which	 contained	 a	 sequence	 of	 valve	operations	and	opening	times.		
7.1.8. Setting	up	a	valve-module		The	 channels	 of	 a	 valve-module	 chip	 (16	 valves	 or	 24	 valves)	 were	 filled	 with	trypan	blue	(Thermo	Fisher	Scientific	Inc.,	USA)	using	a	syringe.	The	braille	display	was	connected	to	a	computer	and	the	valve	structures	of	the	chip	were	aligned	on	top	of	the	pins	(Fig.	7.1B).	A	plexiglass	holder	was	used	to	fix	the	chip	on	the	pins.	Actuating	one	valve	in	the	sample	on	demand	software	started	the	priming	mode	in	which	all	waste	valves	were	open	and	sample	injection	valves	were	closed.	Blocking	channels	was	achieved	by	pins	pushing	 the	elastic	membrane	against	 the	channel	walls.	First	pieces	of	tubing	were	inserted	into	the	waste	outlets.	
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Fig.	7.1	Pictures	braille	display	and	valve-module	
(A)	Picture	of	a	SC-9	braille	display	used	in	this	work.	The	actuation	of	the	white	pins	was	controlled	
by	a	LabVIEW	software	(sample	on	demand).	(B)	Picture	of	a	valve-module:	A	PDMS	chip	was	aligned	
on	top	of	the	white	pins	of	a	SC-9	braille	display.	Chip	was	fixed	by	a	plastic	bar.	Moving	the	pins	up	
and	down	allowed	closing	or	opening	of	the	channels	above.			Subsequently,	the	tubings	connected	to	5	ml	syringes	filled	with	aqueous	solutions	were	inserted	into	the	inlets	of	the	valve-module	device.	Additionally,	5	ml	syringes	filled	with	NovecTM	7500	oil	(3M	Company,	St.	Paul	MN)	were	connected	with	inlets	of	 the	valve-module	chip.	All	syringes	were	mounted	on	syringe	pumps	and	fluids	were	injected	at	500	µl/h.		
7.1.9. Setting	up	a	sample	collector	module		A	sample	collector	chip	bond	to	a	PDMS	membrane	was	filled	with	trypan	blue.	The	chip	was	placed	on	a	Braille	display	with	each	channel	being	on	top	of	a	row	of	four	pins.	 The	 Braille	 display	 was	 connected	 to	 an	 in-house	 LabVIEW	 (National	Instruments,	USA)	software	that	allowed	the	simultaneous	actuation	of	all	four	pins	in	 one	 row.	 The	 two	 rows	 below	 the	 two	 channels	 were	 selected	 and	 one	 was	defined	as	waste	channel	and	one	was	defined	as	collection	channel.	Closing	of	one	channel	 was	 synchronized	 with	 the	 opening	 of	 the	 other	 channel.	 Fluorescence	threshold	and	time	windows	were	set	and	determined	when	and	for	how	long	the	collection	 channel	 was	 opened.	 The	 two	 pieces	 of	 tubing	 from	 the	 drop-makers’	outlets	were	connected	with	two	inlets	on	the	sample	collector.	Two	short	pieces	of	
BA
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tubing	were	inserted	into	the	outlets	of	the	sample	collector	to	direct	droplets	to	a	collection	and	waste	tube.		
7.1.10. Autosampler	operations		The	 autosampler	 (Dionex	 UltiMate	 3000	 Analytical	 Autosampler	 WPS-3000	 SL,	Thermo	 Fischer	 Scientific	 Inc.,	 USA)	 was	 operated	 using	 Chromeleon	 software	(Thermo	 Fisher	 Scientific	 Inc.,	 USA).	 In	 an	 operation	 sheet	 the	wells	 of	 a	 96-well	plate	 were	 selected	 and	 compounds	 were	 aspirated	 by	 the	 autosampler	accordingly.	PBS	was	used	as	a	carrier	fluid	and	was	injected	by	an	external	syringe	pump	 into	 the	 autosampler	 valve	 at	 500	 µl/h	 and	 was	 used	 to	 inject	 aspirated	compounds	into	the	drop-maker.	The	outlet	of	the	autosampler	was	connected	to	a	PEEK	 tubing	 (0.12	 mm	 inner	 diameter,	 Agilent	 Technologies	 Inc.,	 USA)	 that	 was	inserted	 into	 the	 autosampler	 inlet	 of	 a	 drop-maker.	 After	 each	 compound	 the	fluidic	system	of	the	autosampler	was	rinsed	by	an	internal	syringe	pump	with	400	µl	PBS.	For	each	experiment	the	waiting	time	between	each	injection	was	adapted	in	 the	 command	 sheet	 of	 Chromeleon	 software	 to	 match	 the	 production	 and	injection	times	of	compound	plugs	from	a	valve-module.		
7.1.11. Optical	 set-up	 used	 for	 measuring	 fluorescence	 intensities	 of	plugs	and	droplets			Spectroscopic	 fluorescence	 measurements	 were	 performed	 using	 an	 in-house	optical	system.	Laser	beams	with	wavelengths	of	375	nm,	488	nm	and	561	nm	were	directed	over	dichroic	mirrors	 into	 the	objectives	of	 an	 inverted	 light	microscope	(Eclipse	 Ti-S,	 Nikon	 GmbH,	 Germany).	 For	 all	measurements	 a	 40x	 objective	was	used.	 The	 emitted	 light	 was	 directed	 through	 bandpass	 filters	 on	 a	 set	 of	 three	photomultipliers	 (PMTs)	 and	 allowed	 simultaneous	 measurements	 of	 three	fluorescence	dyes.			
7.1.12. Cell	encapsulation	into	droplets	K562	 cells	 were	 cultured	 in	 IMDM	 media	 (Thermo	 Fisher	 Scientific	 Inc.,	 USA)	supplemented	with	 10	%	 fetal	 bovine	 serum	 (FBS,	 Thermo	 Fisher	 Scientific	 Inc.,	USA)	and	1	%	Pencillin	Streptomycin	(Thermo	Fisher	Scientific	Inc.,	USA).	For	cell	encapsulation	 experiments,	 K562	 cells	 were	 washed	 in	 PBS	 and	 resuspended	 in	Gibco	FreeStyleTM	293	Expression	Media	 (FS	media,	Thermo	Fisher	Scientific	 Inc.,	
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USA)	with	4%	FBS	at	a	concentration	of	2x106	cells/ml.	K562	cell	suspensions	were	loaded	into	a	3	ml	syringe	together	with	a	magnetic	mixing	disc	(VP	Scientific,	USA).	Syringe	was	mounted	 on	 a	 syringe	 pump	with	 the	 needle	 facing	 downwards	 and	connected	with	 the	 cell	 inlet	 of	 a	 drop-maker.	 To	 prevent	 cell	 sedimentation,	 the	magnetic	 disc	 was	 rotated	 at	 a	 low	 speed	 using	 a	 magnetic	 stirring	 system	 (VP	Scientific,	USA).	In	all	cell-based	experiments	done	for	this	work,	injected	cells	were	diluted	 on	 the	 chip	 by	 other	 aqueous	 phases	 down	 to	 a	 concentration	 of	 5x105	cells/ml.		
7.1.13. Microfluidic	pipeline	for	combining	compounds	injected	into	the	valve-module	This	 chapter	 aims	 at	 describing	 the	 general	 set	 up	 of	 the	 microfluidic	 pipeline	described	 in	 chapter	 3.	 A	 valve-module	with	 16	 inlets	was	 set-up	 and	 connected	with	 14	 syringes	 containing	 barcodes	 and	 fluorescent	 dyes	 and	 2	 syringes	 filled	with	 Novec	 oil.	 All	 liquids	 were	 injected	 at	 500	 µl/h	 into	 the	 valve-module	 and	valves	were	operated	using	 a	CVS	 file	with	 the	 following	 sequence	 for	 combining	valves	A	to	G	with	valves	1	to	7:		
Valves	 Opening	times	 Plugs	
A	+	1	 5s	 Collection	Plug	
2	x	oil	 2s	 Oil	Spacer	
A	+	2	 3s	 Waste	/	Washing	Plug	
2x	oil	 5s	 Oil	Spacer	
A	+	2	 5s	 Collection	Plug	
…	 …	 …	
G	+	7	 5s	 Collection	Plug		A	 short	 tubing	was	 used	 to	 connect	 the	 outlet	 of	 the	 valve-module	 chip	with	 the	braille	inlet	of	the	drop-maker,	which	was	placed	under	the	microscope.	The	second	inlet	of	the	drop-maker	chip	was	used	to	continuously	inject	the	3x	ligation	mix	at	500	 µl/h.	 QX200TM	 droplet	 generation	 oil	 (BioRad	 Laboratories	 Inc.,	 USA)	 was	injected	 at	 4500	 µl/h	 to	 produce	 droplets	 with	 a	 volume	 of	 approx.	 800	 pl.	 The	sample	collector	was	connected	over	two	short	pieces	of	tubing	with	the	outlets	of	the	 drop-maker.	 Fluorescence	 intensities	 of	 incoming	 plugs	 were	 measured	
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upstream	of	the	flow-focussing	junction	and	were	used	to	control	droplet	collection.	For	a	5s	collection	plug,	a	delay	time	of	500	ms	was	followed	by	a	collection	time	of	4	sec.	The	waiting	time	was	set	to	8.6	sec	to	ensure	that	the	system	did	not	collect	any	droplets	generated	from	washing	plugs,	but	was	ready	for	the	next	cycle	before	the	subsequent	collection	plug	was	injected.	One	cycle	of	49	combinations	with	5s	opening	 times	 took	 12	min	 and	 15	 sec	 and	 produced	 approx.	 2000	 droplets	 per	combination.	 For	 experiments	with	 varying	 collection	 times,	 the	 time	 for	 droplet	collection	was	adjusted	accordingly.		
7.1.14. Microfluidic	 pipeline	 for	 generating	 combinations	 out	 of	compounds	from	the	valve-module	and	autosampler		This	chapter	aims	at	describing	the	general	set-up	of	the	microfluidic	pipeline	used	in	 chapter	 4.	 Here,	 a	 valve-module	 with	 24	 inlets	 was	 used	 to	 generate	combinations	with	 compounds	 from	 a	 96-well	 plate.	 20	 5	ml	 syringes	 filled	with	compound-barcode	mixtures	stained	with	fluorescence	dyes	were	injected	into	the	valve-module	(valves	3	to	22).	The	two	outermost	valves	on	both	sides	were	used	to	 inject	 Novec	 oil	 supplemented	with	 0.1%	 1H,1H,2H,2H-Perfluorooctanol	 (PFO;	abcr	 GmbH,	 Germany)	 to	 prevent	 wetting	 at	 the	 channel	 walls.	 All	 liquids	 were	injected	at	500	µl/h	and	compound	plugs	were	produced	by	the	valve-module	using	a	 CSV	 file	 for	 the	 sample	 on	 demand	 software	 with	 the	 following	 valve	 opening	sequence:		
Valves	 Opening	times	 Plugs	
A	 7	sec	 Compound	Plug	
4	x	oil	 2	sec	 Oil	Spacer	
B	 7	sec	 Compound	Plug	
4	x	oil	 2s	 Oil	Spacer	
…	 …	 …	
T	 7	sec	 Compound	Plug	
2	x	oil	 ~120	sec	 Plug	injection		The	 opening	 times	 for	 compound	 plugs	 can	 be	 varied	 in	 order	 to	 produce	more	droplets	 from	 each	 compound	 combination.	 The	 opening	 time	 for	 plug	 injection	was	 adapted	 for	 each	 experiment	 to	 match	 the	 time	 necessary	 to	 inject	 all	
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compound	plugs.	 The	 length	of	 the	delay	 tubing	 (connected	 to	 the	 valve-modules	outlet)	was	determined,	by	 injecting	all	20	compound	plugs	 into	 the	delay	 tubing.	Then	the	tubing	was	cut	before	the	point	were	the	first	compound	plug	was	located	and	 inserted	 from	 the	 side	 into	 braille	 inlet	 of	 the	 drop-maker.	 The	 drop-maker	chip	was	placed	under	the	microscope	to	measure	fluorescence	emissions.	The	cell	inlet	of	the	drop-maker	was	connected	with	a	3	ml	syringe	filled	with	a	single	cell	suspension	at	2x106	cells/ml,	which	was	injected	at	500	µl/h.	The	autosampler	inlet	was	 connected	 with	 the	 autosampler	 and	 carrier	 fluid	 was	 injected	 at	 500	 µl/h.	Novec	oil	with	1%	Pico-Surf1	surfactant	 (Sphere	Fluidics,	UK)	connected	with	 the	oil	 inlet	was	 injected	at	6000	µl/h	 in	order	 to	produce	droplets	of	approx.	800	pl,	which	were	collected	in	a	15	ml	tube	(Becton	Dickinson,	USA)	on	ice.	Once	the	set-up	was	running,	the	sample	on	demand	software	was	set	to	generate	21	cycles	of	20	compound	 plug	 and	 their	 injection	 at	 1000	 µl/h	 (2	 x	 oil	 at	 500	 µl/h).	 Once	 five	compound	 plugs	 (A-E)	 of	 the	 first	 cycle	 were	 produced	 the	 autosampler-based	injection	of	compounds	from	a	96-well	plate	was	started.	Thereby,	we	ensured	that	the	plateau	concentration	of	compound	injected	from	the	96	well-plate	was	reached	once	 the	 first	 compound	plug	was	 injected	 into	 the	 drop-maker.	 Combinations	 of	compounds	 from	 the	 braille	 display	 with	 21	 compounds	 from	 the	 autosampler	were	produced	and	collected	in	a	single	tube.		
7.1.15. Picoinjection	for	cell	lysis	and	barcode	ligation		A	picoinjection	device	was	placed	on	a	hotplate	at	95	°C	until	the	PDMS	was	heated	up.	Subsequently,	low	melting	solder	was	inserted	into	the	ports	for	the	electrodes,	which	 were	 connected	 with	 cables	 (Fig.	 7.2A).	 The	 channels	 of	 the	 device	 were	treated	with	Aquapel.	Electrodes	were	connected	to	the	high	voltage	amplifier	and	ground.	Novec	supplemented	with	1%	surfactant	(Pico-Surf	1,	Sphere	Fluidics)	was	injected	 into	 the	 oil	 inlet	 to	 flush	 all	 channels	 with	 oil.	 A	 droplet	 emulsion	 was	loaded	into	a	3	ml	syringe	connected	to	a	piece	of	tubing.	Syringe	was	mounted	on	a	syringe	 pump	with	 the	 needle	 facing	 upwards	 and	 droplets	were	 injected	 at	 500	µl/h.	Once	all	the	air	was	removed	from	the	tubing,	it	was	connected	to	the	droplet	inlet	 and	 injected	droplets	were	 spaced	out	by	 the	oil.	At	 the	pico-injector	 inlet	 a	solution	for	cell	lysis	and	ligation	(Ligation	and	Lysis	mix)	was	injected	at	200	µl/h	and	cooled	using	ice	bags.	A	continuous	electrical	field	of	0.1V	was	applied	using	a	function	generator.		
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Fig.	7.2:	Chip	designs	for	Pico-injections	and	Sorting	of	droplets	
(A)	Chip	design	used	to	manufacture	moulds	for	Pico-injection	devices.	Channels	for	electrodes	were	
filled	 with	 solder	 and	 cables	 were	 inserted	 into	 each	 port.	 (B)	 Designs	 for	 manufacturing	 sorting	
devices.	Electrodes	were	filled	with	solder	and	ports	were	connected	to	cables				This	resulted	in	the	injection	of	ligation	and	lysis	reagents	into	each	droplet	passing	by	 the	 nozzle	 of	 the	 pico-injector.	Droplets	were	 collected	 on	 ice	 in	 a	 50	ml	 tube	(Becton	Dickinson,	USA).		
7.1.16. Fluorescence	activated	droplet	sorting		A	soring	device	was	placed	on	a	hotplate	at	95	°C	and	once	the	PDMS	was	heated	up,	 low	melting	 solder	was	 inserted	 into	 the	 electrode	 ports	 and	 connected	with	cables	(Fig.	7.2B).	Two	syringes	filled	with	Novec	were	connected	to	the	oil	inlets	and	 channels	were	 flushed	with	oil.	The	 chip	electrodes	were	 connected	with	 the	high	 voltage	 amplifier	 and	 ground.	 Droplets	 were	 loaded	 into	 an	 1	 ml	 syringe	connected	 to	 a	 piece	 of	 tubing.	 The	 syringe	 was	 placed	 on	 a	 pump	 and	 droplets	were	injected	at	100	µl/h	and	the	flow	rates	of	the	two	oil	injections	were	adjusted	to	 space	 out	 droplets.	 The	waste	 outlet	 of	 the	 sorting	 device	was	 connected	with	short	 piece	 of	 tubing	 (TW24,	 Adtech	 Polymer	 Engineering	 Ltd,	 UK)	 and	 the	collection	 outlet	 to	 a	 slightly	 longer	 piece	 of	 tubing	 (HW30).	 The	 differences	 in	resistance	 between	 the	 two	 connected	 tubings	 caused	 all	 droplets	 to	 enter	 the	waste	 channel.	 We	 used	 an	 in-house	 LabVIEW	 software	 to	 measure	 peak	fluorescence	 intensities	 of	 droplets	 and	 to	 set	 gates	 on	 the	 droplet	 population	 of	interest.	 When	 a	 droplet	 of	 interest	 passed	 the	 laser,	 the	 software	 applied	 an	
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electric	pulse	that	pulled	the	droplet	 into	the	collection	channel	based	on	positive	dielectrophoresis.			
7.1.17. Breaking	emulsions	In	 order	 to	 extract	 droplet	 contents,	 it	 was	 necessary	 to	 break	 the	 emulsion	 by	inducing	 the	coalescence	of	all	droplets.	For	 this	purpose,	oil	at	 the	bottom	of	 the	tube	was	removed	using	a	1	ml	pipette.	Subsequently,	1	ml	of	PFO	was	added	to	an	emulsion	 followed	by	a	couple	of	 firm	shakes.	When	all	droplets	were	broken	 the	aqueous	phase	was	pipetted	into	a	fresh	tube,	otherwise	more	PFO	was	added.		
7.2. Preparation	 of	 samples	 for	 the	 valve-module	 and	autosampler	
7.2.1. Fluorescence	dyes	For	 the	 validation	 of	 the	microfluidic	 pipelines	 used	 in	 this	 work,	 solutions	with	fluorescent	dyes	were	used.	Cascade	Blue	hydrazide	trilithium	salt	(Thermo	Fisher	Scientific	 Inc.,	USA)	was	dissolved	 in	DMSO	and	diluted	 in	PBS	to	20	µM	and	then	loaded	into	5	ml	syringes	for	the	injection	into	inlet	of	a	valve-module.	Fluorescein	sodium	salt	(Sigma-Aldrich	Corporation,	USA)	was	dissolved	in	water	and	diluted	to	10	 µM	 in	 PBS.	 Fluorescein	 solution	 was	 aspirated	 into	 5	 ml	 syringes	 for	 the	injection	into	inlet	of	a	valve-module.		
7.2.2. 	Barcode	design	
Barcodes	encoding	droplet	contents		The	10	bp	barcode	sequences	were	designed	by	nxCode	(Hannon	Lab)	and	further	processed	by	adding	ligation	sites	to	the	3’-end	and	PCR-handles	to	the	5’-end	(Tab.	
7.2).	Fwd	sequences	of	BC-1	to	BC-7	were	ordered	with	a	biotinylation	site	at	 the	5’-end.	Reverse	complements	(Rev)	without	ligation	sites	were	designed	using	Wily	DNA	Editor	(by	A.	Untergasser)	and	ordered	with	a	5’-end	phosphorylation	site	to	enable	ligation.	All	sequences	were	purchased	from	Eurofins	Genomics.			
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Tab.	7.2:	Barcode	sequences	for	droplet	barcoding		
BC-1	to	BC-7		 Fwd:	[BIO]CTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNNNgcggc		
Rev:	[Phos]NNNNNNNNNNAGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
	
BC-A	to	BC-G	 Fwd:	CTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNgccgc	
Rev:	[Phos]NNNNNNNNNNAGATCGGAAGAGCACACGTCTGAACTCCAG	
	
Barcodes	for	combinatorial	barcoding	with	RNA-Seq	The	10	bp	barcode	sequences	were	generated	using	bgen	(gear.embl.de),	a	tool	that	generates	 random	 DNA-sequences	 with	 balanced	 base	 distribution	 and	 defined	length.	The	sequences	of	BC-bio	Fwd	were	attached	to	a	primer	handle	at	the	5’-end	and	 a	 ligation	 site	 at	 the	 3’-end	 (Tab.	 7.3).	 Reverse	 complement	 strands	 (Rev)	without	ligation	site	were	designed	using	Wily	DNA	Editor	(by	A.	Untergasser).	BC-bio	 rev	 sequences	 were	 phosphorylated	 at	 the	 5’-end.	 Fwd	 strands	 of	 BC-dT	barcodes	 had	 a	 poly-desoxythymidin	 (poly-dT)	 sequence	 at	 the	 3’-end	 and	 were	phosphorylated	at	the	5’-end.	The	BC-dT	rev	sequences	were	attached	to	a	ligation	site	 complementary	 to	 the	 one	 of	 BC-bio	 Fwd	 sequences.	 All	 sequences	 were	purchased	from	Eurofins	Genomics.		
Tab.	7.3:	Sequences	for	RNA-Seq	based	combinatorial	barcoding		
BC-bio	
1	to	22	
Fwd:	
Rev:	
[BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACNNNNNNNNNNgcggc	
[Phos]NNNNNNNNNNGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
BC-dT	
A	to	T	
Fwd:	
Rev:	
[Phos]NNNNNNNNNNTTTTTTTTTTTTTTTTTTTTVN	
NNNNNNNNNNgccgc	
7.2.3. Barcode	annealing	Sequences	 were	 dissolved	 in	 nuclease-free	 water	 (Thermo	 Fisher	 Scientific	 Inc.,	USA)	at	100	µM	and	stored	at	-80	°C.	Complementary	sequences	(Fwd	+	Rev)	were	mixed	at	equimolar	concentrations	and	diluted	to	20	µM	using	nuclease-free	water.	Mixtures	were	placed	in	a	thermal	block	at	95	°C	for	10	min	and	subsequently	kept	at	room	temperature	for	1	h.	20	µM	stock	were	stored	at	-20	°C.		
7.2.4. Samples	for	the	generation	of	barcode	combinations			All	 annealed	 barcodes	 (14)	 were	 diluted	 in	 water	 to	 75	 nM.	 BC-A	 to	 BC-G	were	supplemented	with	20	µM	Cascade	Blue	for	plug	detection	by	the	sample	collector.	Barcode	 solutions	 were	 loaded	 into	 5	 ml	 syringes	 connected	 to	 tubing	 for	 the	injection	 into	 a	 valve-module.	 For	 fluorescence	 activated	 sorting	 of	 barcoded	
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droplets,	 BC-3	 solutions	 were	 supplemented	 with	 40	 µg/ml	 of	 Alexa	 Fluor	 488	(Thermo	Fisher	Scientific	Inc.,	USA).		
7.2.5. Barcode	drug	samples	used	for	valve-module	based	injection	All	compounds	were	dissolved	in	DMSO	and	stored	at	-80	°C.	Drugs	used	for	valve-module	 based	 injections	 were	 pre-diluted	 to	 40x	 of	 their	 GR20-concentration	measured	for	K562	cells.	Working	solutions	were	prepared	by	diluting	drugs	1:20	in	 FS	media	 and	 by	 adding	BC-dT	 at	 1	 µM	 to	 their	 assigned	 drugs.	 Drug	 barcode	solutions	were	stained	with	Cascade	Blue	or	Fluorescein,	loaded	into	5	ml	syringes	and	injected	into	the	valve-module.		
7.2.6. Barcode-drug	samples	for	the	autosampler-based	injection	Drugs	that	were	aspirated	from	a	96-well	plate	for	the	autosampler-based	injection	were	pre-diluted	in	96-well	plates	at	80x	of	their	GR20-concentration	measured	for	K562	cells.	Drugs	were	diluted	in	96-well	plates	to	4x	the	GR20-concentration	using	FS-media	and	BC-bio	solutions.	Barcodes	were	added	 to	 their	assigned	drugs	at	4	µM	and	each	drug	barcode	mixture	was	labelled	with	10	µM	Fluorescein.		
7.3. Sequencing	library	preparations		
7.3.1. Prepare	barcode	libraries	for	sequencing	For	ligation	of	barcodes,	droplets	containing	a	set	of	two	barcodes	were	incubated	at	 room	 temperature	 for	 30	min.	 Afterwards	 the	 emulsion	was	 broken	with	 PFO	and	 the	aqueous	phase	was	 transferred	 into	a	 fresh	 tube.	C1	dynabeads	 (Thermo	Fisher	Scientific	Inc.,	USA)	at	5	µg/µl	in	6x	SCC	buffer	(Thermo	Fisher	Scientific	Inc.,	USA)	were	added	at	a	ratio	of	1:1	(v/v)	to	the	ligated	barcodes.	For	the	binding	of	barcodes	 to	 the	beads,	 the	 tube	was	 incubated	 for	20	min	under	rotation	at	room	temperature.	Beads	were	placed	in	a	DynaMagTM	magnet	(Thermo	Fisher	Scientific	Inc.,	 USA)	 and	 were	 washed	 once	 in	 TE-SDS	 and	 two	 times	 in	 water	 and	subsequently	 re-suspended	 in	 water	 at	 10	 µg/µl.	 Barcodes	 were	 amplified	 using	Phusion	PCR	mix	and	 indexed	primer	 sequences	 (NEXTFlex	16s	V1-V3	Amplicon-Seq	Kit,	Bioo	Scientific	Corp.,	USA)	.	PCR	products	were	purified	on	1.8	x	the	volume	of	 Ampure	 XP	 beads	 (Beckman	 Coulter,	 USA)	 according	 to	 the	 manufacturers	
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instructions.	Libraries	were	pooled	and	barcodes	were	sequenced	in	one	direction	on	a	MiSeq	system	(Illumina	Inc.,	USA)	together	with	PhiX	spike-ins	(Illumina	Inc.,	USA).		
PCR-based	quantification	For	qPCR	analysis	of	barcode	abundances,	 ligated	fragments	bound	to	beads	were	diluted	1:100	 in	water.	 1.5	µl	 of	 beads	 at	0.1	µg/µl	were	 added	 to	8.5	µl	 of	 qPCR	master	 mix	 and	 amplified	 in	 StepOneTM	 Real-Time	 PCR	 system	 (Thermo	 Fisher	Scientific	Inc.,	USA).		
7.3.2. Protocol	for	combinatorial	barcoded	RNA-Seq	libraries		
Purification	and	cDNA	synthesis		This	protocol	describes	the	library	preparation	for	one	replicate	of	combinatorially	barcoded	mRNA	 of	 up	 to	 420	 combinations.	 Droplets	 containing	 lysed	 cells	were	incubated	for	30	min	at	room	temperature	for	the	ligation	of	barcode	fragments.	25	ml	of	6xSSC	was	added	to	the	droplets	before	they	were	broken	by	1	ml	of	PFO.	The	solution	was	 centrifuged	 for	 2	min	 at	 4000	 g	 and	 4	 °C	 and	 the	 supernatant	 was	transferred	 into	a	 fresh	50	ml	 tube.	The	solution	was	again	centrifuged	at	4000	g	and	 4	 °C	 for	 5	min	 and	 the	 supernatant	was	 transferred	 into	 a	 fresh	 50	ml	 tube	containing	250	µl	of	C1	dynabeads	at	10	mg/ml.	Barcodes	were	bound	to	the	beads	during	a	20	min	 incubations	step	at	RT	under	rotation.	Beads	were	washed	 three	times	 in	 6xSSC	 using	 an	 in-house	 magnetic	 rack.	 Subsequently,	 beads	 were	 re-suspended	 in	 400	 µl	 RT	 mix	 and	 incubated	 under	 rotation	 for	 30	 min	 at	 room	temperature	followed	for	90	min	at	42	°C.	The	cDNA	libraries	were	washed	in	TE-SDS	and	two	times	in	water	and	then	resuspened	in	500	µl	water.	Barcoded	cDNA	libraries	were	 cleaved	 off	 the	 beads	 using	MseI	 (New	England	BioLabs	 Inc.,	 USA)	restriction	 digestion.	 Released	 fragments	 were	 sized	 selected	 by	 two	 rounds	 of	purification	using	0.6x	the	volume	of	Ampure	XT	beads	and	then	amplified	with	the	whole	transcriptome	amplification	PCR	program	using	KAPA	Hifi	ready	mix	(Kapa	Biosystems,	USA)	with	0.8	µM	SMART	primer.	PCR	products	were	again	purified	on	0.6x	 the	 volume	 of	 Ampure	 XT	 beads	 followed	 by	 a	 fragment	 size	 analysis	 using	high	 sensitivity	 DNA	 chips	 and	 a	 2100	 Bioanalyzer	 instrument	 (Agilent	
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Technologies	 Inc.,	 USA).	 Samples	 were	 diluted	 to	 0.2	 ng/µl	 and	 used	 for	tagmentation.	
Tagmentation-based	3’-end	NGS	library	preparation			Fragmentation	 of	 cDNA	 libraries	 and	 introduction	 of	 linker	 sequences	 was	facilitated	using	Tn5-based	tagmentation.	We	used	a	Tn5-based	library	preparation	protocol	 that	 was	 developed	 in	 house	 (Hennig	 et	 al.,	 2018).	 First,	 linker	oligonucleotides	 (Tn5ME-A	 and	 Tn5ME-B)	 were	 annealed	 with	 Tn5ME-Rev	 and	mixed	with	a	Tn5	stock	(0.5	mg/ml)	at	2.5	µM.	For	loading	Tn5	with	linkers,	the	mix	was	incubated	for	45	min	at	23	°C	under	constant	shacking	at	350	rpm.	8.25	µg/ml	Tn5	with	 linker	was	mixed	with	50	pg/µl	 cDNA	and	one	volume	of	Tagmentation	mix.	The	reaction	mixture	was	 incubated	 for	3	min	at	55	°C	and	subsequently	 the	Tn5	 was	 inactivated	 by	 adding	 0.2%	 SDS.	 Fragmented	 cDNA	 libraries	 were	amplified	 using	 the	 P5-SMART	 adapter	 primer	 and	 i7	 adapter	 index	 primers	(Illumina	 Inc.,	USA)	with	 the	Tagmentation	PCR	Mix.	Amplification	products	were	purified	by	adding	one	volume	of	AMPure	beads	and	size	and	concentration	of	the	fragments	 were	 determined	 using	 a	 high	 sensitivity	 DNA	 chips	 in	 a	 2100	Bioanalyzer.	 Subsequently,	 all	 samples	 were	 pooled	 at	 equimolar	 ratios	 and	sequences	on	a	NextSeq	500	(Illumina	Inc.,	USA)	machine	together	with	PhiX	spike-ins.	Paired-end	libraries	of	barcode	combinations	(Read	1,	26	bp)	and	cDNA	(Read	2,	59	bp)	were	generated.	In	order	to	sequence	the	barcode	combinations	(Read	1),	the	custom	sequencing	primer	was	used.		
7.4. Determining	the	growth	inhibition	rate	of	drugs	Drugs	were	tested	for	their	effect	on	cell	growth	over	three	different	concentration	ranges:	1. 100µM,	10	µM,	1	µM	2. 10	µM,	1	µM,	0.1	µM	3. 1	µM,	0.1	µM	and	0.01	µM	Concentration	ranges	for	individual	drugs	were	selected	based	on	literature.	K562	cells	were	suspended	at	105	cell/ml	in	IMDM	media	(Thermo	Fisher	Scientific	Inc.,	USA)	supplemented	with	10%	FBS	and	200	µl	were	pipetted	in	black	clear	bottom	Corning	 96-well	 plates	 (Sigma	 Aldrich,	 USA).	 Drugs	 were	 added	 and	 each	 drug	
M	A	T	E	R	I	A	L		&		M	E	T	H	O	D	S	
128	
concentration	was	 tested	 in	 triplicates.	 For	 t0	measurements,	 22	 µl	 of	 PrestoBlue	cell	 viability	 reagent	 (Thermo	 Fisher	 Scientific	 Inc.,	 USA)	was	 added	 immediately	after	the	cells	were	plated	and	measured	after	1	h	of	incubation.	All	other	samples	were	 incubated	 for	 48	 h	 before	 22	 µl	 of	 PrestoBlue	 was	 added	 to	 each	 well.	Fluorescence	signals	were	measured	using	a	BioTek	Synergy	(BioTek	Instruments	Inc,	VT)	plate	reader.		
7.5. Data	Analysis		
7.5.1. Fluorescence	measurements		Recorded	 intensities	 measured	 by	 the	 PMTs	 were	 analysed	 using	 R	 scripts.	Fluorescence	 intensities	 of	 compound	 or	 sample	 plugs	was	 plotted	 and	 analysed	using	the	BraDiPlus	package	(Eduati	et	al.,	2018).	Fluorescence	data	recorded	from	droplets	 was	 visualized	 and	 analysed	 using	 ggpubr	 package	 tools.	 The	 fractions	between	 standard	 deviation	 and	 mean	 was	 used	 to	 determine	 the	 coefficient	 of	variance.		
7.5.2. Determination	of	GR20	values		To	compensate	for	cell	division	rates,	fluorescence	measurements	of	cell	viability	of	treated	 and	 untreated	 K562	 cell	 was	 analysed	 using	 the	 R	 package	 GRmetrics	(Hafner	et	al.,	2016).	The	growth	rate	inhibition	(GR)	is	defined	as	the	ratio	of	cell	growth	 under	 drug	 treatment	 at	 a	 given	 concentration	 and	 cell	 growth	 under	untreated	 conditions,	 which	 is	 normalized	 to	 the	 cell	 division	 rate.	 First,	concentrations	at	which	cell	growth	was	inhibited	by	50%	(GR50)	and	the	Hill	slope	of	 the	 sigmoidal	 fit	were	determined.	GR50	values	and	Hill	 slope	 (h)	were	used	 to	calculate	the	GR20	values	for	each	drug	using	the	following	equation:		
𝐺𝑅! = ( 𝐹100 − 𝐹)! ! ∗  𝐺𝑅!"	where	F	is	the	fraction	of	the	maximal	response	which	in	this	case	was	20.		
7.5.3. Demultiplexing	of	sequenced	barcode	libraries		In	 order	 to	 determine	 the	 abundance	 of	 barcode	 combinations	 generated	 in	droplets,	 sequenced	 barcodes	 were	 first	 analysed	 using	 starcode	 (Zorita	 et	 al.,	
	 	 M	A	T	E	R	I	A	L		&		M	E	T	H	O	D	S	
	 	 129	
2015)	 with	 default	 settings.	 Starcode	 clusters	 sequences	 according	 to	 their	similarity	 (max.	 two	 mismatches)	 and	 reports	 read	 counts	 for	 each	 sequence.	Starcode	 results	 were	 processed	 using	 a	 Python	 script	 that	 assigned	 barcode	combination	 and	 counts	 to	 combinations	 of	 indices	 used	 for	 their	 identification,	outputting	a	table	with	barcode	identifiers	sequences	and	read	counts.		
7.5.4. Barcode	abundance	Read	 counts	 for	 individual	 replicates	 were	 first	 normalized	 by	 the	 library	 size.	Barcode	counts	were	visualized	using	the	R	package	ggpubr.	Fold	changes	between	different	collection	times	of	barcodes	were	determined	by	dividing	read	counts	by	the	mean	count	at	a	5	sec	collection	for	each	set	of	seven	combinations	(A1-A7,	B1-B7,	 etc.).	 Log2	 of	 fractions	 was	 used	 to	 visualize	 barcode	 abundance	 and	 to	statistically	compare	abundances	between	 increments	of	droplet	numbers	using	a	pairwise	Wilcox	Rank	 Sum	 test.	 P-values	were	 adjusted	 for	multiple	 comparisons	according	to	Benjamini	&	Hochberg	(Benjamini	and	Hochberg,	1995).		
7.5.5. Demultiplexing	of	sorted	droplets	by	barcodes		Read	 counts	 from	 sorted	 and	 unsorted	 samples	were	 normalized	 by	 their	 library	size.	 Normalized	 read	 counts	 for	 each	 barcode	 were	 divided	 by	 the	 mean	 count	counts	 of	 the	 corresponding	 barcode	 in	 the	 unsorted	 sample.	 The	 resulting	 fold-changes	 for	each	barcode	was	 log2	transformed	and	p-values	between	sorted	and	unsorted	 barcodes	 were	 calculated	 using	 a	 Student’s	 T-Test.	 Calculated	 p-values	were	corrected	for	multiple	comparisons	according	to	Benjamini	&	Hochberg.	The	overall	 enrichment	 of	 sorted	 barcodes	 and	 its	 statistical	 significance	 was	determined	by	comparing	log2	fold-changes	of	BC-3A	to	BC-3G	to	log2-fold	changes	of	all	other	barcodes	using	a	Student’s	T-Test.		
7.5.6. Demultiplexing	and	alignments	of	RNA-Seq	data			Paired-end	 libraries	 of	 combinatorial	 barcoded	 mRNA	 was	 first	 demultiplexed	using	the	in-line	i7	Illumina	indices	to	assign	all	reads	to	replicates.	In	the	next	step,	paired-end	 libraries	were	demultiplex	based	on	sequenced	barcode	combinations.	Demultiplexing	was	performed	using	 the	 Je	demultiplexing	 software	 for	NGS	data	(Girardot	 et	 al.,	 2016).	 Sequenced	 barcodes	 (Read	 1)	 were	 used	 to	 identify	 the	treatment	conditions	by	comparing	Read	1	to	a	reference	of	known	barcode	(each	
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assigned	 to	 a	 drug	 combination).	 Up	 to	 6	 mismatches	 between	 Read	 1	 and	 the	known	barcode	were	allowed	to	unambiguously	assign	the	sequenced	mRNA	(Read	2)	 to	 each	 drug	 combination.	 Once	 mRNA	 sequences	 were	 assigned	 to	 barcode	combinations	 (i.e.	 drug	 treatments),	 the	 data	was	 aligned	 to	 a	 reference	 genome	using	 the	 STAR	 RNA-Seq	 alignment	 tool	 (Dobin	 et	 al.,	 2013).	 Demultiplexing	 and	aligning	 of	 sequencing	 results	 was	 done	 by	 Jonathan	 Landry	 from	 the	 EMBL	Genomic	Core	Facility.		
7.5.7. Filtering,	normalization	and	transformation	of	RNA-Seq	data	Demultiplexed	 and	 aligned	 data	 was	 analysed	 using	 Limma	 and	 EdgeR	 packages	(Ritchie	et	al.,	2015;	Robinson	et	al.,	2010).	Read	count	tables	obtained	form	STAR	were	 loaded	 into	 R	 to	 create	 a	 read-count	 matrix	 comprising	 all	 samples.	 First,	samples	 were	 filtered	 based	 on	 library	 size	 by	 removing	 samples	 exceeding	 one	standard	 deviation	 from	 the	mean	 library	 size	 (mean	 +/-	 sd).	 In	 a	 next	 step,	 we	filtered	out	genes	that	were	not	expression	in	10%	or	50%	of	all	samples	followed	by	trimmed	mean	of	M-values	(TMM)	normalization:	Scale	factors	for	each	sample	were	 calculated	 and	 used	 to	 determine	 the	 effective	 library	 sizes	 for	 individual	samples.	 Subsequently,	 the	 data	 was	 transformed	 using	 voom	 and	 corrected	 for	batch	effects	by	calling	the	corresponding	functions	in	the	Limma	package	(Ritchie	et	al.,	2015).	Dimensional	reduction	of	transformed	data	sets	was	performed	using	t-distributed	stochastic	neighbourhood	embedding	(tSNE,	Rtsne)	with	a	perplexity	of	30.	Gene	expression	signatures	were	determined	by	calculating	z-scores	of	gene	expression	 for	 each	 sample	 and	used	 to	 calculate	 spearman	 correlations	between	samples.			 	
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7.6. Drugs	
Drug	 Targets	 ChEMBL	ID	 Clinical	Phase	 Provider	 Drug	Class	
10Z-Hymenialdisine	 MEK1	 CHEMBL361708	 0	 TOCRIS	
Kinase-
Inhibitor	
5-Fluorouracil	 TYMS	 CHEMBL185	 4	 	
Anti-
metabolite	
5-Iodotubercidine	 ADK/INSR/	PKA/CK1	 CHEMBL99203	 0	 Selleck	
Anti-
metabolite	
AT9283	 AURKA/AURKB/JAK2/JAK3	
CHEMBL4957
27	 2	 Selleck	
Kinase-
Inhibitor	
Baricitinib	 JAK1/JAK2	 CHEMBL2105759	 4	 Selleck	
Kinase-
Inhibitor	
Blebbistatin	 MYH2	 CHEMBL1328324	 0	 Selleck	 Cytoskelleton	
Clofarabine	 RRM1	/	DNA	Polymerase	 CHEMBL1750	 4	 Selleck	
Anti-
metabolite	
Cytarabine	 DNA	/	RNA	Polymerase	 CHEMBL803	 4	 Selleck	
Anti-
metabolite	
Dacarbazine	 DNA	Animetabolite	 CHEMBL476	 4	 Selleck	 Alkylating	Agent	
Decitabine	 DNMT1	 CHEMBL1201129	 4	 Selleck	
Anti-
metabolite	
Dexrazoxane	 TOP2	 CHEMBL1738	 4	 Selleck	 Anthracycline	
Dovitinib	 FLT3/c-Kit/FGFR1/FGFR3	
CHEMBL5228
92	 3	 Selleck	
Kinase-
Inhibitor	
Doxorubicin	 TOP2	 CHEMBL53463	 4	 Selleck	 Anthracycline	
EPIRUBICIN	 TOP2	 CHEMBL1200981	 4	 Selleck	 Anthracycline	
Fludarabine	
Phosphate	 DNA	Animetabolite	
CHEMBL1096
882	 4	 Selleck	
Anti-
metabolite	
Gemcitabine	 DNA	Animetabolite	 CHEMBL888	 4	 Selleck	 Anti-metabolite	
Gimeracil	 DPYD	 CHEMBL1730601	 3	 Selleck	 	
H-7	dihydrochloride	 PRKC/PKG/PKA	 	 0	 TOCRIS	
Kinase-
Inhibitor	
Hematoxylin	 EGFR/ERBB2/c-MET/c-KIT/SRC	
CHEMBL4771
97	 0	 Selleck	 	
Imatinib	 BCR-ABL	 CHEMBL941	 4	 Selleck	 Kinase-Inhibitor	
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Methodextrat	 DHFR	 CHEMBL34259	 4	 Selleck	
Kinase-
Inhibitor	
Mitomycin	C	 DNA	Synthesis	 CHEMBL105	 4	 Selleck	 DNA-crosslinker	
Nelarabine	 DNA	Animetabolite	 CHEMBL1201112	 4	 Selleck	
Anti-
Metabolite	
NMS-1286937	 PLK1	 CHEMBL1094408	 1	 Selleck	
Kinase-
Inhibitor	
Olomoucine	 CDK2/MAPK3	 CHEMBL280074	 0	 TOCRIS	
Kinase-
Inhibitor	
Oxaliplatin	 DNA	 CHEMBL414804	 4	 Selleck	
Alkylating	
Agent	
PF-562271	 FAK	 CHEMBL1084546	 1	 	 	
Pomalidomide	 TNF-alpha	 CHEMBL43452	 4	 Selleck	 	
Sangivamycin	 PKC	 CHEMBL101892	 0	
Santa	
Cruz	 	
SB-747651	 MSK1/MSK2	 CHEMBL188434	 0	 TOCRIS	
Kinase-
Inhibitor	
SF-1126	 PI3K/mTOR	 CHEMBL2326966	 2	
Santa	
Cruz	
Kinase-
Inhibitor	
Sonolisib	 PI3K	 CHEMBL411907	 2	 Abcam	
Kinase-
Inhibitor	
Streptozotocin	 DNA	 CHEMBL1603	 0	 Selleck	 	
Sunitinib	Malate	 VEGFR2/PDGFRb	 CHEMBL1567	 4	 Selleck	 Kinase-Inhibitor	
Tabloid	/	
Thioguanine	 DNMT1	 CHEMBL727	 4	 Selleck	
Anti-
metabolite	
Thiostrepton	 FOXM1	 	 	
Santa	
Cruz	 	
Trametinib	 MEK1/2	 CHEMBL2103875	 4	 Selleck	
Kinase-
Inhibitor	
Triciribine	 AKT1/AKT2/AKT3	 CHEMBL462018	 2	 Selleck	
Kinase-
Inhibitor	
Wortmannin	 PI3K	 CHEMBL428496	 0	 Selleck	
Kinase-
Inhibitor	
YM155	 BIRC5	 CHEMBL2110734	 2	 Selleck	 			
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7.7. Buffers	and	solutions			
3x	Ligation	Mix	 For	200	µl:		
30	µl	T4	DNA	Ligase	(New	England	Biolabs,	USA)		
60	µl	10x	T4	DNA	Ligation	Buffer	(New	England	Biolabs,	USA)	
110	µl	H2O	(Thermo	Fisher	Inc.,	USA)	
Ligation	and	Lysis	Mix	 For	600	µl:	
90	µl	T4	DNA	Ligase	(New	England	Biolabs,	USA)	
90	µl	NxGen	RNase	Inhibitor	(Lucigen,	USA)		
54	µl	10%	Igepal	(Sigma	Aldrich,	USA)		
180	µl	10x	T4	DNA	Ligation	Buffer	(New	England	Biolabs,	USA)	
186	µl	H2O	(Thermo	Fisher	Inc.,	USA)	
TE-SDS	 10	mM	Tris	pH	8	
1	mM	EDTA	
0.5%	SDS	
Phusion	PCR	Mix	 1	x	Reaction	(15	µl):		
3	µl	5x	Phusion	GC	Buffer	(New	England	Biolabs,	USA)	
0.4	µl	10	mM	dNTPs	(Clontech,	USA)			
0.45	µl	DMSO	(New	England	Biolabs,	USA)	
0.15	µl	Phusion	DNA	Polymerase	(New	England	Biolabs,	USA)	
5	µl	H2O	(Thermo	Fisher	Inc.,	USA)	
1	µl	NEXTFlex	Amplicon-Seq	primer	mix	(Bioo	Scientific	Corp.)		
5	µl	Barcode	library		
qPCR	master	mix	 1	x	Reaction	(10	µl)		
5	µl		SYBRTM	Green	PCR	Master	Mix	
0.5	µl	10	µl	Fwd.	Primer		
0.5	µl	10	µl	Rev	Primer		
2.5	µl	H2O	(Thermo	Fisher	Inc.,	USA)		
1.5	µl	sample	(barcode	combination)		
RT	mix	 For	400	µl:	
150	µl	H2O	
80	µl	10x	RT	Buffer	(Thermo	Fisher	Scientific	Inc.)		
80	µl	20%	Ficoll-PM	400	(Sigma	Aldrich)		
40	µl	10	mM	dNTPs	(Clontech)		
10	µl	NXGen	RNase	Inhibitor	(Lucigen,	USA	)		
20	µl	50	µM	TSO		
20	µl	Maxima	-H	RT	(Thermo	Fisher	Scientific	Inc.)		
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Tagmentation	Mix	 20	mM	Tris-HCL	pH	7.5	
20	mM	MgCl2		
50	%	v/v	100%	DMF	(Sigma	Aldrich,	USA)		
Tagmentation	PCR	Mix	 1	x	Reaction	(30	µl)		
20.25	µl	KAPA	Hifi	Ready	mix	(Kapa	Biosystems,	USA)		
2.25	µl	DMSO	(Sigma	Aldrich,	USA)		
3.75	µl	10	µM	P5-SMART	adapter	primer		
3.	75	µl	10	µM	i7	adapter	index	primer	(Illumina,	USA)		
+	18.75	µl	Tagmentation	products		
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7.8. PCR	programs			
Phusion	PCR	for	barcode	amplification		
Step	 Temperature	 Time	
Initial	denaturation		 98	°C		 30	sec	
10	cycles		 98	°C	
70	°C	
72	°C	
10	sec	
20	sec	
20	sec	
Hold	 4	°C	 	
	
Whole	transcriptome	amplification		
Step	 Temperature	 Time	
Initial	denaturation		 95	°C		 3	min	
4	cycles		 98	°C	
65	°C	
72	°C	
20	sec	
45	sec	
3	min	
9	cycles		 98	°C	
67	°C	
72	°C	
20	sec	
20	sec	
3	min	
Final	extension		 72	 5	min	
Hold	 4	°C	 	
	 	 	
	
Tagmentation	PCR		
Step	 Temperature	 Time	
Initial	denaturation		 95	°C		 30	sec	
12	cycles		 98	°C	
58	°C	
72	°C	
20	sec	
15	sec	
30	sec	
Final	extension		 72	 3	min	
Hold	 10	°C	 	
	 	
M	A	T	E	R	I	A	L		&		M	E	T	H	O	D	S	
136	
7.9. DNA	sequences		
Sequence	Name		 Sequence	(5’	->	3’)		
TSO		 AAGCAGTGGTATCAACGCAGAGTGAATrGrGrG		
SMART-Primer	 AAGCAGTGGTATCAACGCAGAGT		
Tn5ME-A	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG		
Tn5ME-B	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG		
Tn5MErev	 [phos]CTGTCTCTTATACACATCT	
i7	index	adapter	primer		 CAAGCAGAAGACGGCATACGAGATnnnnnnnnGTCTCGTGGGCTCGG		
P5-	P5-SMART		
adapter	primer	
AATGATACGGCGACCACCGAGATCTACACGCCT	
GTCCGCGGAAGCAGTGGTATCAACGCAGAGTAC	
Custom	Sequencing	Primer		 GCCTGTCCGCGGAAGCAGTGGTATCAACGCAG	AGTAC	 	
7.9.1. Barcode	sequences	for	RNA-Seq		
Sequences	BC-bio	
BC-1		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACGCTCACCTGCgcggc							
[Pho]GCAGGTGAGCGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-2		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACTA	CCGTCTCGgcggc	
[Pho]CGAGACGGTAGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-3		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTAC	AAGCTGGCTCgcggc	
[Pho]GAGCCAGCTTGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-4		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACAAGTATCCTCgcggc	
[Pho]GAGGATACTTGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-5		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACATCAATCCTCgcggc	
[Pho]GAGGATTGATGTACTCTGCGTTGATACCACTGCTTAAAAAAA			
BC-6		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACACTCACCCTCgcggc	
[Pho]GAGGGTGAGTGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-7		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACTGACGTACTCgcggc	
[Pho]GAGTACGTCAGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-8		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACGTCAAGCATCgcggc	
[Pho]GATGCTTGACGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-9		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACTGCCGTCAAGgcggc	
[Pho]CTTGACGGCAGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-10		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACAATTCCCAGGgcggc	
[Pho]CCTGGGAATTGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
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BC-11		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACCGTCTAACGAgcggc	
[Pho]TCGTTAGACGGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-12		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACCCAATATGTGgcggc	
[Pho]CACATATTGGGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-13		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACGCGTTATGCAgcggc	
[Pho]TGCATAACGCGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-14		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACACTACGTAGTgcggc	
[Pho]ACTACGTAGTGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-15		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACGGCCAATCATgcggc	
[Pho]ATGATTGGCCGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-16		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACTGTCAACAGGgcggc	
[PHO]CCTGTTGACAGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-17		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACATACCGTTGCgcggc	
[PHO]GCAACGGTATGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-18		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACCCAGACATTGgcggc	
[PHO]CAATGTCTGGGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-19		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACTGTACAGGCTgcggc	
[PHO]AGCCTGTACAGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-20		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACATGTGCATGCgcggc	
[PHO]GCATGCACATGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-21		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACGACAGATTCGgcggc	
[PHO]CGAATCTGTCGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	BC-22		 [BIO]TTTTTTTAAGCAGTGGTATCAACGCAGAGTACTCACCGAGATgcggc	
[PHO]ATCTCGGTGAGTACTCTGCGTTGATACCACTGCTTAAAAAAA	
	Sequences	BC-dT	
BC-A	 [Pho]GCTGTGACTGTTTTTTTTTTTTTTTTTTTTVN	
CAGTCACAGCgccgc	
	BC-B		 [Pho]GGACGCA	TAGTTTTTTTTTTTTTTTTTTTTVN	
CTATGCGTCCgccgc	
	BC-C		 [Pho]GGAGGATTCCTTTTTTTTTTTTTTTTTTTTVN	
GGAATCCTCCgccgc	
	BC-D		 [Pho]ACATATATCCTTTTTTTTTTTTTTTTTTTTVN	
GGATATATGTgccgc	
	BC-E		 [Pho]GGATGGAACATTTTTTTTTTTTTTTTTTTTVN	
TGTTCCATCCgccgc	
	BC-F		 [Pho]ACTCTTCGTGTTTTTTTTTTTTTTTTTTTTVN	
CACGAAGAGTgccgc	
	BC-G		 [Pho]CAGTTCCACCTTTTTTTTTTTTTTTTTTTTVN	
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GGTGGAACTGgccgc	
BC-H		 [Pho]CCAGGGAATTTTTTTTTTTTTTTTTTTTTTVN	
CATTCCCTGGgccgc	
	BC-I	 [Pho]CGGTACTTACTTTTTTTTTTTTTTTTTTTTVN	
GTAAGTACCGgccgc	
	BC-J	 [Pho]TCACTGATAGTTTTTTTTTTTTTTTTTTTTVN	
CTATCAGTGAgccgc	
	BC-K		 [Pho]TATCGCGGACTTTTTTTTTTTTTTTTTTTTVN	
GTCCGCGATAgccgc	
	BC-L		 [Pho]CAGAGTGCCTTTTTTTTTTTTTTTTTTTTTVN	
AGGCACTCTGgccgc	
	BC-M		 [Pho]AGATTCGGCTTTTTTTTTTTTTTTTTTTTTVN	
AGCCGAATCTgccgc	
	BC-N		 [Pho]GTCACGGTCATTTTTTTTTTTTTTTTTTTTVN	
TGACCGTGACgccgc	
	BC-O		 [Pho]ACAGTTGCTGTTTTTTTTTTTTTTTTTTTTVN	
CAGCAACTGTgccgc	
	BC-P		 [PHO]ATGTAGCACCTTTTTTTTTTTTTTTTTTTTVN	
GGTGCTACATgccgc	
	BC-Q	 [PHO]CCGTACAAGTTTTTTTTTTTTTTTTTTTTTVN	
ACTTGTACGGgccgc	
	BC-R		 [PHO]CGTAGTCCAGTTTTTTTTTTTTTTTTTTTTVN	
CTGGACTACGgccgc	
	BC-S		 [PHO]AACGCTGTAGTTTTTTTTTTTTTTTTTTTTVN	
CTACAGCGTTgccgc	
	BC-T		 [PHO]GAGGTTCCCATTTTTTTTTTTTTTTTTTTTVN	
TGGGAACCTCgccgc	
	BC-U		 [PHO]GTCCGGAACTTTTTTTTTTTTTTTTTTTTTVN	
AGTTCCGGACgccgc			
BC-V	 [PHO]TACATCGCAGTTTTTTTTTTTTTTTTTTTTVN	
CTGCGATGTAgccgc	
	 7.9.2. Sequences	for	droplet	barcoding		
BC-1	 [Bio]CTCTTTCCCTACACGACGCTCTTCCGATCTGCTCACCTGCgcggc		
[Pho]GCAGGTGAGCAGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
	BC-2	 [Bio]CTCTTTCCCTACACGACGCTCTTCCGATCTTACCGTCTCGgcggc	
[Pho]CGAGACGGTAAGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
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BC-3	 [Bio]CTCTTTCCCTACACGACGCTCTTCCGATCTAAGCTGGCTCgcggc	
[Pho]GAGCCAGCTTAGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
	BC-4	 [Bio]CTCTTTCCCTACACGACGCTCTTCCGATCTAAGTATCCTCgcggc	
[Pho]GAGGATACTT	AGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
	BC-5	 [Bio]CTCTTTCCCTACACGACGCTCTTCCGATCTATCAATCCTCgcggc	
[Pho]GAGGATTGAT	AGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
	BC-6	 [Bio]CTCTTTCCCTACACGACGCTCTTCCGATCTACTCACCCTCgcggc	
[Pho]GAGGGTGAGT	AGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
	BC-7	 [Bio]CTCTTTCCCTACACGACGCTCTTCCGATCTTGACGTACTCgcggc	
[Pho]GAGTACGTCA	AGATCGGAAGAGCGTCGTGTAGGGAAAGAG	
		
BC-A	 CTGGAGTTCAGACGTGTGCTCTTCCGATCT	CAGTCACAGCgccgc	
[Pho]GCTGTGACTG	AGATCGGAAGAGCACACGTCTGAACTCCAG	
	BC-B	 [Pho]GGACGCATAG	AGATCGGAAGAGCACACGTCTGAACTCCAG	
CTGGAGTTCAGACGTGTGCTCTTCCGATCT	CTATGCGTCCgccgc	
	BC-C	 [Pho]GGAGGATTCC	AGATCGGAAGAGCACACGTCTGAACTCCAG	
CTGGAGTTCAGACGTGTGCTCTTCCGATCT	GGAATCCTCCgccgc	
	BC-D	 [Pho]ACATATATCC	AGATCGGAAGAGCACACGTCTGAACTCCAG	
CTGGAGTTCAGACGTGTGCTCTTCCGATCT	GGATATATGTgccgc	
	BC-E	 [Pho]GGATGGAACA	AGATCGGAAGAGCACACGTCTGAACTCCAG	
CTGGAGTTCAGACGTGTGCTCTTCCGATCT	TGTTCCATCCgccgc	
	BC-F	 [Pho]ACTCTTCGTG	AGATCGGAAGAGCACACGTCTGAACTCCAG	
CTGGAGTTCAGACGTGTGCTCTTCCGATCT	CACGAAGAGTgccgc	
	BC-G	 [Pho]CAGTTCCACC	AGATCGGAAGAGCACACGTCTGAACTCCAG	
CTGGAGTTCAGACGTGTGCTCTTCCGATCT	GGTGGAACTGgccgc	
		
	140	
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Fig	9.1:	Cluster	analysis	screen	1	with	improved	library	preparation		
(A)	Cluster	analysis	using	tSNE	of	gene	expression	data	from	399	treatment	conditions	colour	coded	
according	to	drugs	from	the	valve-module	encoded	by	BC-dT.	(B)	Cluster	analysis	of	gene	expression	
data	from	(A)	colored	according	to	the	21	drugs	and	DMSO	injected	by	the	autosampler	encoded	by	
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Fig.	9.2:	Cluster	analysis	after	6h	drug	exposure		
tSNE	based	analysis	of	gene	expression	data	of	cell	treated	with	drug	combination	for	6h.	Each	data	
point	corresponds	to	one	treatment	condition.	Data	points	are	coloured	according	to	drug	injected	
from	the	valve-module	which	were	encoded	by	BC-dT	
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10. Abbreviations				
AS	 Autosampler	
BC	 Barcode	
BC-bio	 Biotinylated	Barcode		
BC-dT	 Poly-dT	Barcode	
Bio	 Biotin		
C	 Celsius		
CV	 Coefficient	of	Variation		
DMSO	 Dimethyl	Sulfoxide	
DNA	 Deoxyribonucleic	acid		
dpi	 Dots	per	inch		
dT	 Desoxythymidin		
EGFR	 Epidermal	Growth	Factor	Receptor		
FADS	 Fluorescence	activated	droplet	sorting	
FBS	 Fetal	bovine	serum		
Fwd	 Forward	
GR	 Growth	reduction		
h	 Hours	
min	 Minutes		
mm	 Millimetre		
mRNA		 messenger	Ribonucleic	Acid	
ms	 Milliseconds		
NGS	 Next	Generation	Sequencing		
NSCLC	 Non-small	cell	lung	cancer	
PBS	 Phosphate	buffered	saline		
PCR	 Polymerase	Chain	Reaction	
PDMS	 Poly-Di-Methyl-Siloxane	
PFO	 1H,1H,2H,2H-Perfluorooctanol	
PMT	 Photomultiplier	Tube	
PMT	 Photomultiplier	tube	
	160	
PS-1	 Pico-Surf	1	
PTFE	 Polytetrafluorethylen		
qPCR	 quantitative	Polymerase	Chain	Reaction		
Rev	 Reverse	
RNA	 Ribonucleic	Acid		
RNA-Seq	 RNA	sequencing		
rpm	 Revolutions	per	minute	
RT	 Reverse	Transcription		
s	 Seconds		
SDS	 Sodium	dodecyl	sulfate	
sec	 Seconds	
tSNE	 t-distributed	Stochastic	Neighbourhood	Embedding				
UV	 Ultraviolet	
	
